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Abstract 
Current national guidance for empiric antibiotic therapy of children with bloodstream 
infections (BSIs) indicates that treatment options are dependent on whether a BSI is 
community-acquired (CA) or hospital-acquired (HA). Recent changes in healthcare delivery 
have seen an emergence of patients from the community with healthcare-associated (HCA) 
BSIs who require different antibiotics compared to ‘classic’ CA BSIs; research in this field has 
predominantly concentrated on adults. This thesis aims to predict the relative proportions of 
CA, HCA and HA BSIs in children aged 1 month to 5 years by identifying demographic and 
clinical characteristics associated with these three groups using two datasets. 
This thesis introduces the structure of the microbiology laboratory surveillance (LabBase2) and 
clinical (Hospital Episode Statistics) datasets and describes the probabilistic methodology used 
to link them, encompassing the match-weight calculation, threshold selection and evaluation 
of the final linked dataset. Three statistical approaches were used to predict CA, HCA and HA 
BSI using indicators of child susceptibility to infection, hospital exposure and timing of BSI.  
The combination of CA and HCA BSI accounted for 74% or more of all BSIs, but differences in 
the ranges of individual CA and HCA BSI estimates from each of the three statistical 
approaches were too wide (difference of 48%) to discern a consistent proportion of either CA 
or HCA BSI; conversely, the estimated proportion of HA BSI was consistently predicted (26% or 
less of all BSI). The cross-tabulation of child characteristics and invasive pathogens by 
predicted CA, HCA and HA BSI group identified only a few low prevalence risk factors (more 
than two chronic conditions, indwelling devices, hospital discharge in the month prior to the 
BSI) that had a high predictive value for HCA as opposed to CA BSI. Pathogens historically 
associated with causing HA BSI, particularly Gram-negative pathogens that are harder to treat 
with antibiotics, were frequently isolated on or before the day of hospital admission.  
This thesis demonstrated the wide range of pathogens isolated before and on admission to 
hospital, reflecting the growing mix of children acquiring CA and HCA BSIs in England in the 
community setting. A few, low-frequency clinical characteristics were predictive of CA, HCA or 
HA BSI, however, additional data from other sources (e.g. outpatient, primary care), may help 
to increase the accuracy of the prediction models. The mix of pathogens isolated from children 
is likely to become more heterogeneous as healthcare provision outside of hospital increases, 
suggesting that the concept of using clinical characteristics to identify the source of BSI is 
becoming less relevant. This highlights the importance of developing rapid indicators, such as 
early bedside testing, to inform appropriate treatment strategies.   
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Chapter 1. Background, aims and 
objectives 
1.1 Introduction 
Bloodstream infections (BSIs) in children are serious, clinical conditions associated with high 
morbidity and mortality, that require prompt initiation of antibiotic therapy.(1) However, 
when a patient presents with a clinical diagnosis of BSI, the causative pathogen and its 
antibiotic susceptibility will not be known for approximately the first two days of treatment 
due to the time required to grow cultures from the blood samples, identify the bacterial 
species and test their antibiotic susceptibilities.(2;3) Hence, empirical selection of the most 
likely effective antibiotic treatment is dependent on knowledge of the relative frequency of 
the main invasive bacterial pathogens and their likely antibiotic susceptibility. To this end, 
clinicians have used definitions such as community-acquired (CA) and hospital-acquired (HA) 
BSIs to guide initial antibiotic treatment due to the inherent differences in pathogens isolated 
from these two patient groups. These definitions have been based on the timing of infection in 
relation to hospital admission: HA usually being defined as more than 48 hours after admission 
and CA as an infection within 48 hours of admission.(4-6) However, changes in the way 
healthcare is delivered outside of the hospital setting mean that an investigation into whether 
these definitions are still appropriate to adequately predict and distinguish the bacterial 
specimens or the antibiotic sensitivities of the bacteria causing BSIs in children is needed.(7-9) 
In September 2013, the UK Government released a five-year (2013-2018) strategy in to 
address the increasing threat of antimicrobial resistance and promote prudent prescribing. As 
children consume a large proportion of the total antibiotics administered in England, the 
strategy highlights the importance and timeliness of this thesis to investigate how best to 
differentiate invasive pathogens for the purposes of ensuring that the most appropriate 
empiric antibiotic therapy is administered.(10;11)  
The work presented herein to address the aims and objectives of this thesis (described later in 
this chapter) was undertaken between October 2011 and June 2016. 
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1.1.1 Structure and content of Chapter 1 
This chapter describes the historical context of the treatment of BSIs in children and aims to 
investigate what information is available to distinguish the locations where BSIs are acquired 
to make inferences about likely patterns of antibiotic susceptibility. The current literature is 
reviewed and discussed, and results of a survey of professional opinions from clinicians and 
microbiologists are reported. The findings are used to underpin the rationale for the aims and 
objectives of my thesis, which are presented at the end of this chapter. 
1.2 Bloodstream infections (BSIs) 
Local infections develop when bacteria are able to penetrate the body’s natural skin and 
mucosal barriers and evade immune defences, sometimes via accidental or medical 
intervention routes (invasive procedures). BSIs can subsequently develop when the bacteria 
causing a local infection spread into the bloodstream. Transient, asymptomatic BSIs are 
common, for example, after tooth brushing.(12) The spread of bacteria via the bloodstream 
can infect other organs in the body and thereby increase the severity of infection due to the 
greater bacteria-dependent tissue damage, and the broader and stronger immune response 
required to combat the infection. The earlier that effective antibiotic treatment is given, the 
lower the risk of bacterial spread, organ damage and death due to the infection. According to 
the Surviving Sepsis Campaign recommendations, patients should receive antibiotic therapy 
within one hour of a severe sepsis diagnosis.(13) Clinically, there is a difference between the 
definition of sepsis and BSIs. Sepsis is the presence of clinical signs and symptoms of bacterial 
bloodstream infection requiring medical attention, whereas BSIs (bacteraemia) are defined by 
microbiologic methods, i.e. detection of bacteria in the blood.(13) Sepsis is theoretically a 
subset of bacteraemia, but in practice in some cases of sepsis, no bacteria can be cultured 
from the blood. The clinical symptoms observed in patients with a BSI can range from no 
clinical symptoms to symptoms of sepsis such as high fever, organ failure and septic shock.(1) 
Antibiotics to treat bacterial infections have been available for medical use since 1932.(14) 
Although increases in antibiotic resistance due to widespread antibiotic use driving the 
development of resistance have been noted for several decades, it is only in recent years that 
resistance has become a major threat due to the paucity of new antibiotics in 
development.(10;11) The continued use of antibiotics can result in selection of resistant 
pathogens, resulting in the emergence and spread of antibiotic resistant infections and loss of 
treatment effectiveness. This is why appropriate empirical treatment given between the time 
of the blood sample and the laboratory results is crucial, and why the proxy indicator of the 
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timing of the infection in relation to hospital admission has been used in the past to predict 
the most likely causative pathogens. 
This thesis focuses on BSIs for several reasons. Firstly, patients with BSIs deteriorate rapidly 
and require quick and appropriate treatment. When a clinician clinically assesses a patient, 
they need to decide whether or not their patient has symptoms consistent with suspected BSI; 
if they do suspect a BSI, they will then have to take a blood sample and make the next decision 
about what antibiotics to treat with whilst awaiting the laboratory results of the blood culture. 
To guide their choice of empiric antibiotic treatment before the laboratory results are 
available, clinicians need a simple way to predict the most likely invasive pathogen(s).(1;11)  
Secondly, blood culture samples should be taken from all patients who have a suspected 
serious bacterial infection, acting as an indicator of severity, and blood samples are rarely 
taken as a routine from patients without symptoms.  
Thirdly, apart from when a patient has a BSI, bacteria should not be in the bloodstream as it is 
a sterile environment. Whereas bacteria can be found at many other sites (e.g. urine, bronchial 
lavage, urine) because of high rates of contamination ((e.g. Coagulase-negative staphylococci 
(CoNS), Corynebacterium spp., Viridans group streptococci, Bacillus spp.) or because of 
ongoing colonisation.(15-19) For these reasons, BSIs are widely used for national monitoring of 
serious bacterial infections.(20)  
1.2.1 Community-acquired (CA) and hospital-acquired (HA) BSI 
The time interval used for distinguishing CA from HA infections is based on pathophysiological 
reasoning, namely the average time when bacteria will become detectable in a blood sample 
after the onset of infection and represents a pragmatic cut-off, although observations allowing 
a distinct transition between CA and HA BSI are limited.(5;21;22) The original CA and HA 
categories reflected a natural differentiation between patient groups in terms of the 
pathogens acquired (and their antibiotic susceptibility) in the community or in hospital.(23) In 
the past, patients needing intensive healthcare procedures were often managed as hospital 
inpatients (IP), often for prolonged periods as there was little provision of appropriate care 
outside the hospital environment. CA bacterial infections were therefore predominantly due to 
organisms that were relatively virulent pathogens capable of infecting otherwise healthy 
people in the community, although patients in hospital were also susceptible to these 
infections.(24) In contrast, HA infections were predominantly due to organisms that flourished 
among patients prone to infection due to a number of pre-disposing factors including: 
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underlying co-morbidities, compromised immunity or invasive procedures that breached the 
body’s external defences allowing pathogens direct entry. Pathogens circulating in the hospital 
are also influenced by the selective pressure from intensive antibiotic use that encourages the 
emergence of resistant strains.(25-27) 
1.2.2 Healthcare-associated (HCA) BSIs 
Since the initial introduction of the CA and HA categories by the US Center for Disease Control 
and Prevention (CDC) in the 1970s, advances in healthcare and delivery have changed 
considerably.(4) For example, congenital and chronic conditions in infants are being diagnosed 
earlier, extending the life expectancy due to the improvement in treatment.(28) This change in 
the delivery of care has resulted in the reduction in the length of hospital stay due to the 
introduction of clinical pathways that increasingly allow patients with complex conditions 
requiring invasive devices to be managed outside hospitals, either at out-patient (OP) clinics or 
at home. For example, the OP parenteral antibiotic therapy service enables patients to 
administer their own antibiotic treatment intravenously at home.(29)  
The type of care for children has changed. More complex conditions are increasingly being 
managed in the community rather than in hospital. The type of care that can be provided in 
the home, is also expanding in range and complexity.(30) The national charity for children’s 
health care, now named Action for Sick Children, changed their name in 1991 from the 
National Association for the Welfare of Children in Hospital due to the recognition of the 
growing delivery of healthcare in the community.(31) One example of healthcare delivery in 
the community is hospital at home services that are accessible to children with life-limiting 
conditions.(32) In addition, the Children’s Community Nursing teams are active in England and 
provide short and long term care for all children requiring healthcare in a community setting. 
Nursing is provided for conditions that include invasive devices, such as intravenous therapy, 
gastrostomy tube feeding and tracheostomy care and therefore present a potential risk for 
HCA infections.(33) To quantify the increase in delivery of community healthcare in England, 
by the 1993 there were 62 generic and 124 specialised services, of which 15% had been 
established in the previous year, increasing slightly to 192 services (proportion of generic to 
specialised unknown) by 2007.(34-36) Patients from the community presenting to hospital 
with a BSI now include a mix of previously healthy individuals and patients with long-term 
illnesses who may have had frequent hospital contact, OP visits or care at home.  
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The changing distribution of bacterial pathogens causing BSIs in different settings is well 
illustrated by the example of methicillin-resistant Staphylococcus aureus (MRSA). After the 
discovery of MRSA in 1961, which was regarded as causing HA BSI, this pathogen later 
emerged in the community setting causing CA BSI.(37) CA-MRSA infections began occurring in 
the 1990s in people with little or no hospital contact (e.g. skin infections in people playing 
close contact sports) or commonly associated risk factors for MRSA, and were found to exhibit 
different molecular and antibiotic susceptibility characteristics.(38) Today, CA-MRSA has gone 
“full circle” and is now responsible for a proportion of HCA and HA infections as well as CA 
infections in children and adults.(39) However, attempts to identify patients who acquire their 
infection from previous healthcare contact (healthcare-associated [HCA] infections) have 
concentrated on adult patients.(9;23;40-43) In adults, the main risk factor used to differentiate 
between CA and HA BSI has been the time interval between hospital admission and a blood 
culture sample that yields a positive bacterial culture. However, variable combinations of risk 
factors have been used a priori to define HCA BSI, for example, the presence of previous 
invasive devices, recent discharge from hospital, and underlying chronic conditions requiring 
invasive treatment.(9;23;40-43) 
1.2.3 BSI in children 
Children are particularly susceptible to infections due to their immature immune systems, 
especially in the first few years of life. A proportion will also be born premature, or born with a 
congenital condition requiring additional medical care, or both.(1;44;45) In the UK, the 
incidence of BSIs (for both uncommon and recurrent BSIs) in children aged 1 month-1 year was 
10-fold higher (362/100,000 population) than in children aged 5-15 years (36/100,000 
population) between 1998 and 2007.(44) Similar differences in rates between age-groups have 
also been reported in other countries.(8;46-48) 
Measures have been taken to reduce the rates of BSI by targeting certain pathogens using 
effective vaccines in the UK.(44;45;49-51) The Haemophilus influenzae type B vaccine was 
introduced in 1992,(52) the meningococcal C vaccine was introduced in 1999,(53) and the 7-
valent conjugate pneumococcal vaccine was introduced in 2006, subsequently replaced by the 
13-valent conjugate pneumococcal vaccine in 2010.(54) However, an increase in infections by 
serotypes not covered by the pneumococcal vaccine has been observed, and BSIs caused by 
other pathogens are still an important burden.(55) 
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In the current British National Formulary for Children (BNF-C) aged between 1 month and 18 
years, guidance for the empirical treatment of BSIs is given for CA and HA BSI, but there is no 
mention of HCA BSI.(56) There are, however, a number of additional antibiotics suggested to 
be given in addition to the first line treatment if certain pathogens are suspected, but there is 
no guidance to suggest how clinicians should suspect different invasive pathogen species that 
might require a different antibiotic combination. To ensure that national guidance is up to 
date, it is crucial that there is evidence to support this guidance to reflect the current 
epidemiology of BSI in children. 
Figure 1.1 illustrates the patient pathway and the decision to treat a BSI both for a patient 
admitted from the community with a suspected infection, and for a patient who develops an 
infection in hospital. Previous recent healthcare contact, known co-morbidities, surgery or 
catheter insertions in a child who is in hospital (or had previous recent healthcare contact) may 
affect the decision to use different antibiotics compared to a patient admitted from the 
community without previous healthcare contact. At a local, clinical level, other factors such as 
case-mix, population demographics, travel history and local antibiotic-resistance patterns may 
also influence a clinician’s choice of antibiotics. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 Flow diagram to illustrate the process of study selection using the inclusion criteria 
 24 
1.2.4 Previous Public Health England work on children with BSI 
Previous surveillance of bacterial infections in children, undertaken by Public Health England 
(PHE), identified national changes in the most frequently isolated pathogens over time 
(children aged 1 month – 18 years), and from a one-hospital study, the small proportion of 
children (aged 0-28 days) with a positive blood culture from all blood cultures tested.(44;57) 
Major limitations of these analyses, however, include the lack of clinical data to supplement 
the microbiology data, a lack of information as to where these changes in aetiology were 
taking place (i.e. the community or hospital setting) and whether there was a particular clinical 
focus, for example a specific group of patients who represented the majority of those with BSI. 
Until 2011, the PHE Department of Healthcare-Associated Infections and Antimicrobial 
Resistance (HCAI & AMR) did not hold the relevant data permissions to link routinely collected 
microbiology data voluntarily submitted by laboratories across England, Wales and Northern 
Ireland to a national clinical dataset for England, which is why this work has not previously 
been undertaken. 
In an attempt to address this lack of clinical data, previous projects have used point prevalence 
surveys or the British Paediatric Surveillance Unit (BPSU) to enhance the microbiology data 
with clinical information.(58;59) However, these studies have either focused on a specific short 
period of time that does not allow for longer term surveillance, on specific bacterial groups, 
such as pathogens causing bacterial meningitis or on a small geographic region. 
However, from 2011, the Department of HCAI & AMR obtained the relevant permissions to 
enable the access to and linkage of Hospital Episode Statistics (HES) data to the national 
microbiology dataset (described in Chapter 2), opening up the possibility for investigating BSI 
in children from a combined microbiology and clinical standpoint. 
1.2.5 Existing Evidence 
To investigate whether the CA and HA BSI categories are still appropriate for differentiating 
the likely source of pathogens causing BSI and thereby, to guide antibiotic treatment, I 
performed a systematic literature review. The aim was to evaluate the consistency of criteria 
used for CA and HA BSI, and whether a category of HCA BSI was considered in describing 
paediatric BSI. If identified, different studies were compared to determine if there was general 
agreement about the type of pathogens, the prevalence of pathogens isolated and whether 
they fit into one or multiple categories, based on timing.  
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1.3 Systematic literature review 
I conducted a systematic review to answer three key questions: 
(1) What are the criteria for CA, HCA and HA BSIs in children?  
(2) What proportion of BSIs are categorised as CA, HCA or HA in children?  
(3) What proportion of BSIs due to specific organisms are categorised as CA, HCA or HA in 
children? 
A copy of the peer-reviewed literature review manuscript, published in the Journal of Hospital 
Infection, can be found in Appendix 1a. 
1.3.1 Methods 
1.3.1.1 Selection criteria: Q1. What are the criteria for CA, HCA and HA BSIs in 
children? 
A systematic review was conducted to extract the criteria for CA, HCA and HA BSIs reported in 
the published research literature and on websites for the UK Department of Health (DoH) and 
the CDC. 
Inclusion criteria comprised any study or review article that defined criteria for both CA and HA 
in children (<19 years old) intended for high income countries (based on the World Bank 
classifications)(60); low income settings were excluded because susceptibility of children to 
infection, the range of causative pathogens and thresholds for access to healthcare differ. We 
restricted studies to those published after 1988, the date when the widely accepted CDC 
guidelines for CA and HA were first published.(5) Included studies had to report criteria for a 
mixed population of children attending hospital with a possible BSI, not criteria restricted to 
children with a specific condition (e.g. cancer). Multi-organism studies reporting CA and HA 
BSIs were selected, and both single and multi-organism studies reporting HCA BSI were 
selected. I excluded studies that were not written in English to minimise time and translation 
costs. 
I searched PubMed from 1988 to 6th March 2012 using synonyms for four concepts: CA 
infection, and HA or HCA infection, and BSI, and child (see Appendix 1b). I (KLH) screened titles 
and abstracts of potentially eligible studies. All potential studies were scrutinised by me and a 
second reviewer (Ruth Gilbert), and full papers were retrieved for studies considered eligible 
by both reviewers. Studies reported in multiple papers were counted as a single study. I 
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extracted data, which were checked by the second reviewer (Ruth Gilbert) against the source 
article. 
1.3.1.2 Selection criteria: Q2. What proportion of BSIs are categorised as CA, HCA or 
HA in children? 
A subset of cross-sectional or cohort studies identified by the systematic review (Figure 1.2) 
that reported CA and HA categories for more than 50 BSI episodes in children were analysed to 
ensure sufficient numbers for sub-group analysis. Data were extracted on the type of 
hospital(s) and age-group in each study and on the number of BSI episodes by CA, HA and HCA 
categories. 
1.3.1.3 Selection criteria: Q3. What proportion of BSIs due to specific organisms are 
categorised as CA, HCA or HA in children? 
A subset of studies identified by the systematic review (Figure 1.2) that reported organisms for 
at least two of the CA, HA and HCA categories in children were compared and analysed. 
1.3.2 Results 
1.3.2.1 Q1. What are the criteria for CA, HCA and HA BSIs in children? 
The search strategy retrieved 303 papers from PubMed (Appendix 1b), of which 23 were 
unique studies from 12 countries (Figure 1.2).(8;61-82) Two of these studies were restricted to 
a single pathogen (MRSA) but reported results for HCA BSI.(81;82) Table 1.1 shows the criteria 
used by the 23 studies to distinguish CA and HA BSI (and HCA where mentioned) according to 
date of publication. 
Thirteen variations of CA BSI and 15 variations of HA BSI were defined by the 23 studies, of 
which four focused exclusively on paediatric patients; these results are summarised in Table 
1.1. Fourteen studies based their criteria on those reported in seven different sources (CDC 
counted as one source).(4-6;9;83-89) The two oldest studies defined CA and HA BSI by whether 
the infection was present or not on admission. Over time, the criteria for HA BSI shifted to be 
based on a positive blood-culture taken at either ≥48 hours, >48 hours or ≥72 hours after 
hospital admission, of which the two former were most frequently applied (14 studies). Several 
variations to these time factors included post-discharge infections and prior hospital contact. 
One study used the number of days since admission instead of the number of hours.(82) Three 
studies used criteria that focused on clinical symptoms of BSI only; timing of the BSI was not 
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defined in their criteria.(63;64;79) From 1999 onwards, five studies defined criteria for HCA 
and included criteria for the timing and type of previous healthcare contact received prior to 
the admission relevant to the BSI sample.  
England’s DoH defined BSI as HA if the positive blood sample was taken on or after day 3 of 
admission to hospital (with day of admission being day 1),(90) which is a proxy for the 48 hour 
threshold (Table 1.1). In contrast, the most recent definition from CDC replaces the previous 
“nosocomial” term for HA infection with “health care-associated infection” in the acute care 
setting.(91) The CDC definition states that infection must not be present or incubating at time 
of admission, but no time-specific cut-off was defined, unlike its 1988 predecessor. It also 
states that the population for which the term clinical sepsis is used is restricted to patients ≤1 
year old, indicating that paediatric patients were considered and that the guidelines hence 
apply to all ages. 
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Figure 1.2. Flow diagram to illustrate the process of study selection using the inclusion criteria 
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Table 1.1. Criteria for CA, HCA and HA BSI in children 
Authors 
 
Study 
period 
Country 
  
Popn  Definition of the presumed location where infection acquired References 
directly 
relating to 
CA, HCA, 
HA criteria 
CA HCA HA 
Hounsom 
et al.(61) 
2007-
2008 
UK C&A • BSI from sample 
taken ≤48hrs after 
admission 
• BSI from sample 
taken ≤48hrs after 
admission and 
• intravenous therapy, 
or  
• haemodialysis within 
30 days, or 
• hospitalised in prior 
90 days 
• BSI from sample 
taken>48hrs after 
admission 
(assumed) 
Friedman 
et al. 
2002(9) 
Bloomfield 
&Briant 
(62) 
2006-
2007 
New 
Zealand 
C&A • BSI from sample 
taken ≤48hrs after 
admission, unless 
organism with long 
incubation period 
(e.g. Salmonella 
Typhi) and 
•not HCA 
• BSI from sample 
taken ≤48hrs after 
admission, and 
• acquired in hospital 
& BSI not present/ 
incubating on 
admission, or  
• complication of 
indwelling device, or  
• BSI <30 days after 
surgery, or  
• incision related to 
BSI performed <48hrs 
before onset of 
infection, or  
• associated with 
neutropenia by 
cytotoxic therapy 
• BSI from sample 
taken >48hrs after 
admission or 
•BSI<48 hrs after 
discharge 
Australian 
Infection 
Control 
Association
, modified 
from 
CDC(89) & 
PHLS, 
UK(84) 
Ang et 
al.(63) 
2006 UK C •Symptom onset 
≤72hrs after 
admission 
  •Symptom onset 
>72hrs after 
admission 
None 
Nicoletti et 
al.(64) 
2002-
2003 
Italy  C&A •Symptom onset 
<72 hrs after 
admission 
  •Symptom onset 
≥72hrs after 
admission 
None 
Raymond 
et al.(65) 
2001 New 
Zealand 
C&A • BSI from sample 
taken ≤48hrs after 
admission, unless 
organism with long 
incubation period 
(e.g. Salmonella 
Typhi) is isolated, 
and  
• not HCA 
• BSI from sample 
taken ≤48hrs after 
admission, and 
• acquired during 
hospitalisation & BSI 
not present/ 
incubating on 
admission, or  
• complication of 
indwelling device, or 
occurring <30 days 
after procedure, or  
• incision related to 
BSI performed <48hrs 
before onset of 
infection, or  
•associated with 
neutropenia by 
cytotoxic therapy 
• BSI from sample 
taken>48hrs after 
admission, or 
•BSI<48 hrs after 
discharge 
Australian 
Infection 
Control 
Association
, modified 
from 
CDC(89) & 
PHLS, 
UK(84) 
Laupland 
et al.(8) 
2000-
2006 
Canada  C • BSI from sample 
taken ≤48hrs after 
admission or BSI 
from sample taken 
>48 hrs after 
discharge, or 
• not HCA 
• BSI from sample 
taken ≤48hrs after 
admission, and 
•attended hospital-
based clinic or A&E 
dept. in prior 2-
30days, or  
• admitted to acute 
care hospital for 2≤ 
days in prior 2-90 days 
 
 
• BSI from sample 
taken>48hrs after 
admission or  
• BSI from sample 
taken<48 hrs after 
discharge 
CDC, 
1996(6) 
Note: C=children; A=adult; BSI=bloodstream infection; OP=outpatient; IP=in-patient; CVC=central venous catheter 
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Authors 
 
Study 
period 
Country 
  
Popn  Definition of the presumed location where infection acquired References 
directly 
relating to 
CA, HCA, 
HA criteria CA HCA HA 
Douglas et 
al.(66)  
2000 Australia C&A • BSI from sample 
taken ≤48hrs after 
admission 
  • BSI from sample 
taken>48hrs after 
admission, or 
• BSI<7 days after 
discharge, or 
• Intensive OP therapy 
with regular hospital 
contact 
adapted 
from CDC, 
1996(6) 
Wyllie et 
al.(67)  
1999-
2005 
UK  C&A • BSI from sample 
taken ≤48hrs after 
admission and 
• no hospital 
contact in last year 
• BSI from sample 
taken ≤48hrs after 
admission and 
• previous IP 
hospital contact in 
last year 
• BSI from sample 
taken>48hrs after 
admission (assumed) 
CDC 
1988(5) 
Friedman 
et al. 
2002(9) 
Marchaim 
et al.(68) 
1997-
2004 
Israel  C&A • BSI from sample 
taken ≤48hrs after 
admission, and 
• not hospitalized in 
preceding month 
  • BSI from sample 
taken >48hrs after 
admission 
None 
Luzzaro et 
al.(69) 
1999-
2000 
Italy  C&A • BSI from sample 
taken<72 hrs after 
admission 
  • BSI from sample 
taken≥72hrs after 
admission 
None 
Raveh et 
al.(70) 
1998 Israel C&A • BSI from sample 
taken<72 hrs after 
admission 
  • BSI from sample 
taken ≥72hrs after 
admission, and  
• no relation between 
infection and original 
reason for admission 
CDC1988(5)
; 1992 (88) 
Khan et 
al.(71) 
1997-
1998 
Qatar C&A • BSI from sample 
taken ≤48hrs after 
admission, and 
• not hospitalised in 
preceding month 
  • BSI from sample 
taken >48hrs after 
admission, or  
•BSI from sample 
taken<48hrs after 
discharge, or  
•preceded by invasive 
procedure, or related 
to CVC 
None 
Gray et 
al.(72) 
1996-
1999 
UK C • BSI from sample 
taken ≤48hrs after 
admission 
  • BSI from sample 
taken>48hrs after 
admission 
None 
Jensen et 
al.(73) 
1992-
1993 
Denmark C&A • BSI from sample 
taken ≤48hrs after 
admission 
  • BSI from sample 
taken>48hrs after 
admission, or 
• infections from 
invasive device 
Weinstein 
et al. 
1983(4) 
McGregor 
&Collignon
(74) 
1990 Australia C&A • BSI from sample 
taken<48hrs after 
admission 
  • BSI from sample 
taken ≥48hrs after 
admission 
CDC,1988(5
) 
Ashkenazi 
et al.(75) 
1988-
1991 
Israel C&A • BSI from sample 
taken ≤48hrsafter 
admission 
  • BSI from sample 
taken>48hrs after 
admission 
CDC, 
1972(83) 
Gomez et 
al.(76) 
1988-
1992 
Spain C&A •"BSI using 72-hr 
rule" 
  •"BSI using 72-hr rule" None 
Iversen & 
Scheel(77) 
1985, 
1989 
Norway C&A • BSI from sample 
taken ≤48hrs after 
admission 
  • BSI from sample 
taken >48hrs after 
admission 
None 
Cheng et 
al.(78) 
1984-
1989 
Hong 
Kong 
C&A • BSI from sample 
taken ≤48hrs after 
admission 
  • BSI from sample 
taken >48hrsafter 
admission 
Weinstein 
et 
al.1983(4) 
McLaws et 
al.(79) 
1984 Australia C&A  • BSI from clinical 
evidence on 
admission 
  • BSI from 
hospitalised patient & 
no clinical evidence of 
BSI on admission 
None 
Eykyn et 
al.(80) 
1969-
1988 
UK  C&A • BSI before 
admission 
  • BSI >0hrs after 
admission 
Gransden 
et 
al.1990(85) 
Note: C=children; A=adult; BSI=bloodstream infection; OP=outpatient; IP=in-patient; CVC=central venous catheter 
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Single pathogen studies 
       
Authors 
 
Study 
period 
Country 
  
Popn  Definition of the presumed location where infection acquired References 
directly 
relating to 
CA, HCA, 
HA criteria CA HCA HA 
Kempker 
et al.(81)  
2005-
2008 
US C&A • <48hrs after 
admission, and  
•no documented 
healthcare risk-
factors 
• <48hrs after 
admission, and 
• 1 or more: CVC, or  
•history of MRSA 
infection/colonization, 
or  
• surgery/dialysis, or  
• long-term care 
facility residence in 
prior year 
• >48hrs after 
admission, and 
• 1 or more: CVC, or  
• history of MRSA 
infection/colonizati
on, or 
• surgery/dialysis, 
or 
• long-term care 
facility residence in 
prior year 
Klevens et 
al. 
2006(86) 
Kallen et 
al.(82)  
 2005-
2008 
US C&A • BSI<4days after 
admission(day 1), or 
BSI from OP, and no 
recent healthcare 
exposure 
• BSI acquired from 
OP, or <4days after 
admission (day 1), and 
•presence of CVC at 
admission, or 
• 1 of following in 
prior year: 
• overnight stay in 
acute care/long-term 
care facility, or  
•dialysis or surgery 
(MRSA colonisation 
does not count) 
• BSI ≥4days  Cohen et 
al. 
2008(87) 
        
Websites               
Authors 
 
Study 
period 
Country 
  
Popn  Definition of the presumed location where infection acquired References 
directly 
relating to 
CA, HCA, 
HA criteria 
CA HCA HA 
Dept. of 
Health(90) 
  UK   Trust-apportioned, 
BSI on day 3 ≤ of 
hospital 
admission(admissio
n=day 1)  
 - 
 
Non-trust 
apportioned, BSI on 
1st or 2nd day of 
hospital admission; 
 
  
CDC 
(Horan et 
al. 
2008)(91) 
  US    Health care-associated 
infection (previously 
termed ‘nosocomial’): 
•No evidence that the 
infection was present 
or incubating at time 
of hospital admission 
and •occurs during 
hospital admission 
    
 Note: C=children; A=adult; BSI=bloodstream infection; OP=outpatient; IP=inpatient; CVC=central venous catheter 
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1.3.2.2 Q2: What proportion of BSIs are categorised as CA, HCA and HA in children? 
Nine studies (Table 1.2) met the selection criteria outlined in Figure 1.2. All nine studies 
included hospitals with specialised paediatric units (e.g. cancer unit). The mean proportion of 
BSIs in children considered to be CA was 50% (95% CI: 48%-52%) when including neonates. The 
two extremes were from Gray et al. who reported <20% CA BSI in a study that focused only on 
children in paediatric intensive care units (PICU),(72) and from the study from Qatar by Khan et 
al., where the epidemiology may have been different and potentially influenced by the small 
sample size (n=63). 
The mean proportion of BSIs in children that were CA increased to 58% (CI: 55%-61%) when 
neonates were excluded from three studies (where age-group was differentiated in the 
study).(8;65;78) Laupland et al. was the only study to report all three categories of CA, HCA 
and HA BSIs, and defined 26% of their reported paediatric BSIs as HCA (when both including 
and excluding neonates).(8) 
Table 1.2. Proportions of BSI that are categorised as CA, HCA and HA in children 
Authors Study 
period 
Country Hospital type or 
region 
Age No. of BSI No. of BSI by category (%) 
CA HCA HA 
Raymon
d et 
al.(65) 
2001 New 
Zealand 
2 hospitals 
(secondary & 
tertiary care) 
0<20yrs 
30d<20yrs 
120 episodes 
70 episodes 
40 (33%) 
40 (57%) 
¥       80 (67%)      ¥ 
¥       30 (43%)      ¥ 
Laupland 
et al.(8) 
2000-
2006 
Canada Calgary region 0<18yrs 
30d<18yrs 
995 episodes 
815 episodes 
475 (48%) 
451 (55%) 
256 (26%) 
209 (26%) 
264 (26%) 
155 (19%) 
Wyllie et 
al. (67) 
1999-
2005 
UK 2 hospitals 2m<24yrs 112 episodes 55 (49%) 57 (51%) - 
Khan et 
al.(71) 
1997-
1998 
Qatar 3 hospitals 
(tertiary referral 
centre) 
0<15yrs 63 patients 51 (81%) - 12 (19%) 
Gray et 
al.(72) 
1996-
1999 
UK 1 Children's 
hospital 
0<18yrs 143 isolates 27 (19%) - 116 (81%) 
Ashkena
zi et 
al.(75) 
1988-
1991 
Israel 1 university 
hospital & 
tertiary centre 
0<19yrs 339 episodes 191 (56%) - 148 (44%) 
Iversen 
& 
Scheel(7
7) 
1985, 
1989 
Norway 1 general 
teaching 
hospital 
0<16yrs 92 episodes 45 (49%) - 47 (51%) 
Cheng et 
al.(78) 
1984-
1989 
Hong 
Kong 
1 regional 
university 
hospital & 
tertiary local 
hospitals 
0<16yrs 
29d<16yrs 
344 episodes 
243 episodes 
188 (55%) 
168 (69%) 
- 156 (45%) 
75 (31%) 
Eykyn et 
al. 
1969-
1988 
UK 1 general 
teaching 
hospital 
0<16yrs 367* episodes 199 (54%) - 168 (46%) 
¥  combined HCA and HA results - given same definition 
* approximate number extracted from graphical data 
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1.3.2.3 Q3: What proportion of BSIs due to specific organisms are categorised as CA, 
HCA, HA BSI in children? 
Five studies (Table 1.3) met the selection criteria outlined in Figure 1.2. Overall, the majority of 
BSIs due to S. pneumoniae (mean CA=78%, 95% CI: 72%-82%) and Salmonella spp. (mean 
CA=93%, 95% CI 0.85%-0.98%) were categorised as CA BSI, and the majority of infections due 
to CoNS (mean HA=90%, 95% CI: 82-94%) and Enterococcus spp. (mean HA=84%, 95% CI: 72-
92%) BSI were classified as HA. S. aureus, E. coli, Pseudomonas spp., Klebsiella spp. and 
Enterobacter spp. did not clearly fit into either the CA or HA BSI categories. These five 
pathogens represented a substantial proportion of paediatric HCA infections in the Laupland et 
al. study, which was the only study to report HCA. 
1.3.3 Key findings 
This is the first overview of the published literature on the criteria used to differentiate 
between CA, HCA and HA BSI in children. The review revealed variable use of sampling after a 
48-hour cut-off following hospital admission to categorise HA BSI and the increasing but 
inconsistent use of criteria to define HCA and re-define CA in recent years. Few pathogens 
were clearly categorised into CA or HA categories in the review and where defined, HCA 
accounted for a substantial proportion of BSIs in children.  
Of the 23 studies in the review that included children in the study population, just under half 
of these addressed the distribution of CA and HA (question 2) with only one study addressing 
CA, HCA and HA BSI, and only five studies addressed the distribution of organisms in CA and 
HA BSI (question 3) where the numbers of children per study were also small. The problems of 
distinguishing between CA, HCA and HA are well illustrated by studies of MRSA in adults and 
children. A meta-analysis by Salgado et al. (2003) investigated criteria used to define CA-MRSA 
in adults and children. They found eight different groups of criteria for CA-MRSA, distributed 
over 31 studies. The range of criteria included positive cultures in samples taken <24 hours (2 
studies), <48 hours (16 studies) and <72 hours (11 studies) after admission, each with and 
without other exclusion criteria including healthcare-associated risk factors. Eight studies did 
not report CA-MRSA criteria.(92) 
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Table 1.3. Proportions of BSI due to specific organisms that are categorised as CA, HCA and HA BSI in 
children 
Authors Study 
Period 
Organism Age BSI (%) No. of 
BSI 
Total 
no. of 
BSI in 
study 
CA HCA HA 
Laupland et al.(8) 2000-2006 S. pneumoniae 0<18yrs 76% 21% 3% 159 1,033 
Wyllie et al.(67) 1999-2005 S. pneumoniae 2m<24yrs 50% 50% - 40 112 
Gray et al.(72) 1996-1999 S. pneumoniae 0<18yrs 100% - 0% 3 143 
Ashkenazi et 
al.(75) 
1988-1991 S. pneumoniae 0<19yrs 91% - 9% 22 355 
Cheng et al.(78) 1984-1989 S. pneumoniae 0<16yrs 100% - 0% 43 371 
Laupland et al.(8) 2000-2006 Salmonella spp. 0<18yrs 87% 4% 9% 23 1,033 
Cheng et al.(78) 1984-1989 Salmonella spp. 0<16yrs 96% - 4% 53 371 
Laupland et al.(8) 2000-2006 S. aureus 0<18yrs 56% 17% 27% 120 1,033 
Wyllie et al.(67) 1999-2005 S. aureus 2m<24yrs 38%* 63%
* 
- 32 112 
Gray et al.(72) 1996-1999 S. aureus 0<18yrs 10% - 90% 20 143 
Ashkenazi et 
al.(75) 
1988-1991 S. aureus 0<19yrs 51% - 49% 37 355 
Cheng et al.(78) 1984-1989 S. aureus 0<16yrs 47% - 53% 34 371 
Laupland et al.(8) 2000-2006 E.coli 0<18yrs 39% 40% 21% 119 1,033 
Wyllie et al.(67) 1999-2005 E.coli 2m<24yrs 57% 43% - 40 112 
Gray et al.(72) 1996-1999 E.coli 0<18yrs 25% - 75% 8 143 
Ashkenazi et 
al.(75) 
1988-1991 E.coli 0<19yrs 73% - 27% 30 355 
Cheng et al.(78) 1984-1989 E.coli 0<16yrs 78% - 22% 27 371 
Laupland et al.(8) 2000-2006 Pseudomonas spp. 0<18yrs 11% 39% 50% 18 1,033 
Gray et al.(72) 1996-1999 Pseudomonas spp. 0<18yrs 38% - 62% 8 143 
Ashkenazi et 
al.(75) 
1988-1991 Pseudomonas spp. 0<19yrs 52% - 48% 31 355 
Cheng et al.(78) 1984-1989 Pseudomonas spp. 0<16yrs 25% - 75% 20 371 
Laupland et al.(8) 2000-2006 Enterobacter spp. 0<18yrs 10% 10% 80% 20 1,033 
Gray et al.(72) 1996-1999 Enterobacter spp. 0<18yrs 0% - 100% 3 143 
Ashkenazi et 
al.(75) 
1988-1991 Enterobacter spp. 0<19yrs 54% - 46% 24 355 
Laupland et al.(8) 2000-2006 Klebsiella spp. 0<18yrs 15% 39% 46% 26 1,033 
Gray et al.(72) 1996-1999 Klebsiella spp. 0<18yrs 0% - 100% 9 143 
Ashkenazi et 
al.(75) 
1988-1991 Klebsiella spp. 0<19yrs 29% - 71% 41 355 
Cheng et al.(78) 1984-1989 Klebsiella spp. 0<16yrs 50% - 50% 8 371 
Laupland et al.(8) 2000-2006 CoNS 0<18yrs 8% 9% 83% 52 1,033 
Gray et al.(72) 1996-1999 CoNS 0<18yrs 0% - 100% 45 143 
Cheng et al.(78) 1984-1989 CoNS 0<16yrs 17% - 83% 18 371 
Laupland et al.(8) 2000-2006 Enterococcus spp. 0<18yrs 13% 23% 64% 31 1,033 
Gray et al.(72) 1996-1999 Enterococcus spp. 0<18yrs 0% - 100% 15 143 
Ashkenazi et 
al.(75) 
1988-1991 Enterococcus spp. 0<19yrs 25% - 75% 12 355 
Cheng et al.(78) 1984-1989 Enterococcus spp. 0<16yrs 0% - 100% 3 371 
*CA=12 MSSA; HA=3 MRSA & 17 MSSA 
Similarly, other studies in adults focusing on infections acquired before hospital admission 
have reported a wide variety of clinical criteria, in addition to the timing of the infection, used 
to distinguish HCA BSI from CA BSI.(9;23;40;41) There is a lack of national data to support 
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changing the BNF-C guidelines, as observed by the systematic literature review, from a focus of 
CA and HA BSIs only, to including the changes in paediatric BSI epidemiology and the 
increasing role of HCA BSI.(56) A subsequent paper by Gray, which was excluded from the 
systematic review because the data overlapped with Gray’s earlier article, reports the overall 
proportion of CA BSI (51.8%) and HA BSI (48.2%).(7) However, as opposed to the first paper, 
Gray chose to differentiate the organisms causing BSI according to whether they were from 
children with serious underlying chronic medical conditions versus those without, rather than 
as CA or HA BSI, because the majority of BSIs occurred in patients with regular hospital contact 
and serious underlying chronic conditions. For example, of all the CA BSI identified in his study 
(n=1,224), only 11.9% were in children who had previously been healthy.(7) 
Clinicians deciding on empirical treatment, before blood culture results are known, can use 
their clinical judgement and additional information, such as co-morbidity, recent healthcare 
contacts or a history of invasive procedures, to make an informed decision about appropriate 
antibiotic treatment.  
To enhance the information obtained in the systematic review and gain more information 
from front line staff treating children with BSI, I investigated what pathogens clinicians and 
microbiologists perceived to be causing HA BSI in the UK. 
1.4 Professional opinion survey: what pathogens causing paediatric 
BSI are judged to be (or not be) HA BSI in the UK? 
To capture professional opinions from across the UK, I surveyed frontline paediatricians and 
paediatric microbiologists, via an online survey (screenshot example is shown in Figure 1.3), to 
elicit their opinions on the proportion of BSI episodes they believed to be HA for 12 frequently 
isolated BSI causing pathogens. 
1.4.1 Methods 
The aim of the questionnaire was to ascertain clinicians’ views on what proportion of BSIs in 
children, by type of bacteria, they judged to be HA. I surveyed clinicians by sending them a 
brief questionnaire via email to ask them, based on their experience, what proportion of BSI 
due to 12 different pathogens that commonly cause BSI would be HA in children aged 3 
months – 5 years. Neonates aged <3 months were excluded to avoid vertically transmitted BSI 
and to maximise the likelihood of having time at home to enable exposure to CA infections. 
The 12 pathogens included in the survey were: S. aureus (split into MRSA and methicillin-
 36 
susceptible S. aureus [MSSA] where a methicillin susceptibility result was reported), non-
pyogenic streptococci, Enterococcus spp., group B streptococcus (GBS; Streptococcus 
agalactiae), Streptococcus pneumoniae, group A streptococcus (GAS; Streptococcus pyogenes), 
Escherichia coli, Klebsiella spp., Enterobacter spp., Pseudomonas aeruginosa, Salmonella spp., 
and Neisseria meningitidis. 
I developed the online survey using the survey facilities of ‘Eval & Go’ (www.evalandgo.com), 
one of the very few companies to offer a sliding scale of 21 points (0%-100% in 5% increments) 
within a survey design. Each of the 12 pathogens had a sliding scale, positioned at 50%, where 
the clinician or microbiologist could slide the scale up or down depending on their chosen 
estimate. Survey questions included the geographic region of work and whether the 
respondents were trainees or consultants. The survey was open for completion from February 
2012 onwards and was closed in May 2012 once two consecutive weeks of no new responses 
had elapsed. A screenshot of the survey can be seen in Figure 1.3. No definition of HA BSI was 
given so that individual professionals could report their estimates according to their definition.  
Permission to distribute this survey to the national paediatrician and paediatric microbiologist 
professionals was sought from the British Paediatric Allergy, Immunology and Infectious 
Diseases Group (BPAIIG) and the Paediatric Microbiologists’ Group (PMG) respectively. A 
sample survey was sent to a contact from each group for checking. Agreement was reached 
with both parties, after having piloted the survey on three microbiologists and two 
paediatricians (who did not go on to complete the final survey) with the understanding that 
the surveys were anonymous and no follow up would be possible. These central contacts 
emailed the link to the survey with a brief introduction about the study to their respective 
members: 286 members (107 consultants and 179 trainees) of BPAIIG and 25 members of 
PMG. 
1.4.2 Results 
Between February and May 2012, 34 responses to the web-based survey were received. The 
respondents comprised 9 paediatric microbiologists (8 consultants; 1 trainee) from five English 
regions (East Midlands, London, South-East, West Midlands, and Yorkshire and the Humber) 
and 25 paediatricians (7 consultants, 17 trainee paediatricians, 1 not disclosed) from Scotland 
and eight English regions (London, North-East, North-West, South-East, South-West, Wales, 
West Midlands, Yorkshire and the Humber). Frequency distributions of the estimates of the 
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proportion of patients seen with these BSIs considered by the respondents to be HA are shown 
in Figure 1.4a-m. 
Microbiologists agreed that few children (5% or less) with S. pneumoniae (median: 5%), GAS 
(median: 5%), N. meningitidis (median: 0%), or Salmonella spp. (median: 0%) BSI had a HA 
infection. Paediatricians showed similar agreement for these pathogens but the range of 
estimated proportions of BSIs due to HA were more variable (range: 0-50%). The majority of 
microbiologists and paediatricians considered GBS (Figure 1.4e) to cause BSIs that were not HA 
(median: 5%, range: 0-75%). For the remaining pathogens (Figure 1.4a-d,h-k), there were no 
consistent responses in the estimated proportions of BSI that were likely to be HA (range 0-
100%). 
A few of the respondents added extra comments at the end of the survey. From the 
paediatrician responses, as no definition for HA BSI was given at the beginning of the survey, 
one trainee reported that they were using a time threshold for any infection occurring >72-
hours after admission as HA BSI. Two other trainee clinicians reported that their percentages 
for HA BSI were very rough estimates, where one had ‘no good guess’ for either Enterobacter 
spp. or Enterococcus spp., and the other commented that these percentages would vary from 
hospital to hospital depending on the classification as a tertiary or specialist centre for 
example.  
From the microbiologist responses, one consultant discussed how a large proportion 
(unquantified) of patients with BSIs comprise regular hospital attenders; from this I inferred 
that many of the cases that this consultant witnessed are most likely HCA BSI cases. They also 
reported that as the numbers of BSI cases within their own hospitals are relatively small, it is 
hard to estimate an overall percentage. Another microbiologist gave either a 0% or 5% 
contribution to HA BSI for all 12 pathogens, justifying their results by explaining that they had 
observed very few HA BSIs in this age-group over the past 2 years.  
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Figure 1.3. Screenshot example of the online professional opinion survey 
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Figure 1.4a-m. Professional opinion survey results from UK Paediatrician and Microbiologists for 12 
pathogens for the percentage of BSIs caused by each pathogen, in their opinion, is likely to be HA 
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1.4.3 Key findings 
The professional opinion survey demonstrated consistency in identifying those pathogens 
causing BSI that were likely not to be HA (S. pneumoniae, GAS and GBS, Salmonella spp. and N. 
meningitidis). The wide range of estimated prevalence rates for pathogens historically 
considered to be HA, for example Klebsiella spp. and Enterococcus spp., may reflect the 
increasing uncertainty in the contribution of these pathogens to HA versus HCA BSI. From the 
responders’ additional comments, there was awareness of HCA BSI as an emerging group of 
BSI. The general low numbers of BSIs at a hospital-level increased the level of uncertainty over 
the professionals’ perceived levels of HA BSI causing pathogens. 
A limitation of the professional opinion survey was the low response rate of paediatric 
microbiologists (36%) and paediatricians (9%). However, no follow-up emails to potential 
responders were permitted in the original agreement with the two groups. With the aim of 
keeping the survey short to increase response rates, we did not ask about different cut-off 
definitions for HA BSI.  
1.5 Discussion 
In both the literature review and the opinion survey, S. pneumoniae, GAS, N. meningitidis and 
Salmonella spp. were most associated with causing CA BSI, but for the majority of the other 
pathogens there was no clear distinction between their contribution to CA, (HCA in the 
literature review) and HA BSI. 
The inclusion of HCA BSI in the more recent literature suggests that using timing of positive 
blood culture samples to differentiate between CA and HA BSI for paediatric patients is no 
longer valid, as the pathogens being isolated on admission to hospital include those previously 
associated with HA BSI.(8) The high prevalence of isolation of organisms previously considered 
to be HA is also reported by studies in the adult population.(9;42;93) The results of the 
systematic review highlight that there is no universal definition for CA, HCA or HA BSI in 
children. The variable definitions used have become more complex over time, alluding to the 
awareness of the increasing complexity of the epidemiology of paediatric BSI.  
The change in the epidemiology of MRSA exemplified the shift of HA pathogens into the 
community. MRSA was previously considered a HA pathogen but more recent evidence has 
shown its isolation from patients on admission to hospital.(94) MRSA is transmitted from 
person to person predominantly via colonisation or from direct healthcare worker contact 
inadvertently spreading the pathogen between susceptible patients receiving healthcare 
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treatment. This is why there is a cycle of transmission from the hospital to the community 
setting and back to the hospital again, enabled by the movement of people in and out and 
hospital. Of the patients being admitted to hospital with MRSA, currently only a small fraction 
have true CA BSI, where the majority of the burden is in patients with HCA BSI.(92;94-97)  
To further distinguish between CA and HA BSI, many authors have expressed the need for the 
exploration of the third HCA BSI category and the use of demographic and clinical 
characteristics to identify other factors other than time that can be used, which could be more 
clinically meaningful for guiding antibiotic therapy. (7;9;42;66-68;93) 
Classification of CA, HCA and HA infection requires reassessment and a stronger evidence base 
to understand the current epidemiology of BSIs in children. A large, population-based study 
that includes sufficient numbers of infections and clinical characteristics of patients and data 
on recent contact with healthcare would offer a means of evaluating associations between the 
timing and type of infection, patient characteristics, co-morbidities and timing of invasive 
procedures. Due to the high costs of primary data collection and to avoid data duplication, the 
linkage of routinely collected laboratory and clinical data offers an efficient solution.  
1.6 Rationale for PhD 
In this PhD, I link HES IP data for England with national microbiology surveillance data to 
determine associations between clinical characteristics in the patient’s hospitalisation record 
with CA, HCA and HA BSI. My analyses of the linked data aim to estimate the proportion of BSI 
attributable to CA, HCA and HA. The aim is to use the results to make inferences about the 
likely sources of invasive pathogens and patterns of antibiotic resistance. The information can 
be used to target BSI reducing interventions and to develop nationally representative 
algorithms to help guide empirical treatment for children with BSI. Figure 1.5 illustrates the 
data informing the empirical treatment, from the raw data where only timing of the BSI is 
used, to the laboratory confirmed antibiotic susceptibility data. The black boxes encapsulate 
what data I used in this thesis and the grey boxes highlight the data that I either did not have 
permissions to link to (Accident & Emergency [A&E] or OP data), did not have permission to 
access (prescribing data), does not currently exist (national collection of negative culture data) 
or data that was incomplete/insufficient (antimicrobial susceptibility) to analyse, which were 
not included in this thesis. 
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Figure 1.5. Flow diagram of steps to select appropriate antibiotic therapy for children with BSIs 
1.6.1 Aim 
To predict the relative proportion of CA, HCA and HA BSI in children aged 1 month to 5 years 
old, by identifying demographic and clinical characteristics associated with these three groups, 
using linked microbiology surveillance and clinical data for children admitted to National 
Health Service (NHS) hospitals in England. 
1.6.2 Objectives 
1.  Link microbiology surveillance and clinical data and evaluate the effect of match-
weight choice on the final linked dataset. 
2. Develop statistical models to identify patient and clinical characteristics associated 
with CA, HCA and HA BSI in children. 
3.   Predict the proportion of CA, HCA and HA BSI occurring in children in England and the 
distribution of causative pathogens in each group. 
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previous including 
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Current antimicrobial 
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Previous patient-level 
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microbiology: current 
pathogen species
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National collection of 
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Clinical indicators of 
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1.6.3 Thesis structure  
In Chapter 2, I describe the data sources available to address the aim of the thesis and define 
the cohort of children with BSI for analysis  
In Chapter 3, I describe the attributes of different data linkage methods and identify the most 
appropriate method (probabilistic linkage) to link the data sources. I describe the process 
involved in linking the data sources, including the creation of match-weights, and subsequently 
create the cohort for analysis (Objective 1). 
In Chapter 4, I report the indirect markers of child susceptibility and exposure to invasive BSI 
and the direct exposures to invasive BSI from the linked data and introduce the rationale for 
the statistical analysis in Chapter 5. 
In Chapter 5, I propose three different statistical modelling approaches to predict the 
proportion of CA, HCA and HA BSI (Objective 2) and describe the assumptions made 
concerning the linked data. The results of each approach are reported separately, which are 
then compared in Chapter 6. 
In Chapter 6, I compare and evaluate the predicted sources (CA, HCA, HA) of infection from the 
three statistical approaches (Objective 3). I then identify if the clinical and demographic 
characteristics and timing of blood specimen adequately predict the source of infection, and 
reveal the distribution of pathogens for CA, HCA and HA BSI for each of the three approaches. 
Finally, Chapter 7 summarises the key findings from the results, review the rationale for the 
thesis and discusses the limitations and implications of the results on clinical, public health and 
research practice in the future.   
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Chapter 2. Defining the cohort of 
children with BSIs for analysis 
2.1 Introduction: data sources 
The aim of this thesis is to estimate the relative proportion of CA, HCA and HA BSI in children in 
England with positive blood culture results reported to PHE. The data required to address this 
aim are located in two separate databases: the national voluntary microbiology surveillance 
database (LabBase2) and the NHS hospital administrative IP database (HES). 
By linking these two datasets together, the resulting linked dataset will contain the timing of 
when a positive blood specimen was isolated from a patient in relation to the timing of 
admission to hospital and the identity of the causative pathogen. Additional information, 
including the longitudinal hospitalisation record detailing patients’ underlying medical 
conditions, history of previous invasive procedures and hospital admissions are also collected. 
I used a retrospective four-year cohort (April 2007 to March 2011) of linked LabBase2 and HES 
data of children with a BSI. The aspects considered in the selection of the cohort are described 
individually. 
2.2 Structure and Content 
This chapter will describe and summarise the individual strengths and limitations of the 
LabBase2 and HES data that may influence the data linkage, the data fields collected, the 
criteria used to determine what data are included into each database, and the coverage and 
quality of the data. The issues surrounding information governance and permissions to access 
the data will then be outlined. Finally, the selection of the patient cohort and the explanatory 
variables that were used to develop the statistical models to distinguish between CA, HCA and 
HA BSI will be described. Figure 2.1 illustrates Chapter 2 (in red) in context within the 
framework of the thesis. 
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Figure 2.1. Flow diagram of the steps already addressed in previous chapters (grey), those that will be 
addressed in this Chapter (red) and the following chapters 
  
Comparing the results of the statistical models  
• assess the clinical and demographic child characteristics in their ability 
to predict the source of infection and the causative pathogen 
Data linkage LabBase2 and HES to obtain cohort for analysis 
• Describe the methods of data linkage 
• Clean and format the final linked cohort for analysis in Chapters 4-6 
Description of available data sources and defining cohort for analysis  
• Describe the purpose, data content, coverage, structure and patient 
identifier completion in of the microbiology dataset (LabBase2) and in-
patient clinical dataset (HES) for the child population 
• Define the cohort of children with BSI 
Introduction and aim of thesis 
• The systematic literature review and survey results illustrate the move 
from a dichotomous CA and HA BSI distinction based on the timing of 
BSI alone to the incorporation of HCA BSI in children, but with no 
uniformly agreed definitions 
• Aim: distinguish between CA, HCA and HA BSI using additional data 
about child clinical  and demographic characteristics 
Linked study population  
• Determine the baseline clinical and demographic characteristics of 
children with BSI 
• Identify indirect and direct risk factors to predict CA, HCA and HA BSI 
 Chapter 1 
Chapter 2 
Chapter 3 
Methods and results for predicting source of infection (CA, HCA, HA BSI)  
• Develop prediction models to predict the likely source of infection using 
defined child characteristics 
Chapter 4 
Chapter 5 
Chapter 6 
Discussion and conclusions Chapter 7 
 46 
2.3 LabBase2: Public Health England’s surveillance system 
2.3.1 Purpose 
National microbiology data are voluntarily reported by participating laboratories to PHE 
(formally known as the Health Protection Agency [HPA]), and prior to that the Public Health 
Laboratory Service [PHLS]) and stored in a centralised database (LabBase2), which is held at 
the PHE site in Colindale, London.(98) This microbiology data forms the cornerstone of 
communicable disease surveillance in England, Wales and Northern Ireland; Scotland has its 
own microbiology surveillance database ECOSS (Electronic Communication of Surveillance in 
Scotland), which was not included in this thesis.(99)  
LabBase2 contains reports of clinically significant isolates from different specimen types (e.g. 
blood, urine, respiratory isolates), organism identification to species level, antimicrobial 
susceptibility results (where tested and reported), the date the specimen was taken, the 
location where the specimen was taken (e.g. in hospital, at a general practitioners), the source 
laboratory, and patient demographic data (including patient identifiers).(100) There are no 
routinely recorded clinical data (e.g. contact with healthcare, diagnoses, procedures) in the 
voluntary reports to LabBase2. In addition, there are no data on the date of the patient’s 
admission to hospital and therefore this database alone cannot be used to identify the timing 
of a BSI in relation to the date of hospital admission.(44) 
2.3.2 Background 
PHE began collecting results of positive clinical isolates via paper reports in the 1970s as PHLS 
from England, Wales and Northern Ireland for epidemiological surveillance and aiding 
outbreak investigation. In 1989, the first national microbiology database, LabBase1, was 
introduced and direct electronic reporting to this database from the testing laboratories began 
in 1993, first piloted in Wales.(98) This electronic reporting was expanded to a few regions in 
England in 1995, and then to all regions by 1997. This system developed and increased in 
capacity until 2002 when LabBase2 was introduced as a replacement to LabBase1.(101) 
2.3.3 What data are reported to LabBase2? 
The laboratory reporting to LabBase2 is voluntary. To ensure the continuity and 
representativeness of the data, a minimum standard of core pathogens isolated from 
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specimens is requested by the laboratory guidance document for participating 
laboratories.(102) These specimens must be deemed to be clinically significant, although the 
laboratory guidelines do not stipulate the criteria to be used for determining what is and is not 
clinically significant. However, there is no active validation of this process. LabBase2 does not 
collect any results for negative specimens (specimens that do not grow any bacteria). 
In addition to these guidelines, the Health Protection (Notification) Regulations (introduced in 
October 2010) require a specified subset of core causative bacterial pathogens from human 
samples to be reported as notifiable organisms, because these bacteria were considered to 
cause clinically serious infections. The core and notifiable pathogens include the frequently 
isolated bacterial pathogens that this thesis investigated. These core and notifiable organisms 
are listed in Table 2.1. 
Table 2.1. Core and notifiable organisms to be reported to LabBase2 
Core Organisms 
Acinetobacter spp., Actinomyces spp., Aeromonas spp., Bartonella spp., Chlamydia pneuomniae, 
Chlamydia trachomatis, Citrobacter spp., Clostridium spp., Coxiella spp., Enterobacter spp., 
Enterococcus spp., Erysipelothrix spp., Escherichia coli, Klebsiella spp., Leptospira spp., Listeria 
spp., Morganella morganii, Mycobacterium spp., Mycoplasma spp., Neisseria gonorrhoeae, 
Nocardia spp., Pasteurella spp., Plesiomonas spp., Proteus spp., Providencia spp., Pseudomonas 
spp., Serratia spp., Staphylococcus aureus, Staphylococcus spp., Stenotrophomonas maltophilia, 
Streptobacillus moniliformis, Streptococcus spp., Treponema spp., Vibrio spp., Yersimina spp. 
Of which the following are notifiable organisms 
Bacillus anthracis, B. cereus, Bordetella pertussis, Berrelia spp., Brucella spp., Burkholderia 
mallei/pseudomallei, Campylobacter spp., Chlamydophila psittaci, Clostridium spp., 
Corynebacterium spp., Coxiella burnetii, Francisella tularenis, Haemophilus influenzae, Legionella 
spp., Leptospira interrogans, Listeria monocytogenes, Mycobacterium tuberculosis, Neisseria 
meningitidis, Rickettsia spp., Salmonella spp., Shigella spp., Streptococcus pneumoniae, S. 
pyogenes, Vibrio cholera, Yersinia pestis 
 
2.3.4 Capturing data on positive blood cultures 
Local laboratory data are reported to LabBase2 through a national electronic network (Figure 
2.2). The local laboratory reports of clinically significant positive specimen results are 
transferred from the local laboratory information system via CoSurv (a module system used for 
extracting data) using a LabLink+ interface, to the regional centres. The data are cleaned and 
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checked at the regional level before being submitted to the central LabBase2 database in 
Colindale, London.(102) When local laboratories need further testing of isolates, for example 
for speciation or antibiotic susceptibility profile, they send the isolate to one of the 
corresponding national reference laboratories. Results from isolates tested at the national 
reference laboratories feed straight into the LabBase2 system, bypassing CoSurv. 
Data can be uploaded daily into LabBase2, which allows for timely analysis of current data. In a 
recent analysis of LabBase2 data, although the median reporting delay of isolate reports to 
LabBase2 was nine days (Inter-Quartile Range: 6-16 days) across all trusts, the variation by 
trust was substantial.(100) It was found that 45% of laboratories (75/167) reported isolates in 
a timely manner, whereas 12 trusts were responsible for the largest delays in the 90th centile 
of reporting (>100 days delay). The timeliness in reporting did improve after October 2010 
when the additional Health Protection (Notification) Regulations were brought in.(102)  
 
 
 
 
 
 
 
 
Figure 2.2. Flow diagram showing the path of the specimen results data from the local laboratories to 
the national LabBase2 database. 
2.3.5 Coverage  
As a voluntary system, LabBase2 does not receive all the positive bacterial specimen results. 
However, a parallel PHE mandatory reporting system for S. aureus and E. coli BSI can be used 
as a proxy to monitor the difference between the numbers of positive isolates reported to the 
two systems.(98;103) The trends of voluntary and mandatory reporting have been similar over 
time where the voluntary system received approximately 80% (S. aureus) and 84% (E. coli) of 
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the reports submitted to the mandatory surveillance system in 2011.(104;105) Whilst the 
proportion of completion for other pathogens in LabBase2 is not routinely investigated by PHE, 
these results are used as a proxy for the level of reporting in LabBase2. 
To evaluate the estimated ascertainment of records in LabBase2, part of the work that Harron 
et al. undertook compared microbiology results from children (aged <16 years) that were 
eligible for reporting to LabBase2 and those that were retrievable, in reality, from LabBase2 
between 2003-2010 for two gold-standard hospital laboratories (Birmingham Children’s 
Hospital and Royal London Hospital). The estimated ascertainment was 81.5% and 79.5% for 
each laboratory respectively.(106) In the wider study of the 22 laboratories that could report 
PICU microbiology data to LabBase2, 548/2,596 (21%) laboratory-months were found to have 
incomplete reporting.(106) In her PhD thesis, Harron reports the difficulties associated with 
determining the process of data collection at the various stages of the data flow for LabBase2. 
The reasons for unreported and/or inconsistent reporting of data, which included data upload 
issues, information technology problems and variable staff support, indicates that the nature 
of the under-reporting is a system-level issue rather than a pathogen-level issue. The 
assumption was therefore made that the representativeness of the data by pathogen species 
should not be negatively impacted.(107) 
2.3.6 Data structure 
The LabBase2 data are formatted and stored as a line-list. Each row contains data specific to 
each blood specimen reported. A patient may have one or more rows for each infection 
episode depending on how many reported blood specimens (with different specimen dates) 
isolated the same pathogen. 
2.3.7 Identification of infection episodes 
Each record in LabBase2 is identified using an Organism Patient Illness Episode (OPIE). An OPIE 
represents an infection episode for a patient where a pathogen is isolated from a specimen 
and is considered clinically significant; it does not identify the patient uniquely within the 
database, where one patient may have multiple OPIEs. Every positive isolate record is assigned 
its own row in the database. Figure 2.3 demonstrates that the same patient (identified by the 
matching NHS number) is assigned two different OPIEs if the pathogen species isolated is 
different, even if they are from the same specimen type and isolated on the same date. 
LabBase2 has a standard time-period of 14 days for a bacterial infection episode (isolated from 
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blood and flagged as a bacteraemia), where any subsequent positive bacterial specimen taken 
within 14 days of the first specimen for the same pathogen for that patient is considered as 
part of the same infection, retaining the earliest specimen date in addition to the new 
specimen date for the new specimen.(102)  
 
NHS no. OPIE Organism species Earliest 
specimen date 
Specimen 
date 
Type 
1111111111 AAAAA S. pneumoniae 03/02/2010 03/02/2010 Sputum 
1111111111 AAAAA S. pneumoniae 03/02/2010 05/02/2010 Blood 
1111111111 BBBBB H. influenzae  03/02/2010 03/02/2010 Sputum 
1111111111 BBBBB H. influenzae  03/02/2010 05/02/2010 Blood 
Figure 2.3. Example demonstrating that OPIEs are assigned based on the organism species 
2.3.8 Matching BSI episode reports to the same patient episode 
For an electronic isolate result to be accepted into the LabBase2 system and be assigned an 
OPIE, it must pass through a three-stage process. These three stages comprise the loading, de-
duplication and merging of potential records. 
2.3.8.1 Stage 1: Data Loading 
An isolate report passes through a loading check process in order to be submitted from the 
local laboratory to the national LabBase2 database. It is presented to the system to be either 
accepted or rejected based on whether the report is deemed to be valid or not (e.g. the 
correct format). If invalid, the report may be corrected for a re-load attempt into the system, 
otherwise this is one stage where data are lost.(102) Once validated, the report is then tagged 
to be passed through to the duplicate identification stage. 
2.3.8.2 Stage 2: Data de-duplication 
Stage 1 tagged reports are individually compared against already processed records to identify 
duplicates that have to match on three levels: 
a) Organism name 
b) The same episode (within the 14-day period) 
c) The same patient 
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For Levels a) and b), duplicates of an OPIE may occur when more than one positive specimen 
of the same species sub-group is isolated from any source (e.g. blood, urine etc.) from the 
same patient within a 14-day window. In contrast, if two different organisms, including 
different sub-types of a species, are isolated during the same 14-day episode, then two 
different OPIEs are assigned to the same patient to identify each organism as demonstrated in 
Figure 2.3. Equally, more than one OPIE is assigned if a patient has one or more re-infections 
with the same species outside of the primary infection time-period, implying that they have 
recovered after the first infection before getting the subsequent infection and so on.  
For level c), to identify the same patient, the probability that two records match is assessed 
using the available patient identifiable data: patient name, soundex (phonetic algorithm of 
patient name), sex, date of birth, hospital number, NHS number, and postcode. This is 
performed by comparing every possible combinational pairing between the tagged reports and 
LabBase2 reports. A total match-weight is then given to each pair of records depending on 
how well (high weight) or poorly (low weight) they matched. Although this process maximises 
the potential matches by using a combination of patient identifiers to identify duplicates, 
those reports that have limited or no patient identifiers will not be merged with a current 
LabBase2 record, even if they are a real duplicate, due to a lack of information. This is one of 
the issues with regards to the voluntary nature of the dataset. 
2.3.8.3 Stage 3: Data merging 
Subsequent new records that are found to be duplicates of already existing records in the 
database are then merged together and assigned a new ‘merged’ OPIE, removing the original 
OPIE from the LabBase2 confirmed model. The original OPIEs are kept in a separate table 
should the records need to be unmerged at a later point. 
To merge records successfully, the laboratory regulations state that at least one of the 
following patient identifiers must be present:(102)  
 Patient’s surname and initial, or soundex code and initial 
 Patient’s Hospital number 
 Patient’s NHS number 
The regulations do state that although the patient identification details are passed onto the 
regional information managers by the reporting laboratories, the laboratories are able to 
suppress some identifiers before onward submission of the data. This is another step where 
data may be lost before reaching LabBase2. 
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2.3.9 Query design for LabBase2 data extraction 
To ensure all the possible LabBase2 OPIEs were captured, a comprehensive query to extract 
data between April 2007 and March 2011 was created. The extraction criteria for the query 
and a fictitious data output example are outlined in Figure 2.4. This query extracted a total of 
39,297 reports, accounting for 35,497 unique OPIEs. Within this extract, environmental 
isolates and National External Quality Assessment Service (NEQAS) test isolates were identified 
and removed, leaving a total of 35,555 reports accounting for 32,536 unique OPIEs.  
Variables Selected for Example output 
OPIE   01AAA11111/01 
Organism name   HAEMOPHILUS INFLUENZAE 
Earliest specimen date   DD/MM/YYYY 
Specimen date 01/04/2007 - 31/03/2011 DD/MM/YYYY 
Patient initial   R 
Patient surname   RICKON 
Patient forename   STARK 
Patient NHS number   1111111111 
Patient hospital number   ST22222 
Sex   M 
Date of birth  02/04/2001-31/03/2011 DD/MM/YYYY 
Patient postcode prefix   WT1  
Patient postcode suffix   3FL 
Hospital name   NORTH HOSPITAL 
Organism classification description  BACTERIA, FUNGI BACTERIA 
Age Group 0-9 YEARS OLD, UNKNOWN  0-9 YEARS OLD 
Laboratory name   NORTH MICROBIOLOGY 
Laboratory country  
ENGLAND, WALES, SCOTLAND, 
ISLE OF MAN, CHANNEL 
ISLANDS, UNKNOWN 
ENGLAND 
Method of id description    CULTURE 
Parent specimen type code  BLOOD, CSF BLOOD 
Specimen source type description   INPATIENT 
Figure 2.4. Example of a LabBase2 query (fictitious data) 
2.3.9.1 OPIE anomalies 
Of the 32,536 unique OPIEs in the pre-linked LabBase2 dataset, 17 OPIEs (0.05%) had a >14 day 
difference between the first and last specimen date indicating that there may have been a 
data entry error. There is no way to check from the LabBase2-user access level, as the earliest 
specimen date and date loaded are all automatically duplicated from the first specimen in the 
OPIE to all subsequent specimens reported.  
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2.3.10 Patient identifiers in LabBase2  
The patient identifiers reported in LabBase2 are patient name, soundex, NHS number, hospital 
number, sex, date of birth and postcode. To assess the completion of the identifier fields in 
LabBase2 that are also found in the HES dataset, the number of unique patient identifiers from 
positive blood specimen records from children aged 0 – 5 years old, as well as patients with an 
unknown date of birth (32,536 OPIEs) reported between April 2007 and March 2011, are 
plotted in Figure 2.5. 
The level of completion was lowest for NHS number and patient postcode, ranging from 51%-
70% and 65%-75% respectively over the four-year period. Date of birth and sex are the most 
complete (average of 95%), followed by hospital number (88-91%). Although the proportion of 
completion improves over time, none of the identifiers were 100% complete.  
The completion does not necessarily reflect fully qualified data entries as some may contain 
errors. To try and overcome this potential error problem, additional data was retrieved and 
included as a result of tracing all the patient data through the Demographic Batch Service 
(DBS) to optimise NHS number and sex for the data linkage process described in more detail in 
the following paragraph.   
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Figure 2.5. Proportion of identifier records with a data entry for each of the six patient identifiers in 
LabBase2 between 2007/08 and 2010/11 for children aged 0-5 years and patients with no date of 
birth 
2.3.10.1 Demographic Batch Service (DBS) and data pre-processing 
An additional method employed to enhance the data completion of the patient identifiers in 
the LabBase2 data is the DBS system. The DBS is used by the NHS and related organisations to 
trace files of patient data using the Personal Demographics Service (PDS).(108) One purpose is 
to obtain additional patient data for entries that may be missing, for example to find out the 
NHS number of a patient if one was not completed in the original file. The fields that are 
submitted include date of birth (mandatory), NHS number, surname, forename, gender and 
postcode. In order for a positive match to be returned, the uploaded file must contain one of 
the following: 
1) a valid NHS number and date of birth; or 
2) a valid NHS number, date of birth (2/3 of the day, month and year items need to 
match), surname (first three characters) and forename initial; or 
3) surname, forename, date of birth and gender must match if no NHS number is given. 
The patient identifier data for the 32,536 OPIEs (35,555 records) were then sent to the DBS for 
tracing to enhance the completion of the NHS number and sex fields. 
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Date of birth is crucial at all three stages of the trace; therefore no additional information was 
available for those without a date of birth (5%) in the LabBase2 data. No changes were made 
to any LabBase2 postcodes whether missing or different to the DBS patient postcode. This was 
to avoid changing any historical data that would be potentially incorrect at the time of the 
positive specimen, as patients can frequently move residence. Between LabBase2 and the DBS, 
23,180 (65%) records matched perfectly out of the total 35,555 records (32,536 OPIEs) that 
were traced and did not require any further enhancement. Of the remaining 35% (12,375 
records), I accepted new NHS numbers from the DBS trace where the LabBase2 entry was 
missing if they matched on: 
 forename, surname and date of birth = 1,904 (15%) NHS numbers accepted 
 surname, date of birth and postcode = 94 (0.8%) NHS numbers accepted 
 forename, surname and date of birth (accounting for minor spelling errors) = 33 
(0.3%) NHS numbers accepted 
Sex was reassigned for 29 records where forename, surname, and date of birth matched.  
2.3.10.2 Other patient identifier considerations 
All patients who are registered with the NHS in England and Wales are assigned a unique, 10-
digit identification NHS number. Patients admitted to hospital are assigned a hospital number 
for that hospital spell, which is unique to the hospital, but may not be unique between 
hospitals.  
In LabBase2, the local General Practitioner (GP) postcode is used as a proxy if the patient’s 
postcode is not entered, and if there is no GP postcode, then the system will default to the 
hospital postcode. How often a patient’s family moves address may also provide more than 
one linkable postcode. Patients who are not current residents in the UK are assigned a 
postcode where the prefix is always “ZZ99” and the 3-digit suffix will denote the country or 
geographic area of residence.(109) 
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2.4 Hospital Episode Statistics (HES) 
2.4.1 Purpose 
The HES database holds routinely collected IP, OP and A&E patient data for England. NHS 
providers supply data for every patient (including private and foreign patients) attending an 
NHS hospital or an independent sector hospital funded by the NHS in England.(110) The IP 
database can capture over 100 pieces of data per patient episode that include data on hospital 
admission and discharge, patient identifiers, patient demographics, clinical diagnoses, 
operations, length of stay, socio-economic status and geographical location of care. HES does 
not contain microbiology data or specific information as to whether infections were acquired 
in the community or from hospital, although there may be indications from some treatment 
codes.(110) The original purpose of HES was to capture detailed patient records for episodes 
of care following an investigation into how hospital activity data were gathered and used.(110) 
2.4.2 Background 
The Health and Social Care Information Centre (HSCIC) is responsible for the HES national 
statistical data warehouse (http://www.hesonline.nhs.uk). HES was first established in 1987 to 
collect national IP data. Prior to this, only a small subset (10%) of patient admission data had 
been collected. The first complete year of data was the 1989-1990 HES dataset.(110) 
The methods of data collection have been adapted over time to account for organisational 
change. Originally, the collation of data was at the regional level compared to the most recent 
change in 2006 to the National Programme for Information Technology’s Secondary Uses 
Service.(111) Additional data fields have also been added over time which has offered 
flexibility to the amount of detail recorded [examples: expanding number of diagnoses fields to 
20 and procedures to 24). OP and A&E datasets were introduced as additional experimental 
datasets reporting data from 2003-04 for OP and 2007-08 for A&E. The OP dataset became 
accredited as a national statistic in 2008; these datasets will not be considered in this study 
because both datasets were still experimental at the start of the cohort period, and had 
variable data completion.(110)  
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2.4.3 Data format 
There are over 100 cleaning and validation rules that IP data are subject to in HES.(112) A 
certain proportion of the fields that undergo the validation rules are populated by data derived 
from other data sources within the IP dataset. For example, episode duration and patient age 
at start of episode are derived from the start and end episode dates and the difference 
between the patient’s date of birth and the episode start date respectively. 
The majority of HES fields are coded. Diagnoses fields are populated by ICD-10 (International 
Classification of Diseases, 10th Revision) codes, which replaced the ICD-9 codes in 1995. ICD-10 
codes are a method of categorising clinical diagnoses within the healthcare environment for 
patient management, for surveillance purposes and can be used as a resource allocation tool. 
There are approximately 69,000 different ICD-10 codes that are categorised into 22 chapters. 
Of these chapters, 14 are dedicated to diseases affecting body systems including neoplasms, 
infectious diseases, parasitic diseases, mental disorders, circulatory and nervous system 
disorders. Three chapters are for pregnancy, perinatal conditions and malformations. The 
remaining five chapters cover external causes of harm such as poisoning or accidents, external 
causes of morbidity and mortality, factors affecting health status and special additional codes 
that come about from emerging health related diseases.(113) 
Procedures and intervention fields are populated by OPCS-4 (Office of Population, Censuses 
and Surveys: Classification of Interventions and Procedures, 4th Revision) codes. These codes 
are entered by professionally trained coders who refer to the available patient hospital notes 
recorded by the medical staff in the hospitals.(114) 
2.4.3.1 Coding error in HES 
As a national dataset collecting millions of records each year, there is inevitably a margin of 
error. Although coding in HES has improved with time, coding errors can occur in the form of 
completely random errors, or vary between different hospitals.(115-117) A way of measuring 
error was introduced by the Audit Commission using the Payment by Results Data Assurance 
Framework that was introduced within the NHS in England between 2003 and 2005.(33) For 
example, the average clinical coding error in 2007/08 for healthcare resource groups was 9.4% 
(ranging from 0.3-52.0%), which had a subsequent economic effect of £3.5 million.(118) HES 
data has improved significantly over time, although the data completion and accuracy do vary 
by variable field.(119) Payment by results has incentivized coding for comorbidities as these 
attract additional payments for hospitals. This is unlikely to be related to BSI results and as PBr 
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has been in place since 2003, coding practices would not have changed substantially during the 
study period. There are also quality control systems in place to ensure adherence to coding 
rules. This has led to improvements in coding quality over time in HES and LabBase2. 
2.4.4 Patient identifiers in HES 
The patient identifiers reported in HES are sex, date of birth, hospital number, NHS number 
and postcode. The completion of the identifier fields in common with the LabBase2 dataset, 
for records from children aged 0 – 5 years old and patients with an unknown date of birth (4.8 
million records) reported between 1st April 2007 and 31st March 2011, is illustrated in Figure 
2.6. Sex, date of birth and hospital number were 100% complete. NHS number completion 
varied between 91% and 97%. Patient postcode completion decreased over the four-year 
period from 65% to 51%. On closer inspection, 99% of patients with missing postcode were 
babies admitted on their date of birth; although this does not explain the decrease in 
completion over the four years, these postcodes were subsequently completed if the children 
were re-admitted to hospital after birth. As with LabBase2, patients who are not current 
residents in the UK are assigned a postcode where the prefix is “ZZ99” and the 3-digit suffix 
will denote the country or geographic area of residence; these form part of the completed 
postcode proportion in Figure 2.6.(109) Data completion does not necessarily reflect valid data 
entry as some may contain errors. 
 
 
 
 
 
 
 
 
Figure 2.6. Proportion of identifier records with a data entry for each of the five patient identifiers in 
HES between 2007/08 and 2010/11 for children aged 0-5 year 
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2.4.5 HESid – identifying patients over time 
To identify and track individual patients during the course of their IP admission, each patient is 
assigned a unique 32-character alphanumeric HES identification code (HESid) that is derived 
from the patient’s identifier information. This HESid is subsequently used to identify any future 
episodes of IP care that the patient receives within the NHS system. This identification process 
searches for a match on patient identifiers of the new admission in the HES database to see 
whether or not there has already been a HESid assigned to that patient. This is achieved by an 
integrated three-step search and matching method. 
2.4.6 HES three-step search and matching method 
For one of the processing stages, a three-pass algorithm is used in the HES database to identify 
a potential HESid match:(120) 
1. Sex AND Date of birth (partial) AND NHS number 
2. Sex AND Date of birth (partial) AND Postcode AND Hospital number within Provider 
3. Sex AND Date of birth (exact) AND Postcode* 
* Postcodes on an exclusion list are exempt from this step. This includes densely populated communal 
facilities such as prisons (Prisons for women - mothers are allowed to keep their babies with them for up 
to 18 months in a Mother and Baby Unit)(121) and hospital to avoid mismatching patients. 
In addition, patients (including foreign patients) with no permanent address in the UK are 
assigned a special postcode depending on their country of residence or their present situation. 
These postcodes begin with a prefix of ‘ZZ99’, and the suffix will indicate their resident 
location. For example, patients from the Republic of Ireland are assigned the postcode ZZ99 
3AZ.  
The HES system is programmed to recognise when there are sufficient patient identifiers to 
achieve a match. Therefore it categorises new episodes into two groups, those that have 
sufficient patient identifiers but do not match a prior HESid, and those that do not match due 
to inadequate patient identifiers in the system. The HESid allows higher probability of 
matching patients instead of solely relying one identifier, which has had varying rates of 
completion over time. There are, however, negative aspects to this process. For example, the 
algorithm uses sex for each stage of the process to assess any matches, therefore if sex is 
misclassified by mistake, a patient is assigned a new HESid regardless of the fact that the NHS 
numbers matched. 
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2.4.7 Episodes and Spells 
The HES data are made up of individual records per period of care for each patient, known as 
‘episodes’.(110) When a patient is admitted to hospital, their first HES episode is their 
‘admission episode’, which represents the majority of cases who are only in hospital for one 
episode under the care of an assigned consultant. If this consultant should change, the patient 
moves into their second episode under a different consultant. This continues until the patient 
is discharged, whereupon their last episode is their ‘discharge episode’. This whole journey 
from one hospital admission to discharge is called a ‘spell’ (Figure 2.7). 
 
 
 
 
 
 
 
 
Figure 2.7. Episodes and spells in HES  
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2.4.8 Data structure 
The HES data are formatted and stored as a line-list. Each row contains unique information 
about each hospital consultant episode for a particular patient, which describes the pathway 
of care a patient receives during their hospital stay (spell). A hospital spell can be made up of 
one or more consultant episodes depending on the number of different consultants a patient 
is assigned during the course of their treatment. For example, a patient can be in hospital for 
20 days under the care of one consultant resulting in just one row of data, or a patient can be 
in hospital for 10 days under the care of five different consultants equating to five rows of data 
that are all linked together by the HESid, admission and discharge dates. 
2.4.9 Query design for HES data extraction 
In the first instance, only the essential components required for the linkage (patient identifiers 
and HESid) were extracted from the HES database to restrict the size and processing time 
required to link the HES and LabBase2 data. Each HES IP financial year was queried in turn 
(2007/08, 2008/09, 2009/10, 2010/11) using the example query shown in Figure 2.8. 
Variables Selected for Example output 
HESid   AAA00AA0000AAAAAA0 
Patient NHS number   1111111111 
Local Patient Identifier (hospital no.)   ST22222 
Sex   M 
Date of birth  02/04/2001-31/03/2011 DD/MM/YYYY 
Patient postcode prefix   WT1  
Patient postcode suffix   3FL 
Figure 2.8. Example of the first restricted, patient identifier-only HES query (fictitious data) 
Once linked, the HES database was queried for the additional demographic and clinical 
information using the linked HESids to extract the remaining data for the analysis, and no 
additional selection were applied (Figure 2.9). 
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Variables Example output 
HESid AAA00AA0000AAAAAA0 
Patient NHS number 1111111111 
Patient hospital number ST22222 
Sex M 
Date of birth DD/MM/YYYY 
Patient postcode prefix WT1  
Patient postcode suffix 3FL 
Hospital name NORTH HOSPITAL 
Admission date DD/MM/YYYY 
Ethnicity BRITISH (WHITE) 
Episode start date DD/MM/YYYY 
Episode end date DD/MM/YYYY 
Discharge date DD/MM/YYYY 
Method of admission EMERGENCY A&E 
Source of admission USUAL RESIDENCE 
Method of discharge ON CLINICAL ADVICE/CONSENT 
Discharge destination USUAL RESIDENCE 
Died on discharge? NO 
Main specialty PAEDIATRICS 
Treatment specialty A&E 
Diagnoses 1-20 A413, R05  
Procedures 1-24 X355 
Dates of procedures DD/MM/YYYY 
Figure 2.9. Example of the second more comprehensive HES query (fictitious data) 
2.5 Data sources: considerations for linkage and analysis 
As described above, LabBase2 captures on average 80% of all positive blood specimens in 
England, with some variability by month, whereas HES captures all cases of patients admitted 
to an NHS hospital, therefore any analyses produced from using the LabBase2 data will be an 
under-representation of the true number of BSI cases. This may be due to a variety of issues 
from laboratories supressing results, to data being rejected at the data loading stage. Patient 
identifiers are more complete in HES compared to LabBase2, suggesting that not all the 
LabBase2 cases will have sufficient information to successfully link to the corresponding HES IP 
data. The comparison of linked versus unlinked LabBase2 cases was analysed to report any 
potential bias between the two groups of patients. 
In comparison, there is some recording of clinical sepsis (unconfirmed BSIs) based on the 
clinician’s medical notes in the HES database, however indicators of suspected BSI are not 
collected in any routine linkable records to create a definition for a BSI case, unless they are 
linked to a microbiology report. Clinical reports of sepsis will not be quantified in this thesis as 
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it falls outside the parameters of the analysis of the microbiology-confirmed BSI when a 
specific specimen date can be used and pathogen detected.  
2.6 Information governance: permissions to access data 
PHE is the custodian of the LabBase2 data and is required to keep all patient identifiable 
information within the confines of the PHE IT system for patient confidentiality assuredness. 
This means that no data linkage by a third party is permitted and any data linkage has to be 
performed within the PHE IT system.  
When I joined the HPA (now PHE) HCAI & AMR Department in 2008, the Department already 
had access to unidentifiable HES data via a standalone computer set up with a remote 
connection to the querying tool, Business Objects. To comply with the HPA data handling 
regulations at the time, I wrote an application to the HSCIC (formally known as the NHS 
Information Centre) and the National Information Governance Board (NIGB) on behalf of the 
HCAI & AMR department to extend our HES data handling permissions to include access to 
patient identifiable data (NHS number, hospital number, date of birth and postcode) for the 
purposes of linkage. This involved upgrading the HPA IT security system to incorporate a 
secure drive with encrypted back-up drive in-line with HSCIC standards of data protection and 
produce a security level system policy to outline and critique the handling and storage of 
patient identifiable HES data. The process took one year to complete. 
2.7 Cohort selection 
I used a retrospective four-year cohort of linked LabBase2 and HES data of children with a BSI. 
The aspects considered in the selection of the cohort and case definition are described 
individually. 
2.7.1 Cohort time period 
The cohort time period contained paediatric data where a positive blood isolate was detected 
between 1st April 2007 and 31st March 2011. This time period ensured that the most recent 
data was obtained at the time of data extraction in December 2011 (the annual HES data 
release for a particular year occurs in late October/early November of the following financial 
year) and sufficient numbers of paediatric BSI records were captured during this time (>10,000 
BSI). This time-frame allowed sufficient time to capture patients’ exposures in relation to the 
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timing of hospital admission whether they spent a short or long period in hospital. It also 
enabled the identification of previous IP exposures up to one year previously.  
The 4-year time period was also selected as the quality of LabBase2 and HES data improved in 
the most recent years, therefore restricting the potential quantity and quality of data for 
analysis. To ensure the majority of laboratory reports had been submitted to LabBase2, I 
observed a six-week lag before extracting the required LabBase2 data.  
2.7.2 Exposure period 
To capture any exposure data including chronic conditions, previous NHS hospital healthcare 
contact and invasive procedures, the exposure period prior to the first BSI per patient in the 
cohort spanned 1 year per child, with a total range of 1st April 2006 to 31st March 2011; Figure 
2.10 illustrates this timeline. The clinical and demographic exposure variables that will be 
considered in the analyses will be described in further detail in Chapter 4. 
 
 
 
Figure 2.10. Diagram indicating cohort time-period with exposure prior to the BSI  
2.7.3 Definition of a child with a BSI 
Children with a BSI were defined as having a positive bacterial blood isolate in LabBase2. 
2.7.4 Definition of a BSI index case  
A BSI index case was identified as the first positive blood culture per patient within an OPIE 
episode (14-day period) identified on or after April 1st 2007 up until and including March 31st 
2011. Any positive bacterial blood isolate found on or after the 1st April 2007, where a positive 
blood isolate for the same OPIE was also cultured before this date was not included in the 
cohort, as the infection episode would have started before the defined cohort start point. 
Examples of the inclusion and exclusion criteria for defining the BSI index case are shown in 
Figure 2.11. OPIE 1) would be accepted into the cohort, OPIE 2) would be excluded as first 
positive blood culture for that episode is outside the cohort time period, and OPIE 3) shows 
HES 2007-11
BSI index case cohort
HES 2006-07
Exposure period for patients up to 1 year before the BSI
Time
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the first being excluded and the second OPIE being included as the first (index) occurrence of a 
BSI within the cohort time period.  
Within the cohort time period, BSIs occurring between 5 days before hospital admission until 
the date of hospital discharge were considered in the analysis. A liberal 5-day cut-off prior to 
an admission was chosen to maximise the number of records in the study. Post-discharge BSIs 
were not considered if there was not a subsequent hospital admission related to the infection 
as no current admission data would be available, indicating a potential miss-match between 
the datasets. 
 
 
 
 
Figure 2.11. Examples of cohort inclusion for OPIE (1, 2, and 3) based on date of the positive blood 
isolate 
2.7.5 Treatment of discharge and re-admission on the same day 
In HES, there are occurrences of patients who are discharged and re-admitted on the same 
day. I have treated these re-admissions as the continuation of the spell because I am unable to 
quantify the time spent in the community as the time in hours is not recorded in HES. 
Therefore, I recoded the discharge date to be the last date where there is not a subsequent 
admission on the same day as that discharge date. An example of this is depicted in Figure 
2.12. 
 
 
 
 
 
Figure 2.12. Treatment of a discharge and a re-admission episodes occurring on the same day 
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2.7.6 Age 
Only patients aged between 1 month and 5 years 364 days old on the date of the positive 
blood culture were included in the cohort. I excluded children aged 0-28 days to avoid 
analysing a high proportion of neonates with vertically transmitted BSI from their mothers (e.g. 
GBS).(122) Collecting a sufficient volume of blood per sample is also technically more 
challenging in neonates as the veins are physically tiny and the quantity of circulating blood is 
small, leading to high rates of contaminated cultures.(123) 
Children with a BSI acquired in hospital (e.g. neonatal intensive care) who had never been 
discharged from the hospital since birth were also excluded. For the purposes of the PhD, 
children need to have been exposed to potential risks within the community setting in order to 
be included; otherwise the focus of the analysis may be skewed. This young age-group of 
children aged 1 month – 5 years has the largest number of reports of BSI in the paediatric 
population.(8;44;46-48)  
The upper age cut-off at 5 years and 364 days was chosen because most paediatric BSI and 
emergency hospital admissions occur in this younger age-group compared to older 
children.(44;124) Social situations (e.g. school), co-morbidities and age-related complications 
(e.g. alcohol-related, pregnancy, sexually transmitted disease) in older children differ to the 
larger concentration of congenital diseases and illnesses linked to immature immune systems 
in younger children. Limiting the cohort to this age-group also made the dataset size 
technically more manageable for the linkage process.  
2.8 Summary 
This chapter describes the content and limitations of both the LabBase2 and HES IP datasets, 
and proposes the inclusion criteria for the analysis cohort. 
Completeness of identifiers in LabBase2 is lower than that of the HES data for all patient 
identifiers, with the exception of patient postcode, especially for NHS number which is the 
most patient discriminating variable due to its unique assignment. This data completeness will 
impact on the internal de-duplication of each dataset and will also affect the ability to link the 
datasets together.  
The collection of laboratory results in LabBase2 is voluntary, and although the analysis is 
limited to reported isolate results, these reports still account for, on average, 80% of all BSI. 
From Harron et al.’s(106) findings in addition to my own research into the structure and 
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reporting of LabBase2, involving discussions with the LabBase2 database managers, I will 
assume that the non-reported data will not be biased according to pathogen but rather 
unreported at random. Additionally, I am not trying to determine overall rates of infection, but 
rather the proportion of infection according to the location where the infection was acquired. 
The cohort will capture sufficient data of children with BSIs (>10,000) over a four-year period 
and the additional explanatory variables using data from both LabBase2 and HES will be used 
to address the aim of this PhD.  
2.9 Conclusion 
This chapter has explored the strengths and weaknesses of both the LabBase2 microbiology 
and HES clinical data, which are the two national datasets that are available, accessible and 
with permission to link them within PHE, to address the aim of this thesis. Based on these 
observations, the criteria for child inclusion into the BSI cohort have been outlined and the 
explanatory variables defined for analysis. This chapter has highlighted some of the key issues 
that will need to be considered when interpreting the results of both the data linkage and the 
analysis in the following chapters. 
  
 68 
Chapter 3. Calculating match-weights to 
probabilistically link LabBase2 and HES 
datasets 
3.1 Introduction 
The linkage of LabBase2 and HES datasets is necessary to create the cohort for analysis, 
described in Chapter 2, as no other national dataset containing both microbiology and clinical 
information exists. This chapter introduces the concept of data linkage and describes the 
method of the chosen data linkage approach. The results of the linkage and the proportion of 
BSI records successfully linked will be reported, followed by a description of the subsequent 
data management that was carried out to prepare the cohort of children with BSI for the 
descriptive data analysis in Chapter 4. Figure 3.1 illustrates the context of this chapter within 
the whole thesis. 
3.2 Data linkage 
3.2.1 Growing demand 
Data linkage has progressed significantly since it was first discussed in the 19th century.(125-
130) In the past few decades, data linkage has become increasingly more popular due to the 
dramatic expansion of electronic data production and the rapid advances in technology that 
have enabled the linkage process to take place. The numbers of global publications that 
mention ‘data’ and ‘linkage’ in PubMed has increased steadily between 1990 and 2013 from 
20,000 to more than 100,000 publications per year. 
Health and social records, among others, have migrated (or are in the process of migrating) 
from paper-based to electronic recording. Electronic records enable users to locate specific 
records more efficiently and quickly on a centralised database rather than sifting through 
thousands of paper copies. In terms of healthcare, children with chronic conditions who 
require long-term treatment, benefit from linked systems that capture all their historical 
medical events so that the medical practitioner treating the present day episode of care is 
aware of the full patient history.   
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Figure 3.1. Flow diagram of the steps already addressed in previous chapters (grey), those that will be 
addressed in this Chapter (red) and the following chapters 
However, as medical systems and delivery of care are also expanding to deliver further 
specialised services, a larger number of record systems for each individual or group of services 
and the integration of this data with established data systems is becoming more 
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important.(131) In addition, the increasing ease with which people can move and relocate 
nationally and internationally highlights the importance of patient record tracing.(127-129) 
Data linkage offers a more time and cost effective approach to collecting data than the 
establishment of new data collection systems.(132;133) It is used for both establishing long-
term linkage systems and ad-hoc linkage datasets for specific research projects; however, it 
depends on the information technology available, the data collection infrastructure, data 
management skills and funding available to support the linkage work. 
3.2.2 Methods of data linkage 
In its simplest form, the desired outcome from data linkage is to successfully link two records 
from two different datasets that are a true match, meaning that a patient from dataset A 
corresponds to the same patient in dataset B. There are four main outcomes when two 
records are linked: a true-match, a false match, a false non-match, or a non-match. This is 
summarised in Figure 3.2. The aim of the linkage process is to reduce the potential error of 
false true-matches (type I error) and false non-matches (type II error) to a minimum to 
increase the sensitivity (proportion of true matches correctly identified) and specificity 
(proportion of non-matches correctly identified) of the linkage in order to avoid analysing 
incorrect data. 
 Match Non-match 
Linked True match 
False true-match 
(Type I error) 
Not-linked 
False non-match 
(Type II error) 
Non-match 
Figure 3.2. Data linkage error 
Unique or partial identifiers common to both datasets have to be present for linkage to be 
possible. There are broadly three types of methods that can be employed to link two or more 
datasets are manual, deterministic, and probabilistic linkage. 
3.2.2.1 Manual linkage 
Manual linkage can be used on small datasets and relies on human interpretation of the data. 
The benefit of this method is that the human eye can identify potential data entry errors (e.g. 
misspelt names) that computer-based only linkage may miss, depending on the level of 
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programming and incorporated algorithms. However, human error may also be introduced if a 
systematic approach is not taken or checks are not in place and the reproducibility of the 
linkage is often challenging. The technical (and practical) limiting factor of manual linkage is 
dependent on the size of the datasets, due to the time consuming nature of this process. The 
method will become more inefficient, and prone to human error as the size of the datasets 
increase, and therefore the manual method is not the most appropriate for linking the 
LabBase2 and HES records. 
3.2.2.2 Deterministic linkage 
Deterministic linkage is where the linkage process tests all the possible match-pair 
combinations using the selected common identifier(s) and returns only those where the 
identifier(s) match exactly between the data records (Figure 3.3).(134) This method has been 
adapted to allow for some variability in the data, where the matching can be done over several 
stages and is known as step-wise deterministic linkage, where if two records do not match in 
the first round, but are only different by one or two identifiers, they could be considered as a 
true match depending on the agreed threshold. 
Deterministic linkage works well for large datasets with good data completion and results in 
high sensitivity and specificity, however, this method is conservative in its matching when 
recording errors and data completion are poor, resulting in a large number of missed-matches. 
Taking this into consideration, deterministic linkage would not be the best approach to take 
with LabBase2 data considering the large proportion of missing patient identifiers (e.g. NHS 
number). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3. Diagram illustrating that when full patient identifiers are known and complete in both 
datasets, there is very high confidence in the match being true 
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3.2.2.3 Probabilistic linkage 
Probabilistic linkage uses a combination of patient identifiers to test the strength of each 
match-pair by calculating the probability of two records matching by chance by estimating the 
error and accounting for the identifier completion variability of both datasets. This allows for 
any variation in the values assigned to each patient identifier between the datasets, for 
example data entry errors or missing entries (Figure 3.4).(134;135) When two datasets are 
probabilistically linked, each record in the first dataset is matched to all potential candidate 
records in the second dataset (i.e. a single record may be matched multiple times). 
The likelihood of a true or false match is quantified by match-weights. Match-weights are 
calculated values that are assigned to each identifiable variable in the linkage process, based 
on the probability that two records should match by chance. Probabilistic linkage match-
weights are calculated from a training dataset, using the equation: match-weight=log2 (m/u), 
where ‘m’ is the probability that an identifier agrees/disagrees/is missing for records that are a 
true match and ‘u’ is the probability that an identifier agrees/ disagrees/is missing by 
chance.(134;136) 
 
 
 
 
 
 
 
 
Figure 3.4. Diagram illustrating that when patient identifiers are missing or there are data entry 
errors, there is less confidence in the match being true 
The training dataset is created from a set of true-match (m-value) pairs of patient identifiers. 
The u-values are subsequently calculated by taking the true matched records from each 
dataset and cross-matching them with each other to artificially generate false-match 
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combinations. The assumption is that the data completion of these artificially created false-
matches reflects the composition of false-matches in the real dataset. The relationship 
between the datasets used to calculate the match-weights and the datasets linked using those 
match-weights is not well reported in the literature. When the linkage occurs, each patient 
identifier (e.g. sex, date of birth) in every linked pair of records is assigned a match-weight 
depending on the type of match (e.g. agree, missing or disagree). The total match-weight 
assigned to each matched-pair is then calculated by summing the individual weight scores of 
each patient identifier: 
 
These match-weights form a spectrum of linked pairs where high match-weight scores are 
deemed to be true above a high-threshold and low match-weight scores are deemed to be 
false below the lower threshold.(134) Inevitably, due to the nature of the data completeness, 
there is often an overlap between records that are true links and those that are false, creating 
a grey area of uncertainty between the true and false links (Figure 3.5). It is then up to the data 
analyst to decide on a threshold, where they accept all the matches equal to and above a 
particular match-weight into the final dataset. This can be done by manually reviewing the 
match-pairs between a conservative threshold (accepting only definite true links without 
including potential false links) that increases the specificity, to a more liberal threshold 
(capturing more of the true links but more false links) that increases the sensitivity but lowers 
the specificity. The threshold selection is subjective and may therefore differ between persons 
linking the data. Upper and lower thresholds for sensitivity analyses can also be defined. 
 
 
 
 
 
 
 
 
Figure 3.5. Range of possible probabilistic linkage thresholds 
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3.2.3 Data linkage in the UK 
Unlike its neighbouring countries, England currently does not have an established national 
data linkage system that routinely links multiple datasets. Both Scotland and Wales have their 
own national linkage systems. Since the 1970s, the Scottish Health Informatics Programme has 
been Scotland’s comprehensive linkage platform [www.scot-ship.ac.uk] made possible by the 
high data completion (93%) of Scotland’s Community Health Index (CHI) number, similar to the 
NHS number. All linkage processes are based on using deterministic linking for patient data 
with a CHI number because data completion is very high and probabilistic linkage for those 
who do not possess a CHI number.(137) The Welsh Secure Anonymised Information Linkage 
databank uses a trusted third party to anonymise and encrypt the datasets on their behalf 
before any data linkage occurs.(138)  
An example of one of the largest regional linkage programmes in England is the Oxford Record 
Linkage Study.(139) Although no longer functional today, the original aim was to link mortality 
and hospital discharge data using NHS number alone; however, the inconsistent completion of 
NHS numbers did not provide a sufficient linkage rate. Instead, probabilistic linkage was used 
to link a wider range if identifying characteristics.(140) Administrative data are very likely to 
contain incomplete or erroneous identifiers indicating a need for probabilistic linkage to 
support epidemiological surveillance and public health policy to inform current and new 
policies. 
3.2.4 Chosen linkage method 
I chose to link the LabBase2 and HES datasets using probabilistic linkage given the sub-optimal 
patient identifier completion found in LabBase2 in Chapter 2 as well as potential data entry 
errors that may be present in such large surveillance and administrative datasets.  
There was no established and validated training dataset for child cases in LabBase2 and HES 
and no external validation dataset is readily available. There was, however, an established and 
validated dataset for calculating match-weights for the probabilistic de-duplication of new 
microbiology records that are submitted to LabBase2. These match-weights were calculated 
from patients of all ages with a positive microbiology result in LabBase2, referred to as MW-All 
from now on.(141)  
Initially, I was only going to use the established match-weights derived from the LabBase2 
database to link the 4-year LabBase2 and HES datasets because the match-weights had been 
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validated, were readily available and would be a quick solution. I decided to investigate the 
creation of new match-weights that would take into account the patient identifier completion 
in HES, as well as calculating child specific match-weights. Adapting the match-weights to the 
specific datasets was inspired from other HPA data linkage work to a different external 
dataset, although a slightly different methodology was undertaken in this thesis.(142) A new 
set of match-weights was therefore created from a linked LabBase2 and HES training dataset 
and will be referred to as MW-Child from now on. 
3.3 Methods: determining probabilistic match-weights 
3.3.1 Patient identifiers 
Five patient identifiers (deconstructed into eight individual parts) common to both the 
LabBase2 and HES data were used to calculate the MW-Child and MW-All match-weights: NHS 
number, hospital number, sex, patient postcode (divided into prefix and full postcode) and 
date of birth (divided into three parts: day, month, and year). 
3.3.1.1 NHS number 
An NHS number is uniquely assigned to a patient receiving NHS treatment for their whole 
lifetime. A pair-wise match on NHS number should therefore indicate a high confidence in the 
probability that two records match. There are of course some caveats to consider such as 
twins or siblings NHS numbers that may be switched in error when attending hospital. 
3.3.1.2 Hospital number 
Hospital number is considered a strong patient identifier, although not to the same extent as 
an NHS number due to the ability to uniquely distinguish patients within one hospital, not 
between hospitals. Therefore, patients may also be assigned multiple hospital numbers. 
3.3.1.3 Postcode 
The average residential postcode in England encompasses 15 households.(143) The probability 
of matching on a less specific area is greatly increased if the suffix has been incorrectly entered 
or is missing, which is why the postcode is split into the prefix only and full postcode for 
matching, to account for any data entry errors of the suffix code. 
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3.3.1.4 Sex 
There are three possible entries for sex where the patient is either male, female, or the sex is 
unknown/not entered and is therefore a weak identifier in isolation. 
3.3.1.5 Date of Birth 
The date of birth is a very important variable. This does not uniquely distinguish patients, but is 
generally well completed and helps to increase the odds of a true match between two records. 
However, data entry errors can occur where the month and date may be accidentally 
switched, for example, from the 05/06/2005 to the 06/05/2005.  
I included laboratory records of patients with a missing date of birth to reduce selection bias 
due to missing data. This inevitably introduced a proportion of adult microbiology records, but 
these records were removed at the linkage stage when no matches with the HES data were 
identified. 
3.3.2 PHE match-weights for all ages (MW-All) 
The MW-All were taken directly from the probabilistic methodology written by A. Grant and 
were published internally within the HPA (now PHE), as described in Chapter 2.(141) The MW-
All were calculated and refined over several years by counting the observations in the data for 
a 12-month period (e.g. 901,046 OPIE records in 2009) after blocking on organism species 
using data held in LabBase2. There were several limitations and the potential introduction of 
bias when using this method: 
1. The MW-All set would not take into account the completion and data quality found 
within the HES dataset. 
2. The MW-All would not necessarily be sensitive to linking child-only records, which may 
require different weighting priorities compared to the whole population, for example, 
a smaller number of possible date of birth combinations. 
3. Soundex, initials, forename or surname are additional variables collected in LabBase2 
that are not collected by the HES database. The exclusion of these variables from the 
total match-weight value may have an impact on the final match-weight to link 
LabBase2 and HES. 
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3.3.3 Calculation of child match-weights (MW-Child) 
3.3.3.1 Training dataset 
The true matches (𝑥=15,046; confirmed by manual review) were selected from a previously 
linked LabBase2 and HES dataset (children aged 1 month – 18 years with a BSI between 
January 2009 and March 2010).(144) Match-weights were calculated from this dataset using 
the following equation:(134;136) 
 𝑚𝑎𝑡𝑐ℎ − 𝑤𝑒𝑖𝑔ℎ𝑡 = log2 (
𝑚
𝑢
) 
𝒎 = Probability that the patient identifier Agrees, Disagrees, or is Missing in at least one dataset given 
that the record is a true match (𝑥) 
𝒖 = Probability that the patient identifier Agrees, Disagrees, or is Missing in at least one dataset by 
chance given that the record is a false match (𝑁 − 𝑥) 
3.3.3.2 Worked example of calculating match-weights 
The following scenario (using a dummy dataset) illustrates the method of match-weight 
calculation for a variable. In this example, the true-match dataset has six records (Figure 3.6). 
 
 
 
 
Figure 3.6. Example dataset containing true-matches 
The ′𝒎′ value was calculated for outcome: 
𝐴𝑔𝑟𝑒𝑒       =  4 6⁄ = 0.67 
𝐷𝑖𝑠𝑎𝑔𝑟𝑒𝑒 =  1 6⁄ = 0.17 
𝑀𝑖𝑠𝑠𝑖𝑛𝑔   =  1 6⁄ = 0.17 
The ′𝒖′ values were calculated by cross-matching the Lab_ID and HES_ID variables to obtain 
the total 30 false-matches (in white, Figure 3.7).  
 
Lab_ID HES_ID Lab_variable HES_variable match 
1 1 F F 
2 2 M F x 
3 3 . M missing 
4 4 M M 
5 5 F F 
6 6 M M 
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Lab_ID HES_ID Lab_variable HES_variable match 
1 1 F F 
1 2 F F 
1 3 F M x 
1 4 F M x 
1 5 F F 
1 6 F M x 
2 1 M F x 
2 2 M F x 
2 3 M M 
2 4 M M 
2 5 M F x 
2 6 M M 
3 1 . F missing 
3 2 . F missing 
3 3 . M missing 
3 4 . M missing 
3 5 . F missing 
3 6 . M missing 
4 1 M F x 
4 2 M F x 
4 3 M M 
4 4 M M 
4 5 M F x 
4 6 M M 
5 1 F F 
5 2 F F 
5 3 F M x 
5 4 F M x 
5 5 F F 
5 6 F M x 
6 1 M F x 
6 2 M F x 
6 3 M M 
6 4 M M 
6 5 M F x 
6 6 M M 
Figure 3.7. Dataset containing true-matches (grey) and false-matches (white) 
The ′𝒖′ value was calculated for each outcome: 
𝐴𝑔𝑟𝑒𝑒  𝑏𝑦 𝑐ℎ𝑎𝑛𝑐𝑒      =  11 30⁄ = 0.37 
𝐷𝑖𝑠𝑎𝑔𝑟𝑒𝑒 𝑏𝑦 𝑐ℎ𝑎𝑛𝑐𝑒 =  14 30⁄ = 0.47 
𝑀𝑖𝑠𝑠𝑖𝑛𝑔 𝑏𝑦 𝑐ℎ𝑎𝑛𝑐𝑒   =     5 30⁄ = 0.17 
The ′𝒎′ and ′𝒖′ values were then used to calculate the match-weight for pairs of the linked 
variable: 
𝐴𝑔𝑟𝑒𝑒       = log2 (
0.67
0.37
) = 0.86 
𝐷𝑖𝑠𝑎𝑔𝑟𝑒𝑒 = log2 (
0.17
0.47
) = −1.47 
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𝑀𝑖𝑠𝑠𝑖𝑛𝑔   = log2 (
0.17
0.17
) = 0 
 
3.4 Results: determining probabilistic match-weights 
The results of the true-matches, false-matches and missing data matches for MW-All and MW-
Child are shown in Table 3.1. The MW-All values for missing data were all negative or neutral, 
whereas MW-Child contained a few positive values apart from NHS number, although these 
were very small values. 
The radar plots in Figure 3.8, Figure 3.9 and Figure 3.10 depict the proportional contribution of 
each patient identifier’s match-weight to the total match-weight for patient identifier pairs 
that agree, disagree or have missing data. Each octagon represents the total match-weight 
(100%); the position of each of the octagon’s vertices on the radar’s scale indicates the 
proportional weight that each patient identifier contributes to the total match-weight. 
For the ‘agree’ match-weights (Figure 3.8), the octagon distribution on each point was very 
similar for both MW-Child and MW-All: NHS number (21% vs. 28%), full postcode (20% vs. 
23%) and hospital number (19% vs. 22%) were the most important patient identifiers when 
there was agreement between two linked records, each receiving a large, positive match-
weighting. More proportional weighting was given to date of birth and postcode prefix for the 
MW-Child than MW-All. Overall, sex had a very low contribution to the ‘agree’ weighting for 
both match-weight sets (1-2%). 
More variance was observed for the ‘disagree’ irregular MW-Child octagon (Figure 3.9) 
compared to the MW-All octagon for all eight variable parts. Disagreement on hospital number 
had the largest disparity between MW-Child (3%) and MW-All (14%), followed by date of birth 
(MW-Child: 18-20%; MW-All: 14%), NHS number (MW-Child: 18%; MW-All: 14%) and sex.  
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Table 3.1. Match-weights for each patient identifier for MW-All and MW-Child 
  Patient identifier MW-All MW-Child 
Agree 
NHS number. 25.8355709 11.4268567 
Sex 0.9985551 0.9719587 
Hospital number 20.2779856 10.1814387 
Date (DD) of birth 4.9040985 4.9072601 
Month (MM) of birth 3.5823147 3.5718076 
Year (YYYY) of birth 4.3895666 3.3975976 
Postcode prefix 11.5586405 8.6782742 
Full postcode 21.1731814 10.6009714 
        
    MW-All MW-Child 
Disagree 
NHS number -7.962896 -9.7328087 
Sex -6.962896 -7.5634034 
Hospital number -7.9628949 -1.4093752 
Date (DD) of birth -7.9139864 -9.7375195 
Month (MM) of birth -7.8373651 -10.9430663 
Year (YYYY) of birth -7.8925067 -10.7333376 
Postcode prefix -4.6142411 -2.6771329 
Full postcode -4.6147092 -1.8666664 
    
      MW-All MW-Child 
Missing 
NHS number -0.6311791 -0.3494677 
Sex -0.0377842 0 
Hospital number -8.450181 0.0003828 
Date (DD) of birth 0 0 
Month (MM) of birth 0 0 
Year (YYYY) of birth 0 0 
Postcode prefix -0.4586327 0.01486 
Full postcode -0.4586327 0.0141547 
                MW = Match-weight 
The proportional weight distribution assigned to linked pairs with missing data was different 
for both sets of match-weights (Figure 3.10). The majority for MW-All (84%) was focused on 
the hospital number, receiving a large penalty (-8.45; Table 3.1) to the total match-weight. 
Although a small combined reduction (-0.34), the proportionally largest (92%) penalty for a 
missing value for MW-Child was NHS number (Figure 3.10). 
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Figure 3.8. Agree match-weights: Radar plot overlaying the sets of match-weights and comparing the 
proportion that each of the eight individual patient identifiers contributes towards the sum of the 
total match-weight (100%). DD = 2-digit day of birth; MM – 2-digit month of birth; YYYY = 4-digit year 
of birth; MW = match-weight 
 
 
 
 
 
 
 
 
Figure 3.9. Disagree match-weights: Radar plot overlaying the sets of match-weights and comparing 
the proportion that each of the eight individual patient identifiers contributes towards the sum of the 
total match-weight (100%); DD = 2-digit day of birth; MM – 2-digit month of birth; YYYY = 4-digit year 
of birth; MW = match-weight 
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Figure 3.10. Missing data match-weights: Radar plot overlaying the sets of match-weights and 
comparing the proportion that each of the eight individual patient identifiers contributes towards the 
sum of the total match-weight (100%); DD = 2-digit day of birth; MM – 2-digit month of birth; YYYY = 
4-digit year of birth; MW = match-weight  
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3.5 Methods: probabilistic linkage of LabBase2 and HES 
The extraction of HES data was based on child’s age at date of admission between birth and 5 
years of age. Although the cohort inclusion criteria only included BSIs occurring between 1 
month and 5 years of life, children less than 1 month old were included in the HES extract 
because the child’s date of admission may have been within the first four weeks of life prior to 
the BSI. 
All the LabBase2 patient identifiers were linked twice using MW-All and MW-Child to each of 
the four financial HES years, as show in Figure 3.11. In-house software to link the datasets was 
developed using Python (version 2.7.2). Figure 3.12 illustrates the computational procedure of 
the full probabilistic linkage methodology which was executed within PHE’s Department of 
HCAI & AMR, Colindale, by the database manager (Dr. Mehdi Minaji). Due to the vast size of 
the data being linked, extra server space and computational power was required for the 
linkage process to be a success. The linkage for each of the two sets of match-weights was 
performed separately, taking three days to run each match-weight set. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.11. Linkage of all the LabBase2 data to each individual year of HES data 
LabBase2
• First positive blood specimen taken 
between 01.04.2007 & 31.03.2011
• Children aged 0-5 years old 
HES_2007-08
• All In-patient 
episodes between 
01.04.2007 & 
31.03.2008 
• Children aged 0-5 yrs
HES_2008-09
• All In-patient 
episodes between 
01.04.2008 & 
31.03.2009 
• Children aged 0-5 yrs
HES_2009-10
• All In-patient 
episodes between 
01.04.2009 & 
31.03.2010 
• Children aged 0-5 yrs
HES_2010-11
• All In-patient 
episodes between 
01.04.2010 & 
31.03.2011 
• Children aged 0-5 yrs
Link
Link Link
Link
LabBase2 = HES links
2007-2011
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Figure 3.12. Computational challenges involved with probabilistic linkage of LabBase2 and HES data 
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3.5.1 Threshold selection 
The match-weight threshold for MW-All and MW-Child were selected by manual review. All 
pairs were reviewed if there were ≤100 linked pairs, or a random sample of 100 linked pairs 
was selected if there were >100 linked pairs for a match-weight (range: 101 pairs to 79 million 
pairs). The reviewed match-weights ranged from the highest positive match-weight to a 
match-weight of -10, where negative match-weights strongly suggest the linked pairs are not a 
true match. To ensure high specificity, the threshold was selected just above the highest 
match-weight for which definite false matches were identified. The thresholds were selected 
separately for MW-All and MW-Child [match-weight >12.65], without any cross-comparison. 
The highest match-weight for each OPIE above the respective thresholds was retained. The 
proportion of linked (above threshold) versus unlinked (below threshold) OPIEs and the 
characteristics of these links by year, region and patient identifier completion were compared 
using chi-square tests and according to age (continuous) using a t-test for both MW-All and 
MW-Child.  
As the distribution of linked pairs is heavily dependent on the selected threshold, a sensitivity 
analysis using a higher threshold was selected for both sets of match-weights at the point 
where all matches were considered true. STATA (v13) was used in the manipulation of the 
data.(145) 
3.6 Results: probabilistic linkage of LabBase2 and HES 
The linkage process resulted in the creation of millions of linked pairs from the fixed number of 
LabBase2 and HES records, with an exponential increase in the number of links where the 
match-weight value decreased (suggesting less evidence of a true match), a large proportion 
resulting from links where identifiers were either missing or did not match. The manual review 
classification of linked pairs per match-weight (considered true, uncertain or false) are 
summarised in Figure 3.13 and Figure 3.14. The match-weight thresholds were selected where 
all match-weights >14.17 for MW-All and >12.65 for MW-Child were retained. There was a 
significant increase in the number of OPIEs linked by both MWs between 2007 and 2011 
(P<0.001). 
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Figure 3.13. Distribution of the total number of linked pairs per match-weight considered as true, uncertain or false matches using the MW-All in relation to the chosen 
threshold (selected via manual review) 
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Figure 3.14. Distribution of the total number of linked pairs per match-weight considered as true, uncertain or false matches using the MW-Child in relation to the chosen 
threshold (selected via manual review) 
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Of the total 21,074 OPIEs that could have been linked, MW-Child linked a total of 17,141 OPIEs 
(81.4%) and MW-All linked a total of 17,166 OPIEs (81.6%; Table 3.2). Of the 17,243 linked 
OPIEs, MW-Child and MW-All both linked the same 17,064 OPIEs (99%); MW-All linked 102 
unique OPIEs that were not linked using the MW-Child method and the MW-Child linked 77 
unique OPIEs that were not linked using the MW-All method (Figure 3.15).  
Table 3.2. Number and proportion of linked OPIEs for MW-All and MW-Child per year for children 
aged 1 month – 5 years in England 
 No. of OPIEs (%) 
Total 
 
2007/08 2008/09 2009/10 2010/11 
No. of OPIEs linked using MW-All 4,337 4,123 4,316 4,390 17,166 
(% linked) (76.7%) (80.7%) (84.2%) (84.7%) (81.6%) 
No. of OPIEs linked using MW-Child 4,336 4,122 4,307 4,376 17,141 
% linked (76.7%) (80.6%) (84.1%) (84.4%) (81.4%) 
Total no. of OPIEs prior to linkage 5,654 5,111 5,124 5,185 21,074 
* OPIE = Organism Patient Illness Episode 
 
 
 
 
Figure 3.15. Number of unique and mutual OPIEs and HESid linked pairs for the MW-All and MW-Child 
3.6.1 Comparison of linked and unlinked OPIEs 
Table 3.3 summarises the total number of OPIEs from LabBase2 that were not linked, 
compared to those that were linked by both MW-Child and MW-All, MW-Child only or MW-All 
only by year, age, region and patient identifiers. Of the patient identifiers, the completion of 
NHS number, hospital number, date of birth and postcode in the linked records was 
significantly higher than in the unlinked records (P<0.001). There was also regional variation 
between the linked and unlinked OPIEs (P<0.001), although among the linked OPIEs, 59 OPIEs 
for MW-Child and 58 OPIEs for MW-All were reported from Welsh laboratories. 
Of the unlinked OPIEs using both MW-Child and MW-All (n=3831), 15% (n=562) were reported 
from laboratories in Wales, the Channel Islands and the Isle of Man, which are geographical 
regions where clinical hospital data is not captured by HES. Of the remaining unlinked OPIEs 
(n=3,269), 34% (n=1,313) were missing date of birth and 87% (n=2,858) were missing NHS 
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number. The missing date of birth records may represent records from a mixture of children 
and adults because no other age proxy was available. This suggests that the actual proportion 
of unlinked child OPIEs is smaller than the total reported in Table 3.3, however, this cannot be 
validated. Where data were reported, there were no statistically significant differences by age 
(t-test, P=0.281) or sex (Chi2, P= 0.054) between the linked and unlinked OPIEs.  
3.6.2 Sensitivity analysis 
For the sensitivity analysis where the threshold was selected at the match-weight above the 
highest uncertain square linked pairs (Figure 3.13 and Figure 3.14), a total of 16,398 (77.8%) of 
the 21,074 OPIEs were linked for MW-Child, and 17,102 (81.1%) for MW-All. Of these, both 
methods linked the same 16,398 OPIEs, highlighting the agreement of the true-match 
weighting between both methods; however, 704 unique OPIEs were linked only by MW-All. To 
avoid reducing the numbers of linked pairs, the original thresholds were maintained for the 
rest of the analysis. 
To compare deterministic linkage (using NHS number only) to probabilistic linkage, 25% more 
OPIE records were linked using the probabilistic linkage MW-Child method (81%, 
n=17,141/21,074 OPIEs) than would have been linked if deterministic linkage had been used 
(58%, n=12,212/21,074 OPIEs). 
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Table 3.3. Number of OPIEs successfully linked to HES data using MW-All and MW-Child out of the 
total number OPIEs extracted from LabBase2 for children aged 1 month–5 years with a BSI, England 
    Total 
OPIEs 
No. not linked 
MW-Child & 
MW-All 
MW-
Child 
MW-All 
Variables n % n % n % n % 
Total 21,074 3,831 18 17,064 81 77 0 102 0 
Year     
 
            
  2007/08 5,654 1,295 23 4,314 76 22 0 23 0 
  2008/09 5,111 966 19 4,100 80 22 0 23 0 
  2009/10 5,124 784 15 4,283 84 24 0 33 1 
  2010/11 5,185 786 15 4,367 84 9 0 23 0 
Age     
 
            
  1m<1y 9,196 1,122 12 8,013 87 44 0 17 0 
  1<2y 3,715 472 13 3,204 86 15 0 24 1 
  2<3y 2,298 310 13 1,973 86 9 0 6 0 
  3<4y 1,898 222 12 1,666 88 7 0 3 0 
  4<5y 1,450 195 13 1,251 86 0 0 4 0 
  5<6y 1,028 137 13 884 86 2 0 5 0 
  missing 1,489 1,373 92 73 5 0 0 43 3 
Region     
 
            
  East Midlands 1,162 121 10 1,034 89 7 1 0 0 
  East of England 1,991 357 18 1,584 80 15 1 35 2 
  London 5,072 749 15 4,288 85 21 0 14 0 
  North East 968 70 7 895 92 0 0 3 0 
  North West 2,611 363 14 2,230 85 9 0 9 0 
  South East 3,203 638 20 2,555 80 1 0 9 0 
  South West 1,233 152 12 1,056 86 7 1 18 1 
  West midlands 1,990 519 26 1,457 73 8 0 6 0 
  Yorkshire & the Humber 2,223 300 13 1,907 86 8 0 8 0 
  Wales 609 550 90 58 10 1 0 0 0 
  CI & IOM* 12 12 100 0 0 0 0 0 0 
NHS number     
 
            
  complete 12,843 614 5 12,210 95 2 0 17 0 
  missing 8,231 3,217 39 4,854 59 75 1 85 1 
Hospital number   
 
            
  complete 18,556 2,977 16 15,416 83 66 0 97 1 
  missing 2,518 854 34 1,648 65 11 0 5 0 
Date of Birth     
 
            
  complete 19,585 2,458 13 16,991 87 77 0 59 0 
  missing 1,489 1,373 92 73 5 0 0 43 3 
Postcode prefix   
 
            
  complete 14,953 996 7 13,857 93 77 1 23 0 
  missing 6,121 2,835 46 3,207 52 0 0 79 1 
Full postcode     
 
            
  complete 14,834 952 6 13,782 93 77 1 23 0 
  missing 6,240 2,879 46 3,282 53 0 0 79 1 
Sex     
 
            
  Female 8,569 1,266 15 7,231 84 28 0 44 1 
  Male 11,286 1,557 14 9,622 85 49 0 58 1 
  Unknown 1,219 1,008 83 211 17 0 0 0 0 
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3.7 Results: Association between MW-All and MW-Child 
The bubble chart in Figure 3.16 summarises the relationship between linked pairs of records 
using MW-All and MW-Child and the number of links (size of the circle is proportional to the 
number of links: the smallest circle = 1 linked pair; the largest circle = 79 million linked pairs) 
assigned to each respective match-weight combination. The selected thresholds for each set of 
match-weights are also depicted. Only links where at least one match-weight was above zero 
are shown in the bubble chart. I considered any linked pair with a match-weight of zero or 
above to have some positive attribute that should be investigated. 
For linked pairs that received a negative match-weight in both MW-Child and MW-All, they 
were considered to indicate poor agreement with insufficient completion of patient identifier 
data or disagreeing linked pairs. There was a positive correlation between the distributions of 
linked pairs and assigned match-weights although some variability in the assignment of match-
weights was visible. Of particular interest were those links above the threshold for one MW 
and below for the other. For example, linked pairs with a MW-All of 12.2 (below the MW-All 
threshold) and MW-Child of 17.9 (above the MW-Child threshold) accounted for 75 linked 
OPIEs, meaning that MW-All would not incorporate these 75 OPIEs that MW-Child considers as 
true-matches into the final dataset. There were few examples where the match-weights had 
very different results. For example, the highest MW-All value assigned a negative MW-Child 
value (-9.82) had a match-weight value of 16.4. The three linked pairs with a match-weight of 
16.4 would be considered true matches if the MW-All weighting methodology was chosen, 
whereas the reverse would be true if the MW-Child weighting was chosen. 
The core differences between the match-weights are reflected by the different characteristics 
of the linked MW-All only or MW-Child only records. Forty-three (3%, 95% CI: 2.1-3.8%) OPIEs 
for patients with missing age (i.e. no date of birth) were linked using the MW-All, whereas 
MW-Child did not link any additional OPIEs where patients were missing date of birth. The 77 
MW-Child only links had completed postcode but had a very low NHS number completion 
(n=2, 3%) compared to MW-All (n=17, 17%). Hospital number completion in both was high 
(84%), which was particularly noticeable for MW-All where the negative weight of -8.45 (Table 
3.1) for missing hospital number would lower the overall weight of any linked pairs with this 
weighting. The majority (57%) of linked records using the MW-Child were from children aged 1 
month < 1 year. There was also a significant variation between linked pairs resulting from 
either MW-Child or MW-All linkage according to region where twice as many cases from the 
East of England and the South-West were linked by MW-Child (P=0.001). 
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Figure 3.16. The number of linked pairs (denoted by the size of each circle) for MW-All compared to MW-Child and their relative assigned match-weights before the 
selection of the highest match-weight per OPIE 
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3.8 Final match-weight set selection 
After comparing MW-All and MW-Child, I decided to select the MW-Child results. Firstly, the 
MW-Child acknowledged and incorporated the data qualities of the HES data, accounting for 
data completion that the MW-All would not. Secondly, although there were some differences 
between the MW-All and MW-Child outputs, there was very little difference in the numbers of 
total linked record pairs, which in this instance would not vastly impact on the results. Thirdly, 
the MW-Child was focused on the child population and incorporating the data completion 
values in HES, which MW-All did not.  
3.8.1 Data management and preparation of linked cohort for analysis 
The highest match-weight link for each OPIE was selected to be taken forward for the analysis. 
The flow diagram in Figure 3.17 outlines the numbers of observations, OPIEs and HESids at 
each stage of the data selection, cleaning, linking and manipulation process and the reasons 
why some observations were removed from the final analysis dataset; the aim was to get a 
final dataset with one row per paediatric patient, where only the index BSI per patient during 
the four year period was recorded. 
I excluded children (n=1,618) who had been in hospital since birth and who had not been 
discharged from hospital before developing a BSI. The rationale for this was that they had no 
possibility of acquiring a BSI in a setting other than in hospital. I also excluded patients who 
had a positive blood specimen after discharge from hospital but who were not subsequently 
re-admitted to hospital (n=200). 
This resulted in a total of 10,606 children with BSI due to 11,319 bacterial pathogens. 
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Figure 3.17. Flow diagram of LabBase2, good-links patient identifiers and HES data linkage, processing, 
manipulation and cleaning.  
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OPIEs 4,772
HESids 3,605
Obs 32,536 Obs 12,931
OPIEs 32,536 OPIEs 6,454
HESids 5,708
2008-09 Single
Obs 3,384
OPIEs 1,911
HESids 1,926
2008-09 Multi
Obs 8,969
OPIEs 4,809
HESids 3,802
Obs 13,253
OPIEs 6,571
HESids 5,728
2009-10 Single
Obs 2,056
OPIEs 1,839
HESids 1,797
2009-10 Multi
Obs 10,980
OPIEs 5,197
HESids 4,093
Obs 13,036
OPIEs 6,927
HESids 5,890
2010-11 Single
Obs 2,022
OPIEs 1,803
HESids 1,769
2010-11 Multi
Obs 11,087
OPIEs 5,156
HESids 4,159
Obs 13,109
OPIEs 6,865
HESids 5,928
2007-08 Multi HESids links to OPIE
Append 2007-08 S+M
Remove duplicates
select 1st specimen date per OPIE
HES data
Good-links >12.65
Sorted order for
2007-08 Single HESids links to OPIE
LabBase2 data Good-Links (Patient Identifiers only)
Append 2008-09 S+M
Append 2009-10 S+M
Append 2010-11 S+M
Children aged 0-5 years & patients 
with no date of birth
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Figure 3.17 (cont.) Flow diagram of LabBase2, good-links patient identifiers and HES data linkage, 
processing, manipulation and cleaning.  
Obs* 52,184
OPIEs 25,705
HESids 21,905
HES searched for 
clinical data
21,905
Hospital Episodes 172,541
HESids 21,905
Observations dropped 16,358
Remaining obs 35,826
OPIEs 25,705
HESids* 20,696
Merged 1:m
Obs 32,536 Obs 35,826
OPIEs 32,536 OPIEs 25,705
Un-linked OPIEs 6,831 Un-linked OPIEs 6,831
Obs 512,825
OPIEs 25,705 Hospital Episodes 172,541
HESids* 20,696 HESids 21,905
Un-linked HESids 1,209
Obs 60,032
OPIEs 8,432
HESids 7,605
Obs 13,426
OPIEs 171
HESids 112
Obs 439,367
OPIEs 17,102
HESids 13,610
No. OPIEs 228
No. Hesids 3,118
Of the OPIEs above:
Private patient, all HESids same 
person
106
Same patient for all HESids 54
Only 1 correct HESid link 38
No correct link on manual 
inspection; delete 
30
HES data
Append 2007-11
Joinby 
HESids
Joinby HES data
Remaining numbers after removing children 
aged <1 month & >5 years
Identify OPIEs that link to multiple HESids - 
are these the same patient or are multiple 
different people linked?
LabBase2 data Good-Links (Patient Identifiers only)
Returned from HES database:
keep highest weight per OPIE
*lost 1,209 HESids at lower weighting
Remove children <1 mth @time of BSI
Remove children>5 yrs @time of BSI
Merge in LabBase2 data
*Obs are high because contains specimen 
dates so that all PII for each date had the 
chance to be matched
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Figure 3.17 (cont.) Flow diagram of LabBase2, good-links patient identifiers and HES data linkage, 
processing, manipulation and cleaning.  
Private patient, all HESids same 
person
Same patient for all HESids 93 HESids 
changed
Only 1 correct HESid link
No correct link on observation, 
delete OPIEid+Hesid links
30 OPIEs + 
78 HESids 
dropped
Obs remaining 438,674
OPIEs 17,072
HESids 12,829
Obs remaining 428,679
OPIEs 16,441
HESids 12,424
Obs remaining 253,281
OPIEs 13,512
HESids 12,424
Obs 13,512
OPIEs 13,512
HESids 12,424
Obs 12,424
OPIEs N/A**
HESids 12,424
Obs 10,806
HESids 10,806
Obs 10,606
HESids 10,606
Format dataset so that only one row per 
HESid (child)
LabBase2 data Good-Links (Patient Identifiers only) HES data
571 HESids 
changed
39 HESids 
dropped
**data distributed within HESid row if more 
than one OPIE pathogen isolated per patient
Created new HESid1 variable merged 
different HESids for same person into 1 to 
avoid later confusion, which is why number 
has reduced so much
Keep if Specimen date between -5 before 
admission to +5 after discharge
Format dataset so that only one row per OPIE
Keep only the first BSI specimen date per 
HESid
Remove children who had not been 
discharged from hospital since birth before 
developing a BSI
Remove children with a positive blood 
specimen after discharge from hospital with 
no re-admission to hospital
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3.8.2 Final distribution of links by MW-Child 
Figure 3.18 illustrates the final highest match-weight assigned to each linked pair of the 12,424 
de-duplicated LabBase2 and HES observations for children aged 1 month – 5 years that was 
reached in Figure 3.17. The majority (97%) of the match-weights are above the weight of 20, 
which is comfortably above the >12.65 threshold. 
 
 
 
 
 
 
 
 
Figure 3.18. MW-Child distribution of the highest match-weight assigned to each linked LabBase2 and 
HES pair of records for children aged 1 month – 5 years, April 2007 – March 2011 
3.9 Discussion 
3.9.1 Limitations 
Data linkage errors (type I and type II errors) can occur and introduce bias into the 
results.(146) The selected threshold was not expected to contain any false matches (even 
though some true or uncertain matches would also have not been included) was used to strike 
a balance between having high specificity and having the largest possible cohort. 
Using the highest match-weight pair per OPIE combination may also have some limitations in 
the analysis of the linked data. The analysis of not just the highest match-pair, but the 
subsequent pairs with lower match-weights above the threshold may offer more information 
as to the probable true matches. Alternatively, the enhancement of patient identifiers using 
multiple imputation may help to improve the accuracy of the data linkage.(147;148) However, 
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due to the enormity of the separate analyses required, these approaches were not employed 
for this thesis. 
To enhance the linkage process of MW-Child, field-specific weightings could have been 
included, which would have taken into account the relative frequency of each of the 
observations within a field. Zhu et al. argue that a match-weight score assigned to an agree-
match should be different depending on whether those matching values are common or 
not.(149) For example, the frequency of the ‘ZZ99’ postcode prefix, denoting a patient without 
current UK residence, occurs more frequently than a specific geographical postcode (i.e. 
‘ME14’ prefix) and therefore the ‘ZZ99’ should be awarded a lower match-weight score for two 
agreeing linked-pairs than in the case of the ‘ME14’ prefix. 
3.9.2 Summary 
Over 80% of all the OPIEs of children with a BSI between April 2007 and March 2011 were 
successfully linked, and 99% of those OPIEs were linked by both MW-Child and MW-All, 
demonstrating a high level of similarity in the final cohort selection. This is the first time that 
match-weights have been calculated to probabilistically link paediatric LabBase2 and HES data. 
The majority of the disparity between MW-Child and MW-All stemmed from the ‘disagree’ and 
‘missing’ match-weights, which was reflected by the linked pairs that were either linked by 
MW-Child or MW-All. Date of birth was more important for the linkage using the child-only 
population (MW-Child) than the whole population (MW-All), which may be because the age-
group in the whole population with the majority of reported BSIs are those aged 65 years and 
over and these match-weights are calculated from a dataset that is less sensitive for linking 
child-only records. 
This chapter has explained and demonstrated the probabilistic linkage employed to link the 
LabBase2 and HES data. Although there was only a small difference between the linkage of 
MW-All and MW-Child, MW-Child linked data best represented the LabBase2 and HES datasets 
as well as the child population and was therefore selected as the chosen set of match-weights 
to probabilistically link the datasets. 
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Chapter 4. Clinical and demographic 
characteristics of children with a BSI 
4.1 Introduction 
The literature review in Chapter 1 demonstrated that the timing of BSI alone no longer 
provides sufficient information to predict the likely invasive pathogen as a result of the 
increasing mix of pathogens isolated from children on admission to hospital with CA and HCA 
BSI.(8;61;62;65-68;71) The aim of this PhD is to determine whether clinical characteristics from 
hospital records in England, in addition to the timing of blood sampling in relation to 
admission, can be used to predict the likely source of infection and the pathogen to inform 
strategies to prevent and treat BSI. This chapter aims to quantify the baseline characteristics of 
children with BSI and identify potential risk factors captured in administrative data that might 
discriminate between CA, HCA and HA BSI. The selection of potential risk factors needs to be 
based on understanding the mechanisms influencing the acquisition of BSI in children. 
Figure 4.1 illustrates Chapter 4 (in red) in context within the framework of the thesis. The risk 
factors identified in this chapter will inform the development of the prediction models in 
chapter 5 to estimate the proportion of CA, HCA and HA BSI. 
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Figure 4.1. Flow diagram of the steps already addressed in previous chapters (grey), those that will be 
addressed in this Chapter (red) and the following chapters 
  
Probabilistically linked LabBase2 and HES to obtain cohort for analysis 
• Calculated new match-weights and probabilistically linked data 
• Selection of linkage threshold, data cleaning  and formatting 
Description of available data sources and defining analysis cohort  
• LabBase2: microbiology dataset containing  reports of bacterial species 
isolated from clinically significant blood specimens and specimen date 
• HES: clinical dataset containing demographic, clinical, admission and 
discharge date data for all in-patient child admissions in England 
• Cohort: children with index BSI between April 2007 and March 2011 who 
were discharged from hospital at least once between birth and the BSI 
Introduction and aim of thesis 
• The systematic literature review and survey results illustrate the move 
from a dichotomous CA and HA BSI distinction based on the timing of 
BSI alone, to the incorporation of HCA BSI in children, but with no 
uniformly agreed definitions  
• Aim: distinguish between CA, HCA and HA BSI using additional data 
about child clinical  and demographic characteristics 
 
 
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Source of infection 
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Linked study population  
Identify indicators of child 
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(including invasive procedures) and 
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Determining whether clinical/ 
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timing of the BSI adequately predict 
the source of infection and reporting 
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category 
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 101 
4.1.1 Mechanisms for acquisition of a BSI 
The development of a BSI is associated with children’s individual susceptibility to serious 
infection and their exposure to external factors that enable invasive pathogens to invade the 
body and multiply. These risk factors can be grouped into three categories: 1) child 
susceptibility (indirect markers of susceptibility and exposure to invasive BSI), 2) direct 
exposure to invasive BSI (including breach of skin barrier), and 3) timing of the BSI. These 
categories are described in more detail in the following three sections and are summarised in 
Figure 4.2. 
4.1.1.1 Child susceptibility to infection 
Two factors influencing children’s susceptibility to infection are the maturity of the immune 
system and underlying chronic conditions. 
Maturation of immune system 
A child’s susceptibility to BSIs is shaped by the development of their immune system over time, 
which has limited functionality at birth. Neonates acquire most protection via vertical 
transmission from the mother (passive immunity via IgG antibodies) in utero and for the first 
few months of life via breast milk.(150;151) This is important as the child’s adaptive immune 
system will have little or no immunological memory due to lack of direct immune response 
exposure to the external environment whilst in utero. The maternally acquired 
immunoglobulin G (IgG) protection, transmitted via the placenta, declines over time and 
breast milk transmitted protection will decline once breast feeding ceases. The component 
cells forming the innate immune system develop at different rates from birth, affecting the 
functionality of the immune system compared to a fully grown adult. For example, neonate’s 
neutrophils are immature at birth, which increases their susceptibility to bacterial infections 
compared to adults with a fully mature immune system. This early-life impairment is amplified 
in neonates who are born prematurely or with low birth-weight.  Other cells, such as 
monocytes and macrophages, are also immature at birth, resulting in a reduced cytokine 
response and impaired antibacterial effector functions (such as phagocytosis and oxidative 
burst) with consequent lack of clearance or killing of potential pathogens.(151;152)  
Child susceptibility indicators in HES include codes for pre-term babies, low birth weight and 
length of postnatal stay. However, vaccination history, as an indicator of child susceptibility to 
bacterial infection, is not collected in HES.  
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Chronic conditions 
Congenital and other chronic conditions may increase a child’s risk of developing a BSI because 
their immune system is compromised and they are more physically susceptible to CA, HCA and 
HA infection from different pathogens: 
 HA: children with chronic conditions will often receive treatment for their condition(s) 
in hospital, including invasive operations, medical tests and the insertion of indwelling 
devices for treatment delivery. This increases their exposure to opportunistic 
pathogens circulating in the hospital. 
 HCA: children with chronic conditions requiring frequent healthcare contact in the 
community (e.g. OP or GP clinics), may undergo invasive procedures and the use of 
indwelling devices for the long-term management of their condition. This increases 
their exposure to pathogens related to healthcare that are in the community 
environment. 
 CA: in the community setting, children with chronic conditions are equally exposed to 
pathogens causing CA BSI and may be more susceptible than healthy children. 
The chronic conditions are measured from the longitudinal health record in HES using ICD-10 
diagnostic codes. Children with chronic and congenital conditions will also have more exposure 
to antibiotics, which can induce the development of resistant bacterial strains that are more 
commonly associated with HCA and HA BSI; however, this is not an indicator that is captured in 
HES. 
4.1.1.2 Direct inpatient exposure to invasive BSI 
Invasive procedures and the insertion of indwelling devices predominantly occur in healthcare 
settings, especially in IP care. They are indicators for HCA and HA BSI as they disrupt the 
natural, protective skin barrier and provide easy access for bacteria to enter the body and 
replicate.(8;61;62;65-68;71) Indwelling devices, in particular, provide a continually open 
pathway for bacteria naturally found on a patient’s skin or from contaminated ward surfaces, 
to enter directly into the bloodstream. Patients are also exposed to potential pathogens via 
contact with healthcare workers who may transmit organisms between patients, from direct 
contact with other patients, and from fomites (e.g. bedding, bed frames, door handles, 
monitors).(9;95;153;154) 
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4.1.1.3 Timing of BSI  
Time is a key determinant of CA, HCA and HA BSI on three levels.  
1) The timing of BSI in relation to the current hospital admission, previous invasive 
procedure, previous indwelling device and previous hospital discharge are all 
important indicators of heightened exposure to invasive pathogens. Children with 
recent healthcare contact have a higher likelihood that the BSI is HCA, whereas a BSI 
occurring during a current admission indicates a higher likelihood that the BSI is HA. 
Conversely, the lack of these indicators suggests that the BSI is more likely to be CA 
BSI. However, this distinction is further complicated by pathogens (e.g. MRSA) that 
were associated with the hospital, causing infections in people in the community 
without any indicators for recent healthcare contact (i.e. previously healthy). 
2) The timing of blood sample is important when determining the proximity of the BSI to 
the indicators mentioned above. Blood samples are routinely taken from children on 
admission to hospital with suspected BSI to microbiologically confirm the pathogen 
causing the (CA or HCA) BSI. Blood samples are also taken at any point during a 
hospital admission when a BSI is suspected. Of these, a proportion of children will have 
a positive blood culture result, a proportion will have a negative blood culture result 
but with clinically diagnosed BSI, and a proportion will have a negative blood culture 
with no clinically diagnosed BSI. Antibiotic treatment is also relevant to the timing of 
when the blood sample is taken, where if the blood sample is taken after antibiotic 
treatment has been administered, the bacteria may not be detectable in the blood 
culture. Only positive blood cultures are reported to LabBase2.   
3) The bacteria circulating in a given environment is influenced by the time the bacteria 
are able to survive outside a human host. For example, N. meningitidis spreads most 
successfully from human to human but can only survive for approximately one day 
outside of a human host on glass or fabric, which is why N. meningitidis predominantly 
causes infection in the community. Conversely, Enterococcus spp., MRSA and 
Acinetobacter spp. are resilient and can survive for weeks on hospital surfaces 
following patient contamination.(95;153;155) 
This chapter describes the selection of risk factors that can be measured in LabBase2 and HES. 
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Figure 4.2. Summary of mechanisms of BSI epidemiology in children admitted to hospital 
Community In-Hospital 
Transmission of CA-BSI 
• all children, regardless of underlying clinical conditions, 
may be exposed to CA-BSI 
• social mixing in the community increases with age (e.g. 
nursery/ pre-school), enabling more transmission of 
pathogens associated with CA-BSI between people 
Movement of children with chronic 
conditions from hospital to 
treatment in the community setting 
3) Sampling and timing of BSI 
• Time between BSI and hospital admission, previous 
invasive procedure, previous indwelling device and 
previous hospital in-patient admission 
• all children with suspected infection and sick enough to 
be admitted to hospital will have a blood sample taken on 
admission 
• pathogen survival outside of human host 
Transmission of HCA-BSI 
1) Child susceptibility 
• compromised immune system increases susceptibility to 
developing a BSI 
o Maturation of immune system 
o congenital/chronic conditions 
 - complex congenital/chronic conditions 
 - frequent healthcare contact 
 - invasive procedures 
 - antibiotic use, increasing resistance 
2) Direct in-patient exposure 
• indwelling devices and/or invasive procedures associated 
with healthcare of chronic conditions 
Transmission of HA-BSI 
1) Child susceptibility 
• compromised immune system increases susceptibility to 
developing a BSI 
• in-hospital environment containing pathogens associated 
with HA-BSI 
• antibiotic use 
2) Direct in-patient exposure 
• indwelling devices and/or invasive procedures associated 
with healthcare of chronic conditions 
• length of hospital stay 
3) Sampling and timing of BSI 
• pathogen survival outside of human host 
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4.2 Methods 
This chapter describes a set of risk factors in the LabBase2 and HES linked dataset containing 
children with a BSI who have all been exposed to the community setting prior to acquiring 
their first (index) episode of BSI within the 4-year cohort period. The risk factors were detected 
from IP hospital records within a one-year (1-365 days) look back prior to the date of positive 
blood sample (day 0). Each risk factor is summarised in Table 4.1. 
4.2.1 Child susceptibility 
4.2.1.1 Age 
The linked cohort was divided into two age-groups, 1 month to < 1 year and aged 1-5 years to 
reflect the differences in the maturation of the immune system in the first few months of life 
compared to older children with more adaptive immunity exposure and vaccination cover, as 
well as differences in social mixing.(51;151) Infants less than 1 year old will have a short look-
back period (to birth) to identify risk factors than for children aged 1 year or more. 
BSI rates per 100,000 population were calculated using ONS mid-year population data.(156) 
The rates have been adjusted to reflect the estimated 80% case ascertainment by LabBase2 as 
discussed in Chapter 2, section 2.3.5 (by increasing the numerator by an additional 20% of the 
original total). However, rates have not been adjusted for the level of linkage error and serves 
only to indicate the approximate rate of BSI. 
4.2.1.2 Ethnicity 
To account for any differences in the distribution of BSI by ethnicity, the HES coding for 
ethnicity was collapsed into seven groups: White, Mixed, Indian subcontinent, any other Asian, 
Black, other ethnic group, and not known.(157;158) 
4.2.1.3 Evidence of prematurity at birth or low birth-weight 
Prematurity at birth or low birth-weight of any child were identified by the ICD-10 diagnostic 
codes P05 or P07. The baby-tail birth-weight data recorded in the HES baby-tail was not used 
as the data are incomplete.(159)  
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4.2.1.4 Evidence of chronic conditions 
Chronic conditions were selected from a pre-defined list of ICD-10 codes, grouped into eight 
clinical categories according to the clinical focus: 
 Mental health/behavioural  
 Cancer/blood disorders  
 Chronic infections  
 Respiratory  
 Metabolic/endocrine/digestive/renal/genitourinary  
 Musculoskeletal/skin  
 Neurological  
 Codes indicating a non-specific chronic condition 
The categorised list of ICD-10 codes was used in a recent study of child deaths in England and 
can be found in Appendix 4a.(160) All 20 ICD-10 code HES fields were scanned for a matching 
pre-defined ICD-10 code. A child who had multiple ICD-10 codes from the same clinical focus 
was coded as having one chronic condition. If multiple ICD-10 codes were identified from two 
different clinical focus groups, then a child would be coded as having two chronic conditions, 
and so on. I used these codes because there is no internationally agreed coding system for 
grouping chronic conditions in children, unlike the Charlson Comorbidity Index for adults.(161)  
4.2.1.5 Evidence of congenital conditions 
Congenital conditions recorded in any on the 20 ICD-10 code fields (Q01-Q99) were identified 
using the same ICD-10 groupings from the child death study mentioned above.(160) 
4.2.1.6 Length of postnatal stay 
The length of postnatal stay (number of nights in hospital since birth or length of an admission 
within the first seven days of life) was calculated as a proxy indicator for the health status of 
children aged <1 year. Date of birth was not counted as part of the postnatal stay. Children 
who were re-admitted for only one day (within the first seven days of life) without staying 
overnight were recorded as having stayed 0.5 days. 
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4.2.2 Direct exposure to invasive BSI from inpatient healthcare 
To distinguish between prolonged or acute exposure to infection from invasive medical 
interventions, I divided medical interventions into two groups: indwelling devices (e.g. 
catheter insertion that can remain inserted for several weeks) and invasive procedures (e.g. 
surgical procedure lasting a specific number of hours). A previous hospital discharge was used 
as an indicator of prior healthcare contact. 
4.2.2.1 Insertion of last indwelling device 
I used procedure codes to identify the most recent insertion date of an indwelling device in the 
year before the blood specimen date and calculated the number of days between the two 
dates. Indwelling devices included catheters, shunts, and devices associated with the 
gastrointestinal area using the codes outlined in Appendix 4b. As these are operative codes, 
these indwelling devices may represent only those inserted during an operation. Indwelling 
devices inserted on the wards might not have received a procedure code. 
4.2.2.2 Previous invasive procedure 
I identified the date of the most recent invasive procedure in the year before the blood 
specimen date and calculated the number of days between the two dates. To avoid overlap 
with the indwelling device exposure variable, I excluded any indwelling device codes from the 
last invasive procedure variable. I corresponded with the lead author to request the list of 
OPCS invasive procedure codes (Appendix 4b) that were used in the Hardelid et al.’s report to 
distinguish between invasive and non-invasive/low risk for an adverse event procedure.(160) 
Antibiotic prophylaxis prior to surgery was not captured in HES. 
4.2.2.3 Previous hospital discharge 
A more recent discharge indicates that the BSI is more likely to be associated with the previous 
healthcare spell. I calculated the number of days between the last discharge and the current 
admission date in the year before the blood specimen date. 
The measurement of the most recent indwelling device, invasive procedure and hospital 
discharge before the BSI was categorised into four time groupings: 1-6 days before, 7-30 days 
before, 31-90 days before and 91-365 days before the BSI (Table 4.1). Lookback thresholds of 
30-day, 90-day and 1-year have been commonly used in the literature.(8;61;62;65;67) 
England’s Surgical Site Infection Surveillance Service (SSISS) uses a 30-day threshold for the 
 108 
monitoring of surgical site infections (SSIs) for superficial, deep incisional and organ space 
infections where there was no implant involved, or a 1-year threshold if an implant is 
used.(162) I included an additional threshold of day 1-6 before the BSI to add more detail to 
capture any events in very close proximity to the BSI. 
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Table 4.1. Categories for clinical and demographic exposure variables 
 
Category Variable Type Description 
su
sc
ep
ti
b
ili
ty
 o
f 
ch
ild
 
Age  Continuous Between 29 – 2191 days old (1 month - 5 years) 
Gender  Binary 
0 = male 
1 = female 
Ethnicity Categorical 
0 = White 
1 = Mixed 
2 = Indian subcontinent 
3 = Any other Asian 
4 = Black 
5 = Other ethnic group 
6 = Not known 
Premature 
birth/low 
birth-weight 
Binary 
0 = babies weighing ≥2500g at birth and/or born  
      ≥37 weeks gestation 
1 = babies weighing <2500g at birth and/or born  
      <37 weeks gestation 
Chronic 
condition(s) 
Categorical 
0 = no chronic conditions in year prior to the BSI* 
1 = at least 1 ICD-10 code for any chronic  
condition within the same chronic condition  
group* in year prior to the BSI  
2 = at least 1 ICD-10 code for any chronic  
condition* from two different chronic  
condition groups* in year prior to the BSI 
3 = at least 1 ICD-10 code for any chronic  
condition* from three or more chronic  
condition groups* in year prior to the BSI 
Congenital 
condition(s) 
Binary 
0 = no congenital conditions in year prior to the BSI 
1 = at least 1 ICD-10 code for any congenital  
condition in year prior to the BSI 
Postnatal stay Continuous 
Number of nights in hospital after birth, or number 
of nights in hospital when admitted in the first 7 days 
of life 
In
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n
t 
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p
o
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 t
o
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Indwelling 
device 
Categorical 
0 = no indwelling devices in year before the BSI  
      specimen date 
1 = date of last indwelling device insertion between   
      91 days<1 year before the BSI specimen date 
2 = date of last indwelling device insertion between  
      31-90 days before the BSI specimen date 
3 = date of last indwelling device insertion between  
      7-30 days before the BSI specimen date 
4 = date of last indwelling device insertion between   
      1-6 days before the BSI specimen date 
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Category Variable Type Description 
 
 
 
 
 
 Time since 
last invasive 
procedure 
Categorical 
0 = no invasive procedure in year before the BSI  
      specimen date 
1 = last invasive procedure between 91 days<1 year  
      before the BSI specimen date 
2 = last invasive procedure between 31-90 days  
      before the BSI specimen date 
3 = last invasive procedure between 7-30 days  
      before the BSI specimen date 
4 = last invasive procedure between 1-6 days before  
      the BSI specimen date 
Time between 
current 
admission 
date and last 
hospital 
discharge date 
Categorical 
0 = no previous hospital discharge in the year before  
      the BSI specimen date  
1 = last discharge between 91 days<1 year before  
      the current admission date 
2 = last discharge between 31-90 days before the  
      current admission date 
3 = last discharge between 7-30 days before the   
      current admission date 
4 = last discharge between 1-6 days before the  
      current admission date 
 
*outlined in appendix 4a 
4.2.3 Timing of positive blood samples in relation to hospital admission 
The timing of the blood sampling in relation to hospital admission was determined by 
identifying the hospital spell where the blood specimen date fell between the admission and 
discharge dates, or within the five days prior to the admission date to capture GP samples, OP 
samples or A&E samples prior to being admitted as an IP for their infection. 
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4.3 Results  
4.3.1 Child susceptibility 
Between 1st April 2007 and 31st March 2011, 4,422 children aged 1 month < 1 year and 6,184 
children aged 1-5 years had an index case of BSI. Figure 4.3 illustrates the frequency 
distribution of BSI by child age (categorised into 3-month blocks). The highest number of 
positive blood specimens were taken in the youngest children aged 1 month to < 3 months (n = 
1,595). The frequency of blood specimens subsequently decreased rapidly in the first year of 
life, having halved for children aged 6 months to <9 months (n=816), and continued to 
decrease with increasing age. The lowest number of positive specimens were for children aged 
5 years or more (range: 147-166 isolates/3-months). 
 
 
 
 
 
 
 
 
 
 
Figure 4.3. Frequency distribution of children with a BSI by quarter year of age 
The average ratio of BSI in children aged 1 month < 1 year was 3.9 BSI to every 1 BSI in children 
aged 1-5 years (Table 4.2). By year, for every child aged 1< 2 years with a BSI (n = 2,283), there 
were nearly twice as many children (n = 4,422) aged 1 month < 1 year with a BSI. The 
comparative ratio increased to 7.8 BSI in children aged 1 month < 1 year (n = 4,422) for each 
BSI in children aged 5 < 6 years (n = 619). 
1m < 1yr 1-5 yrs 
1m < 1yr 1-5 yrs 
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Table 4.2. Ratio of BSI for children aged 1 month < 1 year compared to children aged 1-5 years by year 
of age 
1m < 1 yr age-group 
 
Ratio of BSI 
by age 
category 
 
1-5 yrs age-group 
category 
No. of children 
with BSI   
No. of children 
with BSI 
category 
1m < 1yr 4,422 
 
2.1 : 1 
 
2,283 1 < 2 yrs 
1m < 1yr 4,422 
 
3.7 : 1 
 
1,288 2 < 3 yrs 
1m < 1yr 4,422 
 
4.3 : 1 
 
1,113 3 < 4 yrs 
1m < 1yr 4,422 
 
5.5 : 1 
 
881 4 < 5 yrs 
1m < 1yr 4,422 
 
7.8 : 1 
 
619 5 < 6 yrs 
1m < 1yr 4,422 
 
3.9 : 1 
 
1,237 year average 
 
Between 1st April 2007 and 31st March 2011, the average rate of BSI in children aged 1 month 
< 1 year was 209.0/100,000 population compared to an average rate of 62.4/100,000 
population in children aged 1-5 years. The annual rates are shown in Table 4.3. The rate by 
population is four times higher in younger children (aged 1 month < 1 year) compared to the 
older children (1-5 years). 
Table 4.3 Rate of BSI by 1,000 bed-days and by 100,000 population, adjusted for the approximate 80% 
voluntary reporting of laboratory data to LabBase2 
Age-
group 
HES 
year 
No. of children with 
BSI (estimated 80% 
captured by 
LabBase2) 
Estimated no. of 
children with BSI 
(adjusted to 
100%) 
Estimated BSI 
rate/100,000 
population 
  
1m < 1 yr            
  2007/08 1,050 1,312 204.2 * 
  2008/09 1,069 1,336 200.1 * 
  2009/10 1,100 1,375 207.5 * 
  2010/11 1,203 1,504 223.8 * 
            
1-5 yrs           
  2007/08 1,622 2,027 68.3   
  2008/09 1,472 1,840 60.3   
  2009/10 1,509 1,886 59.9   
  2010/11 1,581 1,976 61.4   
*ONS population based on all children aged 0<1 year; could not differentiate child age in 
months   
 
The characteristics of children with a BSI are summarized by age-group in Table 4.4. More BSIs 
were isolated from boys than girls in both the 1 month > 1 year and 1-5 years age-groups 
(59.2% and 56.4% respectively). There were similar ethnic group proportions in both age-
groups, with White being the predominant ethnic group (67.9% and 67.5% respectively). 
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Nearly 20% of the younger children were either premature or had a low birth-weight, 
compared to 9% in the older age-group.  
A total of 52% (n = 2,279) of children aged 1 month < 1 year and 56% (n = 3,467) of children 
aged 1-5 years had either a chronic or congenital condition (or both) regardless of the blood 
sample date. Children with at least one chronic condition and congenital condition accounted 
for 18% (n = 799/4,422) of children aged 1 month < 1 year and 10% (600/6,184) of children 
aged 1-5 years. Of children with blood samples taken prior to or on the day of admission, 39% 
(n = 1,139/2,886) of children aged 1 month < 1 year and 50% (n = 2,225/4,420) of children 
aged 1-5 years had at least one chronic condition.  
Eighty-three per cent (n = 3,671) of children aged 1 month < 1 year had a birth record in HES 
and a postnatal stay (range= day-case to 331 nights; mean= 11.5 nights; median= 2 nights). The 
frequency and distribution of the length of postnatal stay for the 3,671 children is illustrated in 
Figure 4.4. The majority (58%; n = 2,121) of postnatal stays were two-nights or less, where 13% 
(n = 493) were day cases only, 26% (n = 945) were one-night hospital spells and 19% (n = 483) 
were two-night hospital spells. 
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Table 4.4. Susceptibility of child: Study population demographic and clinical characteristics by age-
group 
Category Variable 1m<1yr % 
1-
5yrs 
% Total % 
su
sc
ep
ti
b
ili
ty
 o
f 
ch
ild
 
Age group 4,422 41.7% 6,184 58.3% 10,606 100% 
                
Sex               
  Boy 2,618 59.2% 3,488 56.4% 6,106 57.6% 
  Girl 1,804 40.8% 2,696 43.6% 4,500 42.4% 
                
Ethnicity             
  White 2,999 67.8% 4,173 67.5% 7,172 67.6% 
  Mixed 143 3.2% 198 3.2% 341 3.2% 
  Indian subcontinent 411 9.3% 555 9.0% 966 9.1% 
  Any other Asian 125 2.8% 174 2.8% 299 2.8% 
  Black 245 5.5% 398 6.4% 643 6.1% 
  other ethnic group 163 3.7% 201 3.3% 364 3.4% 
  NK 336 7.6% 485 7.8% 821 7.7% 
                
Premature birth/low birth-
weight 
            
  no 3,546 80.2% 5,629 91.0% 9,175 86.5% 
  yes 876 19.8% 555 9.0% 1,431 13.5% 
                
Chronic and/or congenital 
condition 
            
  none 2,139 48.4% 2,708 43.8% 4,847 45.7% 
  yes 2,283 51.6% 3,476 56.2% 5,759 54.3% 
                
  Chronic conditions             
  none 2,311 52.3% 2,782 45.0% 5,093 48.0% 
  1 chronic condition 1,123 25.4% 1,703 27.5% 2,826 26.6% 
  2 chronic conditions 437 9.9% 777 12.6% 1,214 11.4% 
  >2 chronic conditions 551 12.5% 922 14.9% 1,473 13.9% 
                
  Congenital conditions             
  none 3,451 78.0% 5,510 89.1% 8,961 84.5% 
  
1 or more congenital 
conditions 
971 22.0% 674 10.9% 1,645 15.5% 
                
Postnatal stay             
  No postnatal stay 751 17.0% - - 751 17.0% 
  
Children with postnatal 
length of stay 
3,671 83.0% - - 3,671 83.0% 
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Figure 4.4. Frequency distribution of inpatient postnatal length of stay (no. of nights) for children aged 
1 month < 1 year (0.5 symbolises day admissions only) 
4.3.2 Direct inpatient exposure to infection 
Children with both an invasive procedure and an indwelling device in the past year accounted 
for 12% (n = 527/4,422) of the children aged 1 month < 1 year and 20% (n = 886/6,184) of 
children aged 1-5 years (Table 4.5). The proportion of children with a record of the most recent 
invasive procedure was similar in both age-groups, where 33.5% aged 1 month < 1 year and 
29.7% aged 1-5 years did not have any evidence of an invasive procedure in the year prior to 
the BSI. A total of 13.0% of children aged 1 month < 1 year and 15.6% of children aged 1-5 
years had a record of having an indwelling device inserted in the past year before the BSI. 
Forty-three per cent (n = 2,643) of children aged 1-5 years had a previous discharge from 
hospital in the year before the BSI. In comparison, 87.1% of children aged 1 month < 1 year 
had at least one recorded discharge from hospital in the year prior to the BSI (includes 
discharge after birth delivery).  
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Table 4.5. In-patient exposure to infection: study population demographic and clinical characteristics 
by age-group 
Category Variable 1m<1yr % 
1-
5yrs 
% Total % 
In
-p
at
ie
n
t 
ex
p
o
su
re
 t
o
 in
fe
ct
io
n
 
Indwelling device and/or invasive procedure in 
the year before the BSI specimen date 
          
  no 2,933 66.3% 4,338 70.1% 7,271 68.6% 
  yes 1,489 33.7% 1,846 29.9% 3,335 31.4% 
                
No. days since last indwelling device insertion           
  
no indwelling device in the year 
before the BSI specimen date 
3,846 87.0% 5,217 84.4% 9,063 85.5% 
  last insertion 91 days < 1 yr 151 3.4% 346 5.6% 497 4.7% 
  last insertion 31-90 days 192 4.3% 262 4.2% 454 4.3% 
  last insertion 7-30 days 160 3.6% 246 4.0% 406 3.8% 
  last insertion 1-6 days 73 1.7% 113 1.8% 186 1.8% 
                
No. of days since last invasive procedure           
  
no invasive procedure in the year 
before the BSI specimen date 
2,941 66.5% 4,347 70.3% 7,288 68.7% 
  91 days<1 yr 289 6.5% 401 6.5% 690 6.5% 
  31-90 days 399 9.0% 361 5.8% 760 7.2% 
  7-30 days 410 9.3% 550 8.9% 960 9.1% 
  1-6 days 383 8.7% 525 8.5% 908 8.6% 
                
No. of days between last discharge and current admission       
  
no previous discharge in the year 
before the BSI specimen date 
570 12.9% 3,541 57.3% 6,111 57.6% 
  91 days<1 yr 1,384 31.3% 734 11.9% 2,118 20.0% 
  31-90 days 1,222 27.6% 460 7.4% 1,682 15.9% 
  7-30 days 692 15.6% 616 10.0% 1,308 12.3% 
  1-6 days 554 12.5% 833 13.5% 1,387 13.1% 
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4.3.3 Timing of positive blood samples in relation to hospital admission 
The frequency distribution of children with BSIs is shown by the index blood culture sample 
date in relation to day of hospital admission (day 0 is day admitted to hospital) by age-group in 
Figure 4.5 and Figure 4.6 (log scale on the large graph, and normal scale on the sub-set graph). 
The majority of BSIs from all children (85%; n=8,983/10,606) were isolated <2 days after 
hospital admission. The highest frequency of BSI causing pathogens was observed on day 0 for 
children aged 1 month < 1 year (61%; n=2,673/4,415) and children aged 1-5 years (67%; 
n=4,138/6,184), followed by day 1 for children aged 1 month < 1 year (16%; n=686/4,422) and 
children aged 1-5 years (16%; n=991/6,184) of hospital admission. 
The timing between hospital admission and the BSI sample date was more skewed (longer tail) 
in children aged 1 month < 1 year (range=0-763 days; mean=6.3 days; median=0 days) 
compared to children aged 1-5 years (range=0-268 days; mean=3.7 days; median=0 days). The 
mean length of stay in hospital for the admission containing the BSI was 20.8 days (median=5 
days, range=0-928 days) in children aged 1 month < 1 year and 12.2 days (median=4 days; 
range=0-1,028 days) in children aged 1-5 years. 
Children from both age-groups with a positive blood specimen taken 2-5 days (0.8%; 
n=80/10,606) before hospital admission were from a range of sources. The majority (75%; 
n=60) were emergency admissions from a combination of A&E units, GP or OP admissions. 
Thirteen admissions were elective planned admissions, three were elective booked admissions 
and four were samples taken at another hospital prior to being transferred, however, no 
record of the respective transferring hospital reports were found in HES, which is why the 
admission to the current hospital was considered a new admission. 
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Figure 4.5. Frequency and timing when positive bacterial blood specimens were taken in relation to hospital admission (day 0) for children aged 1 month < 1 year, 2007-
2011. Use of log-scale in main graph, and normal-scale in the excerpt  
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Figure 4.6. Frequency and timing when positive bacterial blood specimens were taken in relation to hospital admission (day 0) for children aged 1 - 5 years, 2007-2011. Use 
of log-scale in main graph, and normal-scale in the excerpt 
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4.4 Discussion 
4.4.1 Child susceptibility to BSI 
There were proportionally more BSIs among children aged 1 month < 1 year than any other 
year-group of children, with the largest difference observed (ratio 7:1 BSI) between the 
youngest and oldest year-group (5<6 years old) respectively. The rate of BSI was higher in the 
younger age-group per 100,000 child population. Proportionally more male than female 
children had BSIs in both age-groups, most noticeably in children aged 1 month < 1 year. Half 
of children, regardless of the timing of their BSI, had complex morbidity from either a chronic 
or congenital condition and were therefore potentially more susceptible to infections from a 
wider range of pathogens than children who were previously healthy (according to the 
reported data) prior to the BSI. In comparison to the literature, the proportion of children with 
chronic conditions was lower than the 88% of children with a BSI in a single-centre children’s 
hospital in England (1995-2002) although this was a tertiary referral centre that would receive 
proportionally more complex cases than the average hospital.(7) A more recent study reported 
similar (58%) proportion of children presenting from the community-setting with chronic 
conditions in a South-West London study (2009-11).(163) 
4.4.2 Direct exposure to invasive BSI from inpatient healthcare 
A third of all children had exposure to previous invasive procedures and recorded indwelling 
devices within the past year. The majority of BSIs in both age-groups were isolated less than 
two days after hospital admission. For in-hospital exposure, children aged 1 month < 1 year 
had longer lengths of hospital stay compared to children aged 1-5 years, giving them greater 
exposure to HA BSI. A recent study reported that more children aged <1 year were admitted 
(and re-admitted) as an emergency admission to hospital in England compared to children 
aged 1-4 years and 5-9 years.(124) 
The majority of children aged 1 month < 1 year had IP hospital contact within the year prior to 
the BSI and postnatal stay. There was, however, a higher than expected proportion of children 
aged 1 month < 1 year who had no birth delivery record (17%). This may be due children born 
at home or born abroad. According to the Office for National Statistics (ONS), only 2-3% of 
births take place outside of an NHS hospital.(164) It may also reflect linkage error. In an ONS 
study of birth registrations occurring in 2007, linked birth records and NHS Numbers for Babies 
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(NN4B) records were linked to baby HES records (not the mothers’ records), where 16% were 
un-linkable.(164) 
4.4.3 Timing of positive blood samples in relation to hospital admission 
The largest proportion of positive blood specimens in both age-groups (60% in children aged 1 
month < 1 year; 67% in children aged 1-5 years) were taken on the day of hospital admission 
compared to any other day, highlighting the large burden of BSI (mixture of CA and HCA) 
coming from the community setting in both age-groups.  
4.4.4 Limitations of cohort 
A potential limitation of the inclusion criteria for the cohort was whether children with a 
minimum exposure (1 day) in the community had sufficient exposure to pathogens circulating 
in the community. Only a very small proportion of children (n=34/4,415, 0.8%) aged 1 month < 
1 year were re-admitted to hospital the day after birth before subsequently developing a BSI 
during that hospital admission where 91% (n=31) had a chronic or congenital condition and 
56% (n=19) had an indwelling device inserted in the past year. They had a very similar 
distribution of clinical characteristics to the 1,618 children who were excluded from the cohort 
for being in hospital since birth when they acquired their BSI, where 89% (n=1,444) had at least 
one chronic or congenital condition and 46% (n=745) had an indwelling device inserted within 
the past year before the BSI. The majority (86%; n=1,385/1,618) of excluded children were 
aged 1<3 months old. Although a small minority of children whose true exposure to the 
community setting is debatable, all of these children developed BSI after having spent at least 
four weeks in hospital and therefore would have been classified as having HA BSI regardless. 
The aim of the thesis was to examine risk factors in all children admitted with BSI to determine 
whether clinical characteristics could be partitioned according to likely source of infection: CA, 
HCA or HA BSI. The study was not designed to answer questions about how to prevent BSI 
because it did not include children without BSI.  Therefore, I did not attempt to determine risk 
factors for BSI. 
The categorisation of chronic diseases into different body systems (0, 1, 2, >2 chronic 
conditions) is a crude indicator of patients with chronic conditions and multi-morbidity. This 
coding is inevitably crude because important clinical information is missing from the HES data, 
such as immune-suppression, antibiotic treatment and test results. The chronic condition 
categorisation is used to determine infection risk and could be used to target certain groups 
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for treatment or not (similar to targeting of vaccines to those with at risk conditions). The 
chronic conditions were grouped together because small numbers in specific chronic disease 
categories would reduce the power of the regression models. In practice, clinicians will be 
using all of the available information (including previous antibiotic prescribing, underlying 
chronic conditions and test results from other clinical samples) to inform their clinical decision 
about treatment. 
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Chapter 5. Methods and Results: 
Predicting the proportion of CA, HCA 
and HA BSI 
5.1 Introduction 
Predicting the proportion of CA, HCA and HA BSI in children is a difficult problem to resolve 
due to the complex mechanisms of BSI that were described in Chapter 4. In the absence of 
universally accepted definitions of HCA BSI, it is reasonable to use the linked cohort of children 
with BSI (linked using the MW-Child described in Chapter 4) to determine whether there are 
subgroups of children with distinct clinical and demographic characteristics in addition to the 
timing of infection that might infer different sources of BSI (CA, HCA and HA).  
The rationale for trying to predict the proportions of CA, HCA and HA BSI is that this 
information will enable more efficient and appropriate targeting of prevention BSI strategies in 
children; determining whether the source of infection leads to a clear separation in the 
causative pathogens will be investigated in Chapter 6.  
In this chapter, I present three models (denoted A, B and C) that were developed, using the 
linked dataset described in Chapter 4, to estimate the proportion of CA, HCA and HA BSI in 
children. These models incorporate different assumptions about the relationships between the 
three BSI categories. This is an exploratory method where the aim is not to select one model 
over another, but to obtain a range of likely estimates of the proportions.  
I begin by introducing the definitions and assumptions made about CA, HCA and HA BSI that 
were employed for the analytic approaches. The methodologies of the three statistical 
approaches are subsequently described, followed by the results of each approach. The results 
from the three approaches are then compared and discussed in Chapter 6. Figure 5.1 
illustrates the content of this chapter in relation to the thesis. 
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Figure 5.1. Flow diagram of the steps taken (grey) and those that will be addressed in this chapter 
(red) to predict the proportion of CA, HCA and HA BSI in children 
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isolated from clinically significant blood specimens and specimen date 
• HES: clinical dataset containing demographic, clinical  and  admission/ 
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• Cohort: children with index BSI between April 2007 and March 2011 who 
were discharged from hospital at least once between birth and the BSI 
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5.2 Definitions and assumptions about the linked cohort 
In this chapter, assumptions were made about some BSIs in relation to timing or the causative 
pathogen prior to looking at the actual data obtained (described in Chapter 6). The Figures in 
sections 5.2.1, 5.2.2, 5.3.1 and 5.3.2 are for illustrative purposes only and do not reflect real 
data distributions. 
For two of the statistical approaches (A and B), it was necessary to identify both a group of 
children with ‘defined HA’ BSI and a group who were ‘a priori CA’ to give 2 binary baseline 
variables (defined HA or not, a priori CA or not). 
I excluded child records that detected two or more isolated pathogens where one pathogen 
was classified as defined HA BSI and another pathogen was classified as a priori CA to avoid any 
double counting of BSI episodes in the regression models. This was applied from the first 
threshold HA1 (defined below) for consistency across all the models because the number was 
low. 
5.2.1 Defining children with HA BSI 
HA BSIs were assumed to occur between day 1 of hospital admission and hospital discharge, to 
encapsulate both before and after the commonly used 2-day threshold. To test different time 
thresholds relating to the development of HA versus that of CA or HCA BSI, the time threshold 
was varied from 1 day up to 9 days post admission, subsequently referred to as HA1-HA9 and 
illustrated in Figure 5.2. The HA9 threshold was chosen to ensure the majority, if not all, 
pathogens causing CA or HCA BSI would not be included in the subgroup treated as defined 
HA. The HA1-HA9 range covers a likely over-estimate of defined HA (HA1) through to probable 
under-estimation (HA9) via this initial starting dichotomy. BSI on the day of hospital admission 
(day 0) were not included in the possible HA range because the time (in hours) of admission to 
hospital was not recorded in HES, making it impossible to determine the length of stay on the 
first day of admission and therefore whether or not it was possible for a patient to develop a 
HA BSI in that time. 
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Figure 5.2. Expected timing of specimen date sample in relation to hospital admission: Varying HA1-
HA9 cut-off dates for a priori HA BSI selection 
5.2.2 Defining children with a priori CA BSI 
In the literature review and professional opinion survey in Chapter 1, Neisseria meningitidis, 
Salmonella spp., S. pneumoniae and GAS were identified as predominantly causing CA BSI, with 
little or no evidence of causing HA BSI.(8;72;75;78;165) This is supported by other published 
literature.(165) The survival time outside of a human host is short for both N. meningitidis 
bacteria (<1.25 days on glass or fabric) and Salmonella spp. (1-3 days on inanimate 
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surfaces).(155;166-168) Streptococcal bacteria, however, are more resilient, where S. 
pneumoniae can survive from <1-15 days on glass or fabric, and GAS can survive between 3 
days and 6.5 months on environmental surfaces if they remain dry and untouched by cleaning 
products.(155;168) 
Although GBS in children is predominantly perceived as either vertically transmitted pathogen 
from mother to baby at birth or causing CA BSI, there is some evidence that GBS can also be 
acquired in hospital.(169;170) It was not included as one of the a priori CA BSI pathogens due 
to the occurrence of late-onset sepsis, which can occur up to 90 days after exposure at birth. 
Children with BSI caused by S. pneumoniae, N. meningitidis, GAS or Salmonella spp. were 
labelled as having a priori CA BSI, regardless of the day the positive blood specimen was 
detected in relation to admission, including BSI occurring after the definite HA BSI threshold 
because I assumed delayed detection of an underlying CA BSI.  
Figure 5.3 demonstrates the expected timing of a priori CA BSI (blue) in relation to defined HA 
(yellow), where day 𝑥 varied from 1 to 9 (HA1-HA9), and the remaining mixed CA and HCA BSI 
prior to day 1 of hospital admission (dark grey) and mixed CA, HCA and HA BSI between day 1 
or more of hospital admission and day 𝑥 (light grey). 
 
 
 
 
 
 
 
 
Figure 5.3. Expected timing of specimen date sample in relation to hospital admission for a priori CA 
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5.2.3 Results  
A total of 19 children with BSI were classified as both defined HA (using the HA1 threshold) and 
a priori CA and were removed from the linked dataset. 
5.2.3.1 Children with defined HA BSI 
The number of children with defined HA BSI (that were not a priori CA) for each of the nine 
scenarios is tabulated by age-group in Table 5.1. Proportions varied from 30% in children aged 
1 month < 1 year and 22% in children aged 1-5 years in the lowest HA-threshold (HA1) down to 
12% and 6% respectively for the highest (most conservative) threshold (HA9). The largest 
reduction between consecutive thresholds was between HA1 and HA2 (12% decrease in 
children aged 1 month < 1 year; 11% decrease in children aged 1-5 years). 
Table 5.1. Number of children with defined HA BSI for each of the nine threshold scenarios by age-
group 
Defined HA-threshold 
Age-group 
  1m < 1 y % 1-5y % Total % 
HA1 (day 1 or more) 1,325 30% 1,379 22% 2,704 26% 
HA2 (day 2 or more) 803 18% 688 11% 1,491 14% 
HA3 (day 3 or more) 708 16% 569 9% 1,277 12% 
HA4 (day 4 or more) 661 15% 523 8% 1,184 11% 
HA5 (day 5 or more) 625 14% 478 8% 1,103 10% 
HA6 (day 6 or more) 598 14% 449 7% 1,047 10% 
HA7 (day 7 or more) 578 13% 419 7% 997 9% 
HA8 (day 8 or more) 552 13% 394 6% 946 9% 
HA9 (day 9 or more) 530 12% 373 6% 903 9% 
Total population 4,415 
 
6,172 
 
10,587 
  
The distributions of children with defined HA BSI for thresholds HA1 and HA9 by clinical and 
demographic characteristics are shown in Table 5.2. The proportion of children with any of the 
clinical characteristics increased between day 1 and day 9, highlighting that the children with a 
positive blood specimen occurring later into a hospital admission had more complicated 
medical conditions that required longer medical attention due to the nature of their illness or 
condition.   
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Table 5.2. Tabulation of defined HA1 and HA9 cases by demographic and clinical characteristics from 
HES in the 12 months prior to the BSI 
Characteristic Aged 1m<1y Aged 1-5y 
 
Aged 1m<1y Aged 1-5y 
  
HA1 % HA1 % 
 
HA9 % HA9 % 
Sex                     
  Boy 759 57% 762 55%   295 56% 216 58% 
  Girl 566 43% 617 45%   235 44% 157 42% 
Ethnicity                   
  White 821 62% 916 66%   290 55% 232 62% 
  Mixed 44 3% 61 4%   16 3% 8 2% 
  Indian subcontinent 147 11% 136 10%   56 11% 39 10% 
  Any other Asian 47 4% 44 3%   19 4% 10 3% 
  Black 79 6% 78 6%   37 7% 18 5% 
  other ethnic group 59 4% 46 3%   35 7% 23 6% 
  Not Known 128 10% 128 9%   77 15% 43 12% 
Premature birth/low birth-weight                   
  no 959 72% 1,216 88%   319 60% 314 84% 
  yes 366 28% 163 12%   211 40% 59 16% 
Chronic conditions                   
  No chronic conditions 462 35% 397 29%   42 8% 7 2% 
  1 chronic condition 269 20% 353 26%   89 17% 53 14% 
  2 chronic conditions 210 16% 222 16%   121 23% 72 19% 
  >2 chronic conditions 384 29% 407 30%   278 52% 241 65% 
Congenital conditions                   
  No congenital conditions 756 57% 1,093 79%   174 33% 240 64% 
  1 or more congenital 569 43% 286 21%   356 67% 133 36% 
Days between last discharge and current admission             
 
no previous discharge in the 
year before BSI 207 16% 584 42%   121 23% 117 31% 
  91 days<1 yr 243 18% 171 12%   30 6% 46 12% 
  31-90 days 302 23% 118 9%   56 11% 37 10% 
  7-30 days 267 20% 198 14%   119 22% 63 17% 
  1-6 days 306 23% 308 22%   204 38% 110 29% 
Days since last invasive procedure                   
  
no invasive procedure in the 
year before BSI 526 40% 624 45%   75 14% 42 11% 
  91 days<1 yr 84 6% 87 6%   25 5% 22 6% 
  31-90 days 157 12% 102 7%   100 19% 48 13% 
  7-30 days 274 21% 268 19%   227 43% 171 46% 
  1-6 days 284 21% 298 22%   103 19% 90 24% 
No. days since last indwelling device insertion               
  No device in the year before BSI 939 71% 933 68%   251 47% 132 35% 
  last insertion 91 days<1 yr 74 6% 112 8%   37 7% 45 12% 
  last insertion 31-90 days 115 9% 109 8%   83 16% 62 17% 
  last insertion 7-30 days 138 10% 157 11%   123 23% 109 29% 
  last insertion 1-6 days 59 5% 68 5%   36 7% 25 7% 
Postnatal stay in the 12 months prior to the BSI  
  No postnatal stay 266 20% -   -   126 24%  -  - 
  Postnatal stay 1,059 80%       404 76%     
  Total 1,325   1,379     530   373   
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5.2.3.2 Children with a priori CA BSI 
A total of 848 children aged 1 month < 1 year and 1,711 children aged 1-5 years were classified 
as having a priori CA BSI. As demonstrated in Table 5.3, the majority (90-91%) of the BSI that 
were assumed to be a priori CA in both age-groups were isolated on day 0 and day 1 of 
hospital admission, which correlates with the timing of when the majority of the blood 
samples were taken from children as see in Chapter 4. Four to 5% of a priori CA BSI were 
identified prior to hospital admission. A further 5% of a priori CA were isolated from samples 
taken between day 2 and day 11 (median = day 3) of hospital admission in children aged 1 
month < 1 year, and between day 2 and day 17 (median = day 2) of hospital admission in 
children aged 1-5 years. The relative proportion of a priori CA BSIs by pathogen are shown in 
Figure 5.4 (children aged 1 month < 1 year) and Figure 5.5 (children aged 1-5 years).  
Table 5.3. Distribution of the number of children with a priori CA BSI by day of bacterial isolation in 
relation to hospital admission (day 0) 
Day BSI isolated in relation to 
hospital admission (day 0) 
Age-group 
Total 
1m<1y (%) 1-5y (%) 
-5 to -1 days 38 (4.5%) 74 (4.3%) 112 
0 to 1 days 764 (90.1%) 1,554 (90.8%) 2,318 
2-9 days 44 (5.2%) 79 (4.6%) 123 
10-17 days 2 (0.2%) 4 (0.2%) 6 
Subtotal of a priori CA 
Total children with BSI 
848 
4,415  
1,711 
6,172  
2,559 
10,587 
 
 
Figure 5.4. Proportional distribution of a priori CA pathogens in children aged 1 month < 1 year in 
relation to hospital admission 
0%
20%
40%
60%
80%
100%
-5 to -1
days
0 to 1
days
2-9 days 10-11
days
P
ro
p
o
rt
io
n
 o
f 
a
 p
ri
o
ri
C
A
 B
SI
Day BSI isolated in relation to hospital admission (day 0)
Salmonella spp.
Group A streptococcus
N. meningitidis
S. pneumoniae
 131 
 
 
 
 
 
 
 
 
Figure 5.5 Proportional distribution of a priori CA pathogens in children aged 1-5 years in relation to 
hospital admission 
The demographic and clinical characteristics of children with a priori CA BSI are shown in Table 
5.4, both including and excluding the CA BSIs occurring two or more days after hospital 
admission; this table does not include any duplicate data from the previous defined HA BSI 
table (Table 5.2) because all a priori CA BSI occurring after the HA-threshold remained a priori 
CA (as described in section 5.2.2).  
The majority (≥96%) of children with a priori CA BSI did not have any history of an indwelling 
device in the year before the BSI, less than 15% were born prematurely or with a low birth-
weight, and 83% of children < 1 year old were re-admitted for a certain time period within the 
first week of discharge from hospital after birth. No previous discharge within the past year 
was noted for 75% of children aged 1-5 years. Half of children in both age-groups had at least 
one chronic condition. The frequency of these clinical characteristics in children with a priori 
CA BSI were significantly different when compared to children with defined HA BSI (Chi2 
P<0.005). There was no significant difference by sex for children with a priori CA or defined HA 
BSI in either age-group (Chi2 P=0.051 for children aged 1 month < 1 year; Chi2 P=0.699 for 
children aged 1-5 years). 
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Table 5.4. Tabulation of a priori CA cases by demographic and clinical characteristics 
  
 
all a priori CA 
 
CA <=2 days after admission 
Characteristic 1m<1y 1-5y 
 
1m<1y 1-5y 
  
 
CA % CA % 
 
CA % CA % 
Sex                     
  Boy 480 57% 984 58%   464 56% 956 57% 
  Girl 368 43% 727 42%   359 44% 715 43% 
Ethnicity                 
   White 663 78% 1,184 69%   641 78% 1,158 69% 
  Mixed 23 3% 62 4%   22 3% 60 4% 
  Indian subcontinent 53 6% 133 8%   52 6% 129 8% 
  Any other Asian 7 1% 33 2%   7 1% 33 2% 
  Black 23 3% 98 6%   22 3% 96 6% 
  other ethnic group 22 3% 44 3%   22 3% 42 3% 
  NK 57 7% 157 9%   57 7% 153 9% 
Premature/low birth-weight                   
  No 734 87% 1,585 93%   711 86% 1,552 93% 
  Yes 114 13% 126 7%   112 14% 119 7% 
Chronic conditions           
 
    
   None 436 51% 881 51%   425 52% 864 52% 
  1 chronic condition 300 35% 561 33%   292 35% 550 33% 
  2 chronic conditions 75 9% 157 9%   72 9% 153 9% 
  >2 chronic conditions 37 4% 112 7%   34 4% 104 6% 
Congenital conditions                 
   No  777 92% 1636 96%   759 92% 1,599 96% 
  Yes  71 8% 75 4%   64 8% 72 4% 
Postnatal stay                   
  No 148 17% -  -   139 17% -  - 
  Yes 700 83% -  -    684 83% -  -  
No. days between last discharge and current admission             
  
No reported previous 
discharge in past year 112 13% 1,277 75%   106 13% 1,251 75% 
  91 days<1 yr 446 53% 182 11%   438 53% 178 11% 
  31-90 days 163 19% 84 5%   161 20% 83 5% 
  7-30 days 60 7% 64 4%   55 7% 62 4% 
  1-6 days 67 8% 104 6%   63 8% 97 6% 
Days since last invasive procedure             
 
  
No invasive procedure 
in the past year 696 82% 1,503 88%   686 83% 1,478 88% 
  91 days<1 yr 60 7% 80 5%   59 7% 79 5% 
  31-90 days 30 4% 40 2%   27 3% 37 2% 
  7-30 days 12 1% 31 2%   10 1% 29 2% 
  1-6 days 50 6% 57 3%   41 5% 48 3% 
No. days since last indwelling device insertion  
 
        
  
No indwelling device in 
the past year 815 96% 1,655 97%   797 97% 1,623 97% 
  
last insertion 91 days < 
1 year 16 2% 30 2%   13 2% 29 2% 
  
last insertion 31-90 
days 4 0% 11 1%   3 0% 8 0% 
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all a priori CA 
 
CA <=2 days after admission 
Characteristic 1m<1y 1-5y 
 
1m<1y 1-5y 
  
 
CA % CA % 
 
CA % CA % 
  last insertion 7-30 days 1 0% 6 0%   1 0% 5 0% 
  last insertion 1-6 days 12 1% 9 1%   9 1% 6 0% 
          
 Total 
 
848   1,711     823   1,671   
5.2.4 Summary and discussion 
I have described the assumptions made when determining a sub-group of children with 
defined HA BSI, using different time thresholds after hospital admission, and a priori CA BSI, 
identified by the causative pathogens S. pneumoniae, N. meningitidis, GAS and Salmonella spp.  
Children with defined HA BSI as opposed to a priori CA BSI had higher proportions of chronic 
conditions (65-98% versus 50%, P<0.0005), indwelling devices (32-75% versus 3-4%, P<0.0005) 
and invasive procedures (55-89% versus 12-18%, P<0.0005). It seems reasonable that other CA 
or HA BSI will be in children with similar distributions of clinical characteristics, i.e. where 
children with HA BSI will have proportionally more recent and frequent invasive procedures 
and chronic conditions. These results are similar to previous studies that found children with 
CA BSI were generally healthier and had less healthcare contact compared to children with HA 
BSI.(8;72) However, it was surprising that half of the children with a priori CA BSI had at least 
one chronic condition, emphasising that this group of children were a mixture of healthy and 
immunocompromised children before the BSI. 
The 129 children with a priori CA isolates reported two or more days after hospital admission 
may be due to other circumstances not necessarily related to transmission within the hospital 
setting. An initial blood sample may have been negative due to antibiotic treatment prior to 
the blood specimen being taken, making the bacterial load in the blood undetectable. Delayed 
sampling, where a BSI was not initially suspected by the clinician, may also partly explain the 
later timing of the blood specimen date. Unfortunately, these theories cannot be verified in 
the current data. 
In the next section, I describe the statistical analysis models that were to attempt to 
differentiate between children with CA, HCA or HA BSI using clinical and demographic patient 
characteristics. Nine different predicted proportions of CA BSI, HCA BSI and HA BSI in children, 
related to the different HA1-HA9 cut-offs, were outputted for each age-group using each of 
the 3 methods. 
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5.3 Methods of the statistical approaches A, B and C 
I used three different approaches to estimate the proportional burden of CA, HCA and HA BSI 
in children by using clinical and demographic risk factors in the linked dataset containing 
10,,587 children with BSI (described in Chapter 4). The first two methods, A and B, used similar 
statistical models but differing assumptions about the relationship between HCA BSI and the 
other categories (CA and HA). The third method, C, used a different statistical approach and 
did not make any assumptions about the relationship between, CA, HCA and HA BSI. The 
purpose of the models was to develop an upper and lower estimate of the predicted 
proportion of CA, HCA and HA BSI. The approaches A, B and C are expanded below. 
The first two approaches (A and B) used different assumptions about the relationship of 
patient characteristics between children with CA, HCA or HA BSI. There have historically been 
mixed reports of the characteristics of patients with HCA BSI compared to the characteristics 
of patients with CA or HA BSI.(9;171) Approach A focuses on the assumption that children with 
HCA BSI have different characteristics compared to children with CA or HA BSI. Approach B 
assumes that children with HCA BSI have similar characteristics to children with HA BSI.  
Both approaches A and B rely on a series of logistic regression models to identify 
characteristics associated with HA or CA in different subgroups. From these models, 
predictions are made about others from the dataset and their likely affiliation. In all logistic 
models, first- and second-degree fractional polynomials were used to characterise changes in 
log odds of being in a given category (CA, HCA or HA) for the continuous variables (age and 
length of postnatal stay).(172) The first-degree (𝑝) and second degree (𝑞) power 
transformation (𝑥𝑝,𝑞) of a continuous variable comprised: -2, -1, -0.5, 0, 0.5, 1, 2. If the first-
degree transformation was the best fit of the data (including a linear fit where 𝑝 = 1), then 
then second-degree was not employed. In summary, there were 36 possible 
combinations.(173) 
Using a best subset framework to identify the best fitting regression model from all the 
possible combinations of explanatory variables specified, a total of 1,023 models (all the 
possible model combinations using 10 explanatory variables listed in Table 4.1, Chapter 4) 
were run for children aged 1month < 1 year, and 551 models (all the possible model 
combinations using 9 explanatory variables listed in Table 4.1, Chapter 4) were run for children 
aged the 1-5 years.  
All the models were evaluated using the Akaike Information Criteria (AIC) and Bayesian 
Information Criterion (BIC) to identify the most succinct and best fitting models, i.e. the model 
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with the lowest AIC score and the model with the lowest BIC score. The AIC measured the 
adequacy of the regression model by estimating the expected information loss considering the 
variables in the model compared to the true model, where the model with the lowest AIC 
value was the model with the lowest expected information loss and therefore 
preferred.(174;175) The BIC is less liberal than the AIC model selection and was more partial to 
selecting simpler models with the lowest BIC value, measuring the degree to which a model 
was the true data-generation model.(176;177) In each case, the BIC model was nested within 
the respective AIC model, and I used a likelihood ratio test to select the best fitting model of 
the two. Odds ratios (ORs) with a P-value<0.05 were considered statistically significant. 
The third approach, C, did not use any prior assumptions but modelled the relationships 
between children’s characteristics to group the children into three distinct groups, which 
would then be deemed to be CA, HCA and HA BSI via consideration of the numbers of a priori 
CA BSI and defined HA BSI in each group.  
The method, hypothesised outcome and assumptions for approaches A, B and C are 
summarised in Table 5.5. Descriptions of approaches A, B and C are each detailed in the 
following section. All figures in the next methods sections are for illustration purposes only and 
do not reflect real data distributions. 
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Table 5.5. Summary of methodological steps and description of approaches A, B and C 
Approach Methodological steps Description 
A Initial assumptions about BSI Defined HA BSI 
all BSI beyond threshold x (x=varying threshold 
between day 1-9 after hospital admission) 
A priori CA BSI 
isolation of S. pneumoniae, N. meningitidis,  
GAS or Salmonella spp.  
 Model 1: Logistic regression Subset: all 
Outcome: child with defined HA BSI vs not. Used 
to determine additional subgroup of HA from 
those not a priori CA with BSI 1 + days from 
admission. 
 Model 2: Logistic regression Subset: Those not defined HA or from the 
additional HA subgroup given by model 1 
Outcome 
child with a priori CA BSI vs not.  
Used to determine additional subgroup of CA (ie. 
with predicted probability > = 0.5) and the 
remainder assumed to be HCA 
B Initial assumptions about BSI Defined HA BSI 
all BSI beyond threshold x (x=varying threshold 
between day 1-9 after hospital admission) 
A priori CA BSI 
isolation of S. pneumoniae, N. meningitidis,  
GAS or Salmonella spp.  
 Model 1: Logistic regression Subset: Those defined HA or a priori CA 
Outcome children with defined HA vs a priori CA 
Used to determine additional subgroup likely CA 
(predicted probability <0.5) and give upper limit 
for HCA (predicted probability >0.5)  
C Initial assumptions about BSI None 
 Model 1: Multiple 
correspondence analysis 
(MCA) 
Summary of relationships between BSI and child 
related variables condensed into 2 or more 
numerical summaries (factors)  
 Model 2: Discriminate 
analysis using K-medians 
Children classified into one of three groups using 
the created MCA numerical summaries 
 Compare Model 2 results to 
assumptions about BSI from 
approach A and B 
The group of children with the largest proportion 
of : 
 defined HA BSI will be considered as having HA 
BSI;  
a priori CA will be considered as having CA BSI 
 The remaining group will be considered having 
HCA BSI 
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5.3.1 Methods: approach A 
Assumption: children with HCA BSI do not have the same characteristics/risk factors as children 
with HA BSI or CA BSI 
Two logistic regression models were used to predict children with CA, HCA or HA BSI. The 
models were run for each of the nine HA BSI thresholds (HA1-HA9) to investigate different 
definitions of HA BSI (as described in section 5.2.1). The first model predicted children with 
likely HA BSI between day 1 and day x of hospital admission (proportion of children in the light 
grey curve, Figure 5.6), and the second model predicted children with CA or HCA BSI 
(proportion of children in the dark and light grey curves, Figure 5.6). 
 
 
 
 
 
 
 
Figure 5.6. Expected timing of specimen date sample in relation to hospital admission in approach A: 
Mixed CA, HCA and HA BSI  
5.3.1.1 Model 1: Predicting HA BSI cases 
I performed the first logistic regression to model the odds of the clinical and demographic 
characteristics of children with defined HA BSI versus all other children before day 𝑥 (including 
children with a priori CA BSI).  
The probability of each child having HA BSI was then predicted using the obtained regression 
model. Children with a BSI 1 or more days after admission and with a predicted probability of 
0.5 or more were classified as having predicted HA BSI (with the exception of children with a 
priori CA BSI who remained in their original classification). The logistic models yielded 
estimated probabilities of the BSI being HA (as opposed to not HA). An estimated probability of 
0.5 inferred that, on the basis of the model, each option was equally likely. BSI with estimated 
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probabilities of 0.5 or greater were classified as HA on the basis that they were more likely to 
be HA than not (i.e. probability (HA) > probability (not HA). This was applied in both Approach 
A and Approach B. Children with a predicted probability of less than 0.5, who were not in the 
defined HA group, remained an unknown mix of CA and HCA BSI Figure 5.7.  
 
 
 
 
 
 
 
 
Figure 5.7. Expected timing of specimen date sample in relation to hospital admission in approach A: 
predicted HA BSI selection 
5.3.1.2 Model 2: Predicting predicted CA and HCA BSI cases 
I removed all children with predicted and defined HA BSI from the dataset before running the 
logistic regression analysis to model the odds of a child having a priori CA or not; i.e. modelling 
the log odds of a priori CA (in blue, Figure 5.7) as opposed to mixed CA and HCA BSI (in grey, 
Figure 5.7). Children with a predicted probability of 0.5 or more were classified as having CA 
BSI; those with a predicted probability less than 0.5 were classified as having HCA BSI (Figure 
5.8). A child with a priori CA BSI was not re-classified as having HCA BSI if the predicted 
probability was less than 0.5. 
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Figure 5.8. Expected timing of specimen date sample in relation to hospital admission in approach A: 
Differentiating between predicted CA BSI and HCA BSI selection 
5.3.2 Methods: approach B 
Assumption: children with HCA BSI have similar characteristics/risk factors to children with HA 
BSI 
5.3.2.1 Model 1: Predicting CA, HCA or HA BSI cases 
Logistic regression was used to model the odds of the clinical and demographic characteristics 
of children with defined HA BSI after day 𝒙 versus children with a priori CA BSI (Figure 5.9). 
 
 
 
 
 
 
 
Figure 5.9. Expected timing of specimen sample date in relation to hospital admission in approach B: 
Using the a priori CA and defined HA BSI cases for the modelling 
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The final regression coefficients from the best fitting models for each age-group and HA-
threshold were used to predict the probability of a child having CA, HCA or HA BSI for the 
remaining children in the sample. Children with a predicted probability less than 0.5 were 
classified as having CA BSI. Children with a 0.5 or more probability in the mixed group (grey 
section in Figure 5.9) were classified as having HCA BSI if their blood specimen was isolated 
before or on the day of hospital admission (day 0), or as a mix of HCA and HA BSI if the 
specimen was isolated between day 1 and day x after hospital admission. An illustrated 
example of these distinctive groups is depicted in Figure 5.10. This approach gave an upper 
estimate of those patients considered to have a HCA BSI (where the mixed HCA and HA BSI, in 
orange in the figure below, were considered to be HCA). 
 
 
 
 
 
 
 
 
 
 
Figure 5.10. Expected timing of specimen sample date in relation to hospital admission in approach B: 
predicted CA, HCA and HA BSI selection 
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5.3.3 Methods: approach C 
This unsupervised approach partitioned all the children with BSI into three distinct groups 
based on the relationships between the demographic and clinical risk factors within and 
between children, as well as the timing of the positive specimen before and after hospital 
admission. I hypothesised that these three groups would reflect a natural distinction between 
children with CA, HCA or HA BSI, resulting in an estimated proportion of HCA BSI in children 
that would be between the lower and upper estimates of HCA BSI identified in approaches A 
and B. 
No prior assumptions or information on the invasive pathogen(s) were used during the 
statistical analysis. The process yielded three distinct subgroups and these were assigned as 
CA, HCA and HA by comparison with those previously determined as a priori CA and defined 
HA. 
5.3.3.1 Step 1: Multiple Correspondence Analysis (MCA) 
I used multiple correspondence analysis (MCA) to identify clusters of children according to the 
associations between their clinical and demographic characteristics. MCA is an exploratory 
method that creates one or more numeric variables (dimensions) that quantify and simplify 
the relationships between categorical variables by measuring the multi-dimensional dispersion 
between them.(178;179) The aim is that a subset of the numeric dimensions account for the 
majority of the inertia (i.e. variance). These numeric dimensions, known as factor scores, will 
be depicted in two (or more) dimensional graphs to illustrate the clustering of characteristics 
according to child similarities across clinical and demographic characteristics.(178;179) The 
dimensional graphs will be divided into four quadrants to describe the relationships between 
the variables. 
MCA requires that explanatory variables are factors and hence the two continuous variables 
(age and re-admitted postnatal length of stay) were transformed into categorical variables as 
described in Table 5.6. The categorical grouping of the number of days between admission and 
the BSI incorporated into Approach C are also described in Table 5.6. The number of 
dimensions was selected to represent the majority of the variation between BSI episodes. 
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Table 5.6 Additional descriptive breakdown of children with the additional categorical variables for 
approach C 
 
5.3.3.2 Step 2: K-medians analysis 
Step 1 produces a series of factor scores for each child BSI to be grouped according to 
similarity. Cluster analysis is a process whereby the numeric distances between two children 
with BSIs on a set of variables are summarised to give a measure of similarity. Over all children 
in the dataset, these similarity measures are compared to find groups that behave more alike 
than others. Using this process, subgroups of children who are relatively similar with respect to 
the factor scores (sets of numeric measures summarising each BSI) are identified. The 
algorithm that is used to do this can be set so that a specified number of subgroups are 
obtained. I used a K-medians cluster analysis to separate the BSI according to the factor scores 
obtained in step 1 into three distinct subgroups as illustrated in Figure 5.11.(180)    
Variable   1m<1yr % 1-5yrs % Total 
Age           
  1<2 months;   1<2 years 999 (22.6%) 2,279 (36.9%) - 
  2<4 months;   2<3 years 1,064 (24.1%) 1,286 (20.8%) - 
  4<6 months;   3<4 years 727 (16.5%) 1,110 (18.0%) - 
  6<9 months;   4<5 years 811 (18.4%) 881 (14.3%) - 
  9<12 months; 5<6 years 814 (18.4%) 616 (10.0%) - 
Re-admitted postnatal length of stay in days      
 Not readmitted 749 (17.0%) - - 749 
 0.5-1 day 1,436 (32.5%) - - 1,436 
 2-6 days 1,324 (30.0%) - - 1,324 
 7-30 days 505 (11.4%) - - 505 
 31-90 days 302 (6.8%) - - 302 
 ≥91 days 99 (2.2%) - - 99 
Use the number of days between admission and BSI 
categories instead of a priori CA or HA 
          
  -5 to -1 day 213 (4.8%) 282 (4.6%) 282 
  0 days (admission date) 2,673 (60.5%) 4,138 (66.9%) 4,138 
  1 day 570 (15.4%) 981 (15.9%) 981 
  2 days  116 (2.6%) 162 (2.6%) 162 
  3 days 53 (1.2%) 57 (0.9%) 57 
  4 days 42 (1.0%) 54 (0.9%) 54 
  5 days 33 (0.7%) 37 (0.6%) 37 
  6 days 23 (0.5%) 31 (0.5%) 31 
  7 days 28 (0.6%) 28 (0.5%) 28 
  8 days 22 (0.5%) 24 (0.4%) 24 
  9+ days 532 (12.1%) 378 (6.1%) 378 
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  Group identified from the model     
  1 2 3     
  n1 n2 n3   n = children 
 
Figure 5.11. K-medians three-group output 
In order to interpret the allocation of children to one of the three K-medians groups, the three 
groups were compared to the number of children categorised as having a priori CA BSI, defined 
HA BSI (defined in section 5.2.1 and 5.2.2) or having an undefined mixed BSI (CA, HCA or HA), 
as illustrated in Figure 5.12. 
  Group identified from the model     
  1 2 3 Total   
defined HA BSI n1a n2a n3a nHA n = children 
a priori CA BSI n1b n2b n3b nCA   
remaining mixed BSI n1c n2c n3c nmixed   
 
Figure 5.12. Distribution of children in the three K-medians output groups compared to defined HA 
BSI, a priori CA BSI and the remaining mixed BSI 
Assuming that the classifications of children with a priori CA or defined HA BSI are true and 
complete, Figure 5.13 illustrates the optimum outcome for the K-medians model and the 
model is aiming to get as close to this outcome as possible. All children with defined HA BSI are 
classified into one group (e.g. group n3a), all children with a priori CA BSI are classified into 
another group (e.g. group n1b), and the remainder of children with mixed BSI being distributed 
between all three groups (e.g. n1c-n3c). It would be assumed that the remaining group (e.g. 
group 2) are associated with children with HCA BSI. In interpreting the results, I determined 
the CA, HCA and HA BSI from the three groups that most closely resembled the results in 
Figure 5.13.  
  Group identified from the model     
  1 2 3 Total   
defined HA BSI 0 0 n3a nHA n = children 
a priori CA BSI n1b 0 0 nCA   
remaining mixed BSI n1c n2c n3c nmixed   
 
Figure 5.13. Example of optimum outcome when comparing the three K-medians groups 
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For each fitted K-medians model, the generation of the group names (1, 2 and 3) varied. For 
ease of comparing the results, after the groups had been created by the models, I ensured that 
the largest proportion of children with defined HA BSI was named as group 3 and a priori CA 
BSI was named as group 1 in both age-groups. 
5.3.4 Sensitivity analyses 
Three sensitivity analyses were undertaken for approaches A, B and C and are described below 
(the results will be presented in Chapter 6). 
1. Hospital trust where the patient was being treated at the time of the BSI was included 
in the final model to account for any clustering 
o approach A and B: hospital trust was added into the final logistic regression 
models as a random effect to adjust for any clustering by hospital 
o approach C: hospital trust was included as an additional fixed effect variable 
and accounted for in the MCA and therefore subsequently in the K-medians 
models 
2. A priori CA cases where the BSI was isolated ≥2 days after hospital admission were 
excluded from the analysis. This was performed to investigate the impact that these 
few observations may have had on the overall predictions of the proportion of CA, 
HCA and HA BSI in children. 
3. CoNS, Micrococcus spp. and diphtheroids were excluded from the analysis. These 
bacteria are frequently considered to be contaminants due to skin contamination 
when a blood sample is taken.(181) However, clinically they are also a common cause 
of BSI associated with indwelling devices. Although all the isolates that are reported by 
laboratories to LabBase2 are defined as clinically significant, this sensitivity test will 
determine if there are any differences in the prediction of CA, HCA or HA BSI.  
5.4 Results of approaches A, B and C 
5.4.1 Results: approach A 
The unadjusted odds ratios for children with defined HA BSI (as opposed to non-defined HA 
BSI) by the demographic and clinical characteristics for both age-groups are shown in Table 
5.7. These values are valid for both Approach A and B. 
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Table 5.7 Unadjusted OR results for explanatory variables used in models A and B with defined HA BSI 
(2 days) as the outcome in children aged 1 month < 1 year 
Characteristic 1 month < 1 year old 
    
Total no. 
of obs. 
No. of 
HA2 
Unadjusted 
OR P>z 95% CI 
Age in days 4,415 803 0.99 0.008 0.99 0.99 
Sex             
  boy 2,615 451 1.00       
  girl 1,800 352 1.17 0.051 1.00 1.36 
Ethnicity             
  White 2,997 452 1.00       
  Mixed 141 26 1.27 0.279 0.82 1.97 
  Indian subcontinent 408 92 1.64 <0.001 1.27 2.11 
  Any other Asian 126 31 1.84 0.004 1.21 2.79 
  Black 246 53 1.55 0.008 1.12 2.13 
  other ethnic group 161 50 2.54 <0.001 1.79 3.59 
  NK 336 99 2.35 <0.001 1.82 3.04 
Premature/low birthweight             
  no 3,540 523 1.00       
  yes 875 280 2.71 <0.001 2.29 3.22 
Chronic conditions             
  no chronic conditions 2,308 124 1.00       
  1 chronic condition 1,119 160 2.94 <0.001 2.30 3.76 
  2 chronic conditions 437 177 11.99 <0.001 9.22 15.60 
  >2 chronic conditions 551 342 28.82 <0.001 22.45 37.00 
Congenital conditions             
  No congenital conditions 3,447 318 1.00       
  1 or more congenital condition(s) 968 485 9.88 <0.001 8.33 11.72 
Days between last discharge and current admission         
  
no previous discharge in the year 
before BSI 569 151 1.00       
  91 days<1 yr 1,381 92 0.20 <0.001 0.15 0.26 
  31-90 days 1,221 125 0.32 <0.001 0.24 0.41 
  7-30 days 692 181 0.98 0.878 0.76 1.26 
  1-6 days 552 254 2.36 <0.001 1.84 3.03 
Days since last invasive procedure             
  
no invasive procedure in the year 
before BSI 2,958 178 1.00       
  91 days<1 yr 296 44 2.73 <0.001 1.91 3.89 
  31-90 days 391 121 7.00 <0.001 5.38 9.10 
  7-30 days 401 250 25.86 <0.001 20.09 33.29 
  1-6 days 369 210 20.63 <0.001 15.97 26.64 
No. of days since last indwelling device insertion           
  no device in the year before BSI 3,840 459 1.00       
  last insertion 91 days<1yr 150 54 4.14 <0.001 2.93 5.86 
  last insertion 31-90 days 192 101 8.18 <0.001 6.06 11.03 
  last insertion 7-30 days 160 132 34.73 <0.001 22.83 52.81 
  last insertion 1-6 days 73 57 26.24 <0.001 14.94 46.08 
Postnatal stay in days             
  no postnatal stay 749 174 1.00       
  postnatal stay 3,666 629 1.02 <0.001 1.01 1.02 
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Table 5.8 Unadjusted OR results for explanatory variables used in models A and B with defined HA BSI 
(2 days) as the outcome in children aged 1-5 years 
Characteristic 1-5 years old 
    
Total no. 
of obs. 
No. of 
HA2 
Unadjusted 
OR P>z 95% CI 
Age in days 6,172 688 0.99 0.68 0.99 1.00 
Sex             
  boy 3,483 393 1.00       
  girl 2,689 295 0.97 0.699 0.83 1.14 
Ethnicity             
  White 4,163 431 1.00       
  Mixed 198 14 0.66 0.139 0.38 1.14 
  Indian subcontinent 552 71 1.28 0.073 0.98 1.67 
  Any other Asian 174 21 1.19 0.469 0.75 1.90 
  Black 397 41 0.99 0.987 0.71 1.40 
  other ethnic group 202 33 1.69 0.008 1.15 2.49 
  NK 486 77 1.63 <0.001 1.25 2.12 
Premature/low birthweight             
  no 5,618 593 1.00       
  yes 554 95 1.75 <0.001 1.38 2.22 
Chronic conditions             
  no chronic conditions 2,779 65 1.00       
  1 chronic condition 1,698 155 4.19 <0.001 3.12 5.64 
  2 chronic conditions 776 131 8.48 <0.001 6.22 11.56 
  >2 chronic conditions 919 337 24.18 <0.001 18.27 32.00 
Congenital conditions             
  No congenital conditions 5,499 481 1.00       
  1 or more congenital condition(s) 673 207 4.63 <0.001 3.84 5.60 
Days between last discharge and current admission         
  
no previous discharge in the year 
before BSI 3,532 230 1.00       
  91 days<1 yr 733 74 1.61 0.001 1.22 2.12 
  31-90 days 460 64 2.32 <0.001 1.73 3.12 
  7-30 days 615 115 3.30 <0.001 2.59 4.21 
  1-6 days 832 205 4.69 <0.001 3.82 5.77 
Days since last invasive procedure             
  
no invasive procedure in the year 
before BSI 4,365 146 1.00       
  91 days<1 yr 403 39 3.10 <0.001 2.14 4.48 
  31-90 days 364 72 7.13 <0.001 5.25 9.68 
  7-30 days 541 220 19.80 <0.001 15.61 25.13 
  1-6 days 499 211 21.17 <0.001 16.61 26.98 
No. of days since last indwelling device insertion           
  no device in the year before BSI 5,207 336 1.00       
  last insertion 91 days<1yr 345 78 4.24 <0.001 3.22 5.58 
  last insertion 31-90 days 262 89 7.46 <0.001 5.64 9.85 
  last insertion 7-30 days 246 130 16.25 <0.001 12.36 21.36 
  last insertion 1-6 days 112 55 13.99 <0.001 9.50 20.59 
Postnatal stay in days             
  no postnatal stay - - - - - - 
  postnatal stay - - - - - - 
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Graphs depicting the results of either the determined best fit AIC or BIC models after the 
likelihood ratio test from 1,023 and 551 logistic regression models by age-group for each of the 
nine scenarios are in Appendix 5. The results (adjusted ORs) of the best fitting logistic 
regression model outputs by age-group and defined HA-threshold are in Appendix 5. 
5.4.1.1 Model 1: Predicting HA BSI cases 
Increasing age in days (no transformation of age) was associated with a statistically significant, 
although very small decrease in the odds of having HA BSI (OR=0.99; 95% CI: 0.99-0.99; 
P<0.001) as opposed to not in children aged 1 month < 1 year. The models indicated some 
association that girls were more likely than boys aged 1 month < 1 year to have HA BSI in the 
HA2 and HA6 models (OR: 1.26; 95% CI: 1.02-1.55, and OR: 1.31; 95% CI: 1.02-1.69 
respectively), this relationship was similar but did not attain statistical significance for HA1 and 
HA3-HA5 models. Gender was not included in the final models for children aged 1-5 years 
suggesting that there was no significant gender difference in the distribution of BSI by defined 
HA BSI or not. 
Children aged 1 month < 1 year with certain clinical characteristics had statistically significant 
higher odds of having a defined HA BSI compared to children without these clinical 
characteristics in the year prior to the BSI for HA2-HA9 models in both age-group: 
premature/low birth-weight (HA2 OR: 1.83, 95% CI: 1.38-2.44; HA9 OR: 1.92, 95% CI: 1.38-
2.67), one or more chronic conditions with the largest odds for children with more than two 
chronic conditions (HA2 OR: 5.87, 95% CI: 4.19-8.22; HA9 OR:9.84, 95% CI: 6.32-15.31), 
indwelling device inserted 1-90 days before the BSI where 7-30 days had the largest OR (HA2 
OR: 4.87, 95% CI: 2.94-8.06; HA9 OR: 8.15, 95% CI:4.94-13.44), previous invasive procedure in 
the past 1-90 days before the BSI where both 1-6 days (HA2 OR: 7.57, 95% CI: 5.42-10.58) and 
7-30 days (HA9 OR: 9.40, 95% CI: 6.09-14.51) before BSI had the largest OR depending on the 
threshold (Appendix 5). The only variable that had significantly lower odds (P<0.001) for 
children with defined HA BSI compared to the rest of the cohort was for a previous discharge in 
the past year (OR ranging from HA2: 0.28 [95% CI: 0.16-0.47], to HA9: 0.05 [95% CI: 0.03-
0.11]). The model using the HA1 threshold returned the least number of statistically significant 
differences in clinical indicators between children with defined HA versus not compared to the 
HA2-HA9 models. 
Children aged 1-5 years with defined HA BSI between the threshold HA2 and HA9 had 
statistically significant higher odds of having one or more chronic conditions with the highest 
odds for children with more than two chronic conditions (HA2 OR: 8.98, 95% CI: 6.25-12.89; 
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HA9 OR: 60.07, 95% CI: 26.40-136.67), a congenital condition (HA2 OR: 2.24, 95% CI: 1.76-2.86; 
HA9 OR: 2.36, 95% CI: 1.74-3.20), an indwelling device previously inserted in the past 1-90 days 
with the highest odds for 7-30 days (HA2: 2.55, 05% CI: 1.79-3.64; HA9: 5.37, 95% CI: 3.49-
8.28) , or an invasive procedure in the past year with the highest odds for 7-30 days (HA2 OR: 
15.57, 95% CI: 10.77-22.51; HA9 OR: 30.87, 95% CI: 18.39-51.84). As with the younger age-
group, children with defined HA BSI had significantly lower odds of having a previous discharge 
in the past year. 
The ranges of predicted probabilities of children having HA BSI in relation to the timing of 
hospital admission by age-group are depicted in Figure 5.14 and Figure 5.15 (jittered data 
points). 
Although the predicted value for children with defined HA BSI did not change their HA 
category, both age-groups contained children with defined HA BSI that had a predicted range 
of 0.06-0.99, (1 month < 1 year median: HA1= 0.50, HA9=0.56; 1-5 years median: HA1=0.27, 
HA9=0.33). As expected, the majority of children with a priori CA BSI had a low predicted 
probability of having HA BSI (aged 1 month < 1 year mean: HA1=0.15, HA9=0.01; 1-5 years 
mean: HA1=0.14, HA9=0.01). The predicted probability of all other children having a HA BSI 
ranged between 0-0.98 (median: HA1=0.17, HA9=0.01) for children aged 1 month < 1 year and 
0-0.85 (mean: HA1=0.15, HA9=0.01) for children aged 1-5 years.  
Table 5.9 reports the number of children who were predicted to have HA BSI in addition to 
children with defined HA BSI. 
Table 5.9. Defined HA BSI and predicted HA BSI for the range of cut-off days (HA1-HA9) 
HA-
threshold 
1 month < 1 year old 
 
1-5 years old 
defined 
HA BSI 
predicted 
HA BSI 
 
defined HA 
BSI 
predicted 
HA BSI 
day 1 1,325 0 
 
1,379 0 
day 2 803 36 
 
688 24 
day 3 708 46 
 
569 27 
day 4 661 50 
 
523 30 
day 5 625 54 
 
478 28 
day 6 598 58 
 
449 29 
day 7 578 56 
 
419 22 
day 8 552 55 
 
394 22 
day 9 530 58 
 
373 23 
  
  
1
4
9
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.14a-i. Distribution of the predicted HA cases (≥0.5) in relation to all the other cases of BSI between -5 and +30 of hospital admission in children aged 1 month < 1 
year (jittered data points) 
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5
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Figure 5.15a-i. Distribution of the predicted HA cases (≥0.5) in relation to all the other cases of BSI between -5 and +30 of hospital admission in children aged 1-5 years 
(jittered data points) 
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5.4.1.2 Model 2: Predicting CA and HCA BSI cases 
Comparing children with a priori CA to the remaining children with a mixture of CA and HCA 
BSI, children from the following ethnic groups had a lower odds of having a priori CA BSI 
compared to the children from the white ethnicity group for all thresholds in both age-groups 
(HA1-HA9): Indian subcontinent (e.g. 1 month < 1 year HA2 OR: 0.60, 95% CI: 0.44-0.84), any 
other Asian (e.g. 1 month < 1 year HA2 OR: 0.23, 95% CI: 0.10-0.52) and Black ethnicities (e.g. 1 
month < 1 year HA2 OR: 0.36, 95% CI: 0.23-0.58). For children aged 1-5 years, sex was not 
included in any of the models. 
In the younger age-group, children who were born prematurely or with low birthweight (single 
variable) were more likely to have a priori CA BSI (HA1: OR: 1.56 [95% CI: 1.12-2.18]; HA9 OR: 
1.57 [95% CI: 1.14-2.15]) compared to the rest of the population in the HA1-HA9 scenarios. 
This variable was not included in the final models for children aged 1-5 years. 
Children with congenital conditions, in both age-groups, were less likely to have a priori CA BSI 
compared to the remaining population of children (e.g. 1 month < 1 year HA2 OR: 0.66, 95% CI: 
0.48-0.92; 1-5 years HA2 OR: 0.60, 95% CI: 0.46-0.80). However, children with one or more 
chronic conditions in both age-groups had higher odds of having a priori CA BSI than other 
children (e.g. 1 month < 1 year HA2 OR for 1 chronic condition: 2.05, 95% CI: 1.70-2.47; 1-5 
years HA2 OR for 1 chronic condition: 1.53, 95%CI: 1.33-1.75).  
For the HA2-HA9 models, children in both age-groups with an invasive procedure in the last 7-
30 days had statistically significant lower odds of having a priori CA BSI (lowest in the younger 
age-group, for example 1 month < 1 year HA2 OR: 0.34, 95% CI: 0.18-0.66; 1-5 years HA2 OR: 
0.59, 95% CI: 0.37-0.94); the odds of having an a priori CA BSI were not statistically different 
for children with or without an invasive procedure in the previous 1-6 days.  
Children aged 1 month < 1 year with an indwelling device in the year prior to the BSI had very 
low odds of having a priori CA BSI, except for when the indwelling device was inserted 1-6 days 
prior to the BSI, where the odds of having a priori CA BSI ranged from two- to eight-fold higher 
(HA2 OR: 8.16, 95% CI: 1.70-39.21; HA9 OR: 2.49, 95% CI: 1.04-5.94). The higher odds in the 1-
6 days prior are due to 12 children (eight N. meningitidis BSI, four S. pneumoniae BSI) with a 
priori CA BSI with an indwelling device during this time period. In children aged 1-5 years, 
children with an indwelling device in the last 7 days < 1 year had significantly reduced odds of 
having a priori CA BSI compared to other children (e.g. HA2 7-30 days: 0.20 95% CI: 0.08-0.48; 
31-<90 days OR: 0.24, 05% CI: 0.12-0.47; 91 days < 1 year OR: 0.46, 05% CI: 0.29-0.71). 
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The range of predicted values (using the coefficients from the logistic regression models) in 
relation to the timing of hospital admission by age-group are depicted in Figure 5.16 and 
Figure 5.17 (jittered data points). The children with BSI are colour-coded into the a priori CA 
BSI (dark blue), predicted CA BSI (light blue) or predicted HCA BSI (pink). The predicted 
probability of children with BSI that were predicted as CA (≥0.5) ranged from 0.50-0.93 (n=118) 
for HA1 and 0.50-0.76 (n=62) for HA9 in children aged 1 month < 1 year, and 0.50-0.69 (n=237) 
for HA1 and 0.50-0.62 (n=77) for HA9 in children aged 1-5 years.  
Table 5.10 and Table 5.11 report the number and proportion of children with predicted CA and 
predicted HCA compared to the a priori CA BSI, defined HA and predicted HA BSI by age-group. 
The proportion of predicted CA BSI consistently accounted for 21-22% of all BSI in children 
1m<1y; this proportion was nearly 10% higher in the older age-group, from 29-32%. The 
proportion of predicted HCA BSI was similar in both age-groups accounting for nearly two 
thirds of all BSI. The proportion of predicted HA BSI was highest in the younger age-group (13-
19% between HA2-HA9; 30% on HA1) compared to the 1-5 year olds (7-12%). The largest 
difference between the nine different scenarios was between HA1 and HA2.  
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Table 5.10. Approach A: Predicted proportions of CA BSI, HCA BSI and HA BSI in children aged 1 month 
< 1 year 
    CA BSI   HCA BSI   HA BSI 
HA 
threshold 
Total 
a 
priori 
predicted %   predicted %   defined predicted % 
HA1 4,415 848 124 22%   2,118 48%   1,325 0 30% 
HA2 4,415 848 93 21%   2,635 60%   803 36 19% 
HA3 4,415 848 83 21%   2,730 62%   708 46 17% 
HA4 4,415 848 79 21%   2,777 63%   661 50 16% 
HA5 4,415 848 75 21%   2,813 64%   625 54 15% 
HA6 4,415 848 82 21%   2,829 64%   598 58 15% 
HA7 4,415 848 84 21%   2,849 65%   578 56 14% 
HA8 4,415 848 85 21%   2,875 65%   552 55 14% 
HA9 4,415 848 75 21%   2,904 66%   530 58 13% 
 
Table 5.11. Approach A: Predicted proportions of CA BSI, HCA BSI and HA BSI in children aged 1-5 
years 
  CA BSI   HCA BSI   HA BSI 
HA 
threshold 
Total 
a 
priori 
predicted %   predicted %   defined predicted % 
HA1 6,172 1,711 253 32%   2,829 46%   1,379 0 22% 
HA2 6,172 1,711 128 30%   3,621 59%   688 24 12% 
HA3 6,172 1,711 103 29%   3,762 61%   569 27 10% 
HA4 6,172 1,711 99 29%   3,809 62%   523 30 9% 
HA5 6,172 1,711 98 29%   3,857 63%   478 28 8% 
HA6 6,172 1,711 89 29%   3,894 63%   449 29 8% 
HA7 6,172 1,711 88 29%   3,932 64%   419 22 7% 
HA8 6,172 1,711 87 29%   3,958 64%   394 22 7% 
HA9 6,172 1,711 86 29%   3,979 64%   373 23 6% 
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Figure 5.16. Distribution of predicted CA cases in relation to predicted HCA and a priori CA cases between -5 and +30 of hospital admission in children aged 1 month < 1 year 
(jittered data points) 
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Figure 5.17. Distribution of predicted CA cases in relation to predicted HCA and a priori CA cases between -5 and +30 of hospital admission in children aged 1-5 years 
(jittered data points) 
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5.4.1.3 Summary of approach A results 
Just under a half (HA1) to two-thirds (HA2-HA9) of children in both age-groups with BSI were 
predicted to have HCA BSI, based on the assumption that children with HCA BSI did not have 
similar characteristics to children with CA or HA BSI.  
There was a clear separation between children with defined HA BSI versus not in Model 1, 
where children in hospital had more severe clinical characteristics than children with CA or 
HCA BSI. A higher proportion of HA BSI was observed in the children aged 1 month < 1 year. In 
contrast, there was no clear separation between children with CA and HCA BSI in Model 2 
regardless of the HA threshold.  
The results of the logistic regression to determine predicted HA BSI supports the hypothesis 
that the children with HA BSI will have the most clinical risk factors such as chronic conditions, 
exposure to invasive procedures or indwelling devices compared to other BSI. A child’s 
previous discharge from hospital was the only risk factor that had lower odds than all other 
BSI, which is most likely explained because HA BSI is due to an infection acquired in the current 
admission rather than any previous hospital admissions, which is more likely linked to HCA BSI. 
It was surprising to observe that children with one or more chronic conditions had statistically 
significant higher odds of having a priori CA BSI compared to children with mixed CA or HCA 
BSI, particularly because chronic conditions are often more associated with patients who 
require frequent healthcare contact in the literature. This does support the suggestion that a 
significant number of children with chronic conditions in the community are at risk of both CA 
and HCA BSI, whereas children who stay in hospital are at less risk from CA BSI due to 
restricted contact with the community environment.  
Age was an important factor for differentiating between defined HA BSI or not. As children got 
older, the odds of them having a HA BSI decreased as opposed to children with other BSIs. 
Patients born with complications or who develop them very early on will require more acute 
hospital treatment at a very young age to treat and manage the medical condition(s) before 
being discharged, whereas with older children, many more medical conditions can be managed 
in the community or OP setting. 
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5.4.2 Results: approach B 
5.4.2.1 Predicting CA, HCA or HA BSI cases 
All the AIC and BIC values for the model combinations and the Adjusted ORs for the selected 
final models (HA1-HA9) for each age-group are shown in Appendix 5. 
All the models for both age-groups found that children with two or more chronic conditions 
had the highest statistically significant odds of having defined HA BSI (Children aged 1 month < 
1 year OR HA1: 2.05, 95% CI: 1.30-3.21; HA9 OR: 18.11, 95% CI: 8.38-39.14. Children aged 1-5 
years OR HA1: 1.47, 95% CI: 1.07-2.03; HA9 OR: 64.68, 95% CI: 24.64-169.77). Of the other 
variables, the models found that children with an invasive procedure in the past 30 days 
(children aged 1 month < 1 year) or the past 90 days (children aged 1-5 years), had higher odds 
of having a HA BSI. Children with an indwelling device in the preceding 7-90 days (P<0.01; 
children aged 1 month < 1 year), or 1-90 days (P<0.01; children aged 1-5 years) had higher 
odds of having HA BSI, with the highest odds occurring in children with an indwelling device in 
the 7-30 days prior to the BSI (1m<1y OR: 15.57-56.48; 1-5y OR: 7.82-75.06). 
Previous discharge was not included in the model with the lowest AIC or BIC in the HA1-HA3 
models in the younger age-group, but was included and found to be a statistically significant 
indicator for a reduced odds of HA BSI from HA4-HA9 where there was a previous discharge 
between 7 days and up to a year previously (P<0.01). Similarly, children aged 1-5 years with a 
previous discharge between 7-90 days prior to the BSI for the HA5-HA9 thresholds had 
significantly lower odds of having defined HA BSI compared to all other children with BSI. The 
only difference was the HA1 and HA2 threshold in the older age-group, where children with a 
previous discharge in the 7-30 days for HA1 (OR=2.07, 95% CI: 1.43-3.00; HA2 OR=2.78), and 
four-fold for HA2 (OR=4.19, 95% CI: 2.95-5.94) had double the odds of having HA BSI.  
In children aged 1 month < 1 year, the variable age in the HA1-HA3 models was transformed by 
a power of (-0.5), inverting the age values so that the youngest age becomes the highest value, 
therefore the odds (OR = 6.19-9.36) are for age(-0.5), so that increasing age was associated with 
lower odds of having a HA BSI. For HA4-HA9, the variable age was not transformed, unlike 
HA1-HA3, and therefore as age increased, the odds of the BSI being HA decreased significantly 
(OR=0.99, P<0.001). 
Information on prematurity or low birth-weight were only included in models HA4-HA9 for 
children aged 1 month < 1 year, where the odds of being premature or born with low-birth-
weight and having defined HA BSI as opposed to a priori CA BSI was more than double (2.09-
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3.11; P<0.01). Sex was either excluded or contributed no statistically significant differences in 
either age-group. 
The range of predicted probabilities (using the coefficients from the logistic regression models) 
in relation to the timing of hospital admission by age-group are depicted in Figure 5.18 and 
Figure 5.19 (jittered data points). There was a clear clustering of defined HA BSI, particularly in 
the top fifth (0.8-1.0) of predicted probability in all of the scenarios and both age-groups: 
709/1,325 (53%; HA1) and 419/530 (79%; HA9) for children age 1 month < 1 year; 506/1,379 
(37%; HA1) and 227/373 (61%) for children aged 1-5 years. 
The majority of children with a priori CA BSI (60% of children aged 1 month < 1 year; 84% of 
children aged 1-5 years) were predicted to have a low probability of having HA BSI between 0 
and 0.4 (as would be expected). The concentration of children with a priori CA BSI and a 
corresponding low prediction of being HA-BSI (between 0 and 0.2) increased as the HA-
threshold moved from HA1 to HA9 (89% of children aged 1 month < 1 year; 92% of children 
aged 1-5 years). Only a small number of children with a priori CA BSI had very similar predicted 
values to children with defined HA BSI.  
Table 5.12 and Table 5.13 report the numbers of children with predicted CA, HCA and HA 
compared to the a priori CA BSI and total HA BSI by age-group. The proportion of total CA BSI 
(a priori and predicted) was the dominant category in both age-groups compared to HCA or HA 
BSI. The proportion of predicted HCA BSI was similar in both age-groups accounting for 
between 11-13% of BSI (with the exception of HA1 in the younger age-group) across the nine 
different scenarios. The proportion of HA BSI was highest in the younger age-group (12-18% 
between HA2-HA9; 30% on HA1) compared to the 1-5 year olds (6-11% between HA2-HA9; 
22% for HA1). The largest difference between the nine different scenarios was between HA1 
and HA2, which may be a reflection of the large sampling of blood samples taken in day 1 
compared to day 2. 
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Table 5.12. Approach B: Predicted proportions of CA BSI, HCA BSI and HA BSI in children aged 1 month 
< 1 year, n=4,415 
HA BSI 
threshold 
CA BSI   HCA/HA BSI   HA BSI 
a 
priori 
predicted %   
predicted 
HCA  
(<1d after 
adm) 
predicted 
HCA & HA 
(1 to x 
days after 
adm) 
% range   defined % 
HA1 848 1,039 43%   1203 0 27%   1,325 30% 
HA2 848 2,207 69%   422 135 10-13%   803 18% 
HA3 848 2,342 72%   373 144 8-12%   708 16% 
HA4 848 2,412 74%   341 153 8-11%   661 15% 
HA5 848 2,457 75%   319 166 7-11%   625 14% 
HA6 848 2,474 75%   317 178 7-11%   598 14% 
HA7 848 2,485 75%   312 192 7-11%   578 13% 
HA8 848 2,523 76%   299 193 7-11%   552 13% 
HA9 848 2,552 77%   284 201 6-11%   530 12% 
 
Table 5.13. Approach B: Predicted proportions of CA BSI, HCA BSI and HA BSI in children aged 1-5 
years, n=6,172 
HA BSI 
threshold 
CA BSI   HCA/HA BSI   HA BSI 
a 
priori 
predicted %   
predicted 
HCA  
(<1d after 
adm) 
predicted 
HCA & HA 
(1 to x 
days after 
adm) 
% range   defined % 
HA1 1,711 2,292 65%   790 0 13%   1,379 22% 
HA2 1,711 3,062 77%   582 129 9-12%   688 11% 
HA3 1,711 3,206 80%   517 169 8-11%   569 9% 
HA4 1,711 3,242 80%   504 192 8-11%   523 8% 
HA5 1,711 3,341 82%   449 193 7-10%   478 8% 
HA6 1,711 3,358 82%   445 209 7-11%   449 7% 
HA7 1,711 3,409 83%   427 206 7-10%   419 7% 
HA8 1,711 3,437 83%   412 218 7-10%   394 6% 
HA9 1,711 3,471 84%   402 215 7-10%   373 6% 
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Figure 5.18. Distribution of predicted HCA, predicted HCA/HA, predicted CA, a priori CA and defined HA BSI between -5 and +30 of hospital admission in children aged 1 
month < 1 year (jittered data points) 
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Figure 5.19. Distribution of the predicted HCA, predicted HCA/HA, predicted CA, a priori CA and defined HA BSI between -5 and +30 of hospital admission in children aged 1-
5 years (jittered data points)  
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5.4.2.2 Summary of approach B results 
In this approach, between 6% and a quarter of children with BSI in both age-groups were 
predicted to have HCA BSI, based on the assumption that children with HCA BSI had similar 
clinical characteristics to children with HA BSI. The majority of BSIs in both age-groups were 
predicted to be CA BSI (43-84%).  
There was a clear distinction between the predicted values for the majority of a priori CA BSI 
and defined HA BSI in the graphs; this was expected since the regression model was based on 
only these two distinct populations and although the timing of the BSI was not directly 
included, the timing of events in relation to the BSIs were included and therefore would be 
highly predictive. The predicted proportions of CA, HCA and HA BSI were consistent when 
using thresholds HA2-HA9 in comparison to HA1. For example, children with a previous 
discharge (using HA1) had statistically significant higher odds of having defined HA BSI, 
whereas between HA5 and HA9, children had lower odds of having defined HA BSI, potentially 
as a result of the impact of selecting this low threshold and over-estimating HA rather than 
HCA BSI. 
Unsurprisingly, children with an indwelling device in the previous 7-90 days had significantly 
higher odds of having a defined HA BSI compared to those with a priori CA BSI. This may be 
one of the reasons why so many children were predicted as having CA BSI because they did not 
have a history of an indwelling device in the year prior to the BSI (data presented in Chapter 6). 
5.4.3 Results: approach C 
5.4.3.1 Model 1: Multiple Correspondence Analysis (MCA) 
The top 15 MCA dimensions and the corresponding proportion of inertia that each dimension 
accounted for are shown in Table 5.14 by age-group. The top 15 dimensions accounted for 
82% (children aged 1 month < 1 year) and 83% (children aged 1-5 years) of all the inertia; the 
contribution to inertia beyond the 15th dimension diminished with each subsequent dimension 
(<0.01% per dimension). Since the first two dimensions accounted for the majority of the 
inertia (72% in children aged 1 month < 1 year; 75% in children aged 1-5 years), I decided to 
use only the first two dimensions for the rest of the approach C analysis.  
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Table 5.14 The MCA dimensions and the proportional inertia that they account for 
  Children aged 1 month < 1 year   Children aged 1-5 years 
Dimension Inertia 
% of 
inertia 
% of inertia 
(cumulative)   Inertia 
% of 
inertia 
%  of inertia 
(cumulative) 
1 0.0751188 62.8 62.8   0.0607750 67.1 67.1 
2 0.0112575 9.4 72.2   0.0072357 8.0 75.1 
3 0.0050917 4.3 76.4   0.0031687 3.5 78.6 
4 0.0029841 2.5 78.9   0.0024434 2.7 81.3 
5 0.0024623 2.1 81.0   0.0005901 0.7 81.9 
6 0.0005174 0.4 81.4   0.0001592 0.2 82.1 
7 0.0004495 0.4 81.8   0.0001415 0.2 82.2 
8 0.0001755 0.2 81.9   0.0001133 0.1 82.4 
9 0.0001240 0.1 82.0   0.0000675 0.1 82.4 
10 0.0000879 0.1 82.1   0.0000416 0.1 82.5 
11 0.0000600 0.1 82.2   0.0000263 <0.1 82.5 
12 0.0000480 <0.1 82.2   0.0000206 <0.1 82.5 
13 0.0000296 <0.1 82.2   0.0000114 <0.1 82.5 
14 0.0000248 <0.1 82.3   0.0000088 <0.1 82.6 
15 0.0000160 <0.1 82.3   0.0000028 <0.1 82.6 
Total 0.1196671 
 
    0.0906173 
 
  
 
The relationships of the clinical and demographic categorical variables from dimension 1 and 
dimension 2 are plotted in Figure 5.20 for children aged 1 month < 1 year and in Figure 5.21 for 
children aged 1-5 years. 
In children aged 1 month < 1 year, there was a cluster of children without any clinical 
characteristics (including no indwelling device, no previous procedure, no chronic or congenital 
conditions) with the exception of those with 1 chronic condition, on the border between 
quadrants I and II, alongside children who had a BSI isolated before hospital admission 
(quadrant I). Children with no previous postnatal stay and no previous discharge within the 
past year were completely separate from all other variables in quadrant II. Children with 
clinical characteristics based on clinical events (including indwelling devices, last invasive 
procedure) happening within a week prior to the BSI were grouped in quadrant III, or in 
quadrant IV if the characteristics were detected further back in time, the majority being for a 
month or more prior to the BSI. The day on which the BSI was isolated in relation to hospital 
admission was split between quadrant III and IV, where the increase in days into a hospital 
admission resulted in a higher negative dimension 1 value away from children who had a 
positive BSI before hospital admission. The clinical characteristics occurring between 7 days < 1 
year before the BSI, and children who were born premature or with low birth-weight, or a 
congenital condition were predominantly grouped in quadrant IV. There were no large 
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differences observed by ethnicity, which were grouped at the meeting point of all four 
quadrants (with the exception of “other” or “not known”). 
For children aged 1-5 years, there was a cluster of children with none of the defined clinical 
characteristics between quadrant I and II of Figure 5.21 (no previous discharge, no chronic or 
congenital conditions, no invasive procedures, no indwelling devices, term or healthy weight 
babies). Patients in the categorised age-groups were all clustered at the central value of zero. 
There was a large spread of children with defined clinical characteristics across quadrants III 
and IV. These were predominantly split into events occurring close to the time of the BSI 
(quadrant III) versus events that occurred further in the past (quadrant IV). In this age-group, 
children with two or more chronic conditions were all grouped in quadrant IV alongside the 
characteristics of congenital conditions, being premature or having a low birth weight. 
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Figure 5.20. Plot of the multiple correspondence analysis results between dimension 1 and 2 for all the explanatory variables; children aged 1 month < 1year  
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Figure 5.21. Plot of the multiple correspondence analysis results between dimension 1 and 2 for all the explanatory variables; children aged 1-5 years  
II 
III 
I 
IV 
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To illustrate the distribution of the individual MCA dimension values assigned to each child, the 
scatter plots in Figure 5.22 and Figure 5.23 demonstrate this distribution by age-group. To help 
interpret the distribution (although the information was not used in the Approach C models), 
the children with a priori CA BSI (blue dots), defined HA (yellow dots; using the HA2 threshold), 
or undefined BSI (grey dots) are highlighted in both figures. 
In both age-groups, there is a visible cluster of children with a priori CA BSI (between -1 to +1 
in Dimension 1; 0 to +1 in Dimension 2) corresponding to children with few clinical 
characteristics, as seen in Figure 5.20 and Figure 5.21. The values for the remaining children 
with defined HA or undefined BSI were dispersed across the plotted range of values between -
4 and +2 in children aged 1 month < 1 year, and from -4 to +4 in children aged 1-5 years. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.22. Scatter plot illustrating the values for dimension 1 and 2 assigned to each child, aged 1 
month < 1 year, in the multiple correspondence analysis 
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Figure 5.23. Scatter plot illustrating the values for dimension 1 and 2 assigned to each child, aged 1-5 
years, in the multiple correspondence analysis 
 
The predicted values from the two dimensions created in the MCA were used to inform the K-
medians discriminatory analysis to identify the three subgroups of children described in the 
methods (section 5.3.3.2).  
5.4.3.2 Model 2: K-medians analysis 
The frequency of children grouped into the three K-medians groups using the MCA 
dimensional results are summarised at the top of Table 5.15 and are cross-tabulated with the a 
priori CA BSI, defined HA BSI and the remaining mixed BSI cases below. As a reminder, the 
three groups were compared to the number of children categorised as having a priori CA BSI 
(group 1), undefined mix of BSI (group 2) or defined HA BSI (group 3). 
The majority of children in both age-groups were allocated to group 1 (60% for 1 month < 1 
year olds; 68% in 1-5 year olds). Children in the younger age-group had the lowest number of 
children allocated to group 2 (15%), whereas the older age-group assigned the least number of 
children to group 3 (14%). 
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When compared to the assumptions made in approaches A and B, not all the a priori CA or 
defined HA BSI cases fitted perfectly into one particular group in either age-group. This is as 
expected since the a priori CA and defined HA groups would not contain all of the CA and HA 
BSI. Nevertheless, the awarded groupings do follow an interpretable pattern where group 1 
accounted for the majority of a priori CA (75% for 1m<1yr; 86% for 1-5 years) and group 3 
accounted for the majority of defined HA BSI (HA1: 50% for 1m<1yr; 39% for 1-5 years; HA9: 
80% for 1m<1yr; 72% for 1-5 years). To predict the proportion of HCA BSI, group 2 would most 
likely represent this group, where between 15-18% of BSI were counted. 
The results in Table 5.15 show that for both age-groups, there were low numbers (<20% for 
HA2, <10% for HA3-HA9) of the a priori CA and defined HA BSI in groups 1 and 3 respectively. 
The a priori CA observations was also low (<20%) in group 2 for all thresholds. There was more 
proportional variability of observations in group 2 for children with defined HA BSI. All but one 
(HA6) of the thresholds for the younger age-group showed <20% of the observations occurring 
in Group 2 for defined HA BSI; in the older age-group, only the HA1 threshold observes <20% of 
the observations occurring in Group 2 for defined HA BSI. 
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Table 5.15. Cross-tabulation of the K-medians groups with the defined HA, a priori CA and the 
remaining mixed BSI-cases by age-group 
 
Optimal outcome:  Group identified from the model     
  1 2 3 Total   
defined HA BSI 0 0 n3a nHA n = children 
a priori CA BSI n1b 0 0 nCA   
remaining mixed BSI n1c n2c n3c nmixed   
 
 
 Children aged 1 mth < 1 yr   Children aged 1 - 5 yrs  
 
Group 
  
Group 
 
 
1 2 3 Total 
 
1 2 3 Total 
Total 2,636 649 1,130 4,415 
 
4,205 1,102 865 6,172 
% 60% 15% 26% 
  
68% 18% 14% 
                     
defined HA1 440 224 661 1,325   591 271 517 1,379 
a priori CA 635 141 72 848   1,478 176 57 1,711 
mixed 1,561 284 397 2,242   2,136 655 291 3,082 
  
    
  
    defined HA2 89 149 565 803   110 151 427 688 
a priori CA 635 141 72 848   1,478 176 57 1,711 
mixed 1,912 359 493 2,764   2,617 775 381 3,773 
  
    
  
    defined HA3 43 137 528 708   50 127 392 569 
a priori CA 635 141 72 848   1,478 176 57 1,711 
mixed 1,958 371 530 2,859   2,677 799 416 3,892 
  
    
  
    defined HA4 29 131 501 661   38 120 365 523 
a priori CA 635 141 72 848   1,478 176 57 1,711 
mixed 1,972 377 557 2,906   2,689 806 443 3,938 
  
    
  
    defined HA5 15 125 485 625   27 109 342 478 
a priori CA 635 141 72 848   1,478 176 57 1,711 
mixed 1,986 383 573 2,942   2,700 817 466 3,983 
  
    
  
    defined HA6 12 123 463 598   19 108 322 449 
a priori CA 635 141 72 848   1,478 176 57 1,711 
mixed 1,989 385 595 2,969   2,708 818 486 4,012 
  
    
  
    defined HA7 12 113 453 578   17 105 297 419 
a priori CA 635 141 72 848   1,478 176 57 1,711 
mixed 1,989 395 605 2,989   2,710 821 511 4,042 
  
    
  
    defined HA8 9 108 435 552   17 104 273 394 
a priori CA 635 141 72 848   1,478 176 57 1,711 
mixed 1,992 400 623 3,015   2,710 822 535 4,067 
  
    
  
    defined HA9 3 106 421 530   16 102 255 373 
a priori CA 635 141 72 848   1,478 176 57 1,711 
mixed 1,998 402 637 3,037   2,711 824 553 4,088 
          Legend <10% 10<20% of total in sub-group (e.g. defined HA, or a priori CA, or mixed) 
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5.4.3.3 Summary of approach C results 
In the MCA analysis, there was an evident separation in both age-groups between the cluster 
of children with very few clinical conditions compared to children with multiple clinical 
conditions occurring in close time proximity to the BSI versus longer term clinical contact or 
conditions. 
The proportion of BSI in groups 1, 2 and 3 remained the same (highlighted in orange in Table 
5.15) regardless of the HA threshold used to interpret the frequency of children with CA, HCA 
and HA BSI. In both age-groups, the majority of BSI was attributed to CA BSI (group 1), with 
HCA BSI predicted to account for 15-18% of all BSI (group 2). There was a higher proportion of 
children predicted to have HA BSI in children aged 1 month < 1 year (26%) than in children 
aged 1-5 years (14%). 
5.5 Chapter summary 
This chapter has described the methods and results of the three statistical approaches used to 
predict the proportion of CA, HCA and HA BSI in children (by age-group), including the 
assumptions that were made in the models.  
There was no consistent predicted proportion of CA or HCA BSI in approaches A, B and C. The 
majority of BSI in approach A were predicted to be HCA BSI (59-60%), whereas the majority of 
BSI in approach B (69-77%) and C (60-68%) were predicted to be CA BSI. Unlike CA and HCA 
BSI, the proportion of predicted HA BSI was more consistently predicted in all three models 
(≤26% in children aged 1 month < 1 year; ≤14% in children aged 1-5 years). 
Although a completely different method was employed for approach C, the results most 
resembled the distributions found by approach B and reflected the clustering of patients with 
very few clinical characteristics compared to all other children, where there was a spectrum 
between recent and older time occurrence of clinical characteristics. 
5.5.1 Discussion and limitations of the methodology 
5.5.1.1 Predicted probability 
In approaches A and B, logistic models were used to identify the features most associated with 
higher probabilities of being HA or CA for various subgroups of the data. These models were 
then applied in a wider group where the true distributions were unknown and all may be HA, 
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all may be CA, or more likely there was an intermediate distribution. To avoid super-imposing 
any prior belief on the percentages expected to be HA (or CA), those with probabilities of 0.5 
or greater were allocated to the outcome category (HA or CA depending on the logistic model) 
on the basis that they were estimated to be more likely to be in that category (p≥0.5) than the 
alternative (p <0.5).     
Selecting an alternative estimated probability as the cut-point for allocation to categories 
would have required making some assumption as to the prior likelihood that a BSI was of a 
particular type (HA or CA). Whilst additional sensitivity models could have been incorporated 
to test the effect of different probability thresholds in Approach A (and Approach B), given that 
the purpose was to identify the percentages who belonged in these categories, this was 
unlikely to be of practical use to interpretation. 
5.5.1.2 Best subset framework 
Since all potential stepwise models are considered in the best subsets approach (which 
evaluates all possible models), it would be expected that the best subsets approach would be 
superior. The technique has long been shown to have advantages over other selection models 
in terms of selecting the correct model.(182) Berk made both theoretical and empirical 
comparisons to show that best subsets frequently outperforms other methods and is unlikely 
to perform poorly.(182) Whilst this is accepted, there is criticism that different subset size may 
have an effect on the selected subset, which is not a favorable feature. In my analyses, I was 
aware of the problems of interpreting major fluctuations in the included variable set with 
increasing subset sizes, but there were none so this was not an issue.  The major disadvantage 
of best subsets is increased computation but this is now mostly negated by availability of 
computing packages with large capabilities. Hence there has been a growth in the use of best 
subset model fitting in recent years as computation has become easier.  
The AIC and BIC are established means of comparing both nested and non-nested regression 
models. They are asymptotically equivalent to Mallows Cp.(183) 
As regards model validation, these models were exploratory with respect to identification of 
individuals whose BSI were HA or CA. However, in the analyses, the models being produced 
are not intended to be used directly by other researchers, so this is likely less important than 
for those producing prognostic models for clinical application. In addition, I did not have the 
true outcomes to compare with my models. The precision of the fitted models could be 
investigated and how this translates into the likely error of predicted percentage distributions 
shown Figure 6.3. Bootstrap sampling may be used to achieve this investigation of the fitted 
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model precision in future work.(184-186) A further validation would be an investigation of 
model outliers using leave-one-out approaches and consideration of beta values for the subset 
used in the production of the models. 
The outcomes of the three approaches will be compared in more detail in Chapter 6 and will 
include the sensitivity analyses in addition to the distribution of clinical characteristics and 
pathogen according to whether the BSI was predicted to be CA, HCA, or HA BSI.  
  
 174 
Chapter 6. Distribution of risk factors 
and pathogens by predicted CA, HCA 
and HA BSI category 
6.1 Introduction 
In the previous chapter, I developed three statistical approaches (A, B and C) using the linked 
(MW-Child) dataset described in Chapters 3 and 4 to predict the proportion of CA, HCA and HA 
BSI using child demographics, clinical characteristics and the timing of positive blood samples 
in relation to hospital admission. This chapter aims to compare the results from approaches A, 
B and C and identify if, i) the clinical/demographic characteristics and timing of blood specimen 
adequately predict the source of infection; ii) the source of infection predicts the pathogen 
(Figure 6.1). Knowledge about the proportional burden of the source of BSI can inform 
preventive strategies according to the burden of BSI in each environment (community, or 
healthcare in the community, or hospital). Ideally, the subsequent identification of the 
causative pathogen, by source of infection, would help to inform treatment strategies. 
Although the optimum outcome would be to detect the antibiotic susceptibility of each 
invasive pathogen to tailor the antibiotic treatment, antibiotic susceptibility data was not 
included in this thesis due to variable completion of the data because of result suppression at 
the laboratory level; the implications of additional antimicrobial susceptibility data will be 
discussed in Chapter 7. 
 
 
 
 
 
 
Figure 6.1. Steps taken in this thesis (in the box) to inform preventive and treatment strategies for 
children with BSI dependent on the prediction capability of the models 
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Appropriate 
antibiotic 
treatment
Preventive 
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Appropriate 
antibiotic 
treatmentThis thesis
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6.1.1 Chapter structure 
I begin by comparing the predicted proportions of CA, HCA and HA BSI results from approaches 
A, B and C and their sensitivity analyses according to the nine HA1-HA9 thresholds. I go on to 
tabulate child demographic and clinical characteristics in relation to the predicted numbers of 
children with CA, HCA and HA BSI to describe the most prevalent risk factors that defined the 
groups of children. Subsequently, I reveal the pathogen distribution by specimen date in 
relation to hospital admission and the model distributions of the pathogen species by age-
group for the three approaches. In the discussion, I consider and compare the predicted 
proportional distribution of CA, HCA and HA BSI from this thesis with the 2-day (proxy for 48-
hour) threshold to determine what proportion of BSI are re-classified as HCA using the model 
predictions from Chapter 5. Figure 6.2 illustrates the context of this chapter (red) in relation to 
the rest of the thesis. 
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Figure 6.2. Flow diagram of the steps taken (grey) and those that will be addressed in this chapter 
(red) to predict the proportion of CA, HCA and HA BSI in children 
Distribution of risk factors and 
pathogens by predicted CA, HCA 
and HA BSI category 
Determining whether clinical/ 
demographic characteristics & 
timing of the BSI adequately predict 
the source of infection and reporting 
the distribution of pathogens by 
category 
Probabilistically linked LabBase2 and HES to obtain cohort for analysis 
• Calculated new match-weights and probabilistically linked data 
• Selection of linkage threshold, data cleaning  and formatting 
Description of available data sources and defining analysis cohort  
• LabBase2: microbiology dataset containing  reports of bacterial species 
isolated from clinically significant blood specimens and specimen date 
• HES: clinical dataset containing demographic, clinical  and  admission/ 
discharge date data for all in-patient child admissions in England 
• Cohort: children with index BSI between April 2007 and March 2011 who 
were discharged from hospital at least once between birth and the BSI 
Introduction and aim of thesis 
• The systematic literature review and survey results illustrate the move 
from a dichotomous CA and HA BSI distinction based on the timing of 
BSI alone to the incorporation of HCA BSI in children, but with no 
uniformly agreed definitions 
• Aim: distinguish between CA, HCA and HA BSI using additional data 
about child clinical  and demographic characteristics 
Chapter 1 
Chapter 2 
Chapter 3 
Clinical/ demographic 
characteristics 
Source of infection 
Causative pathogen 
Methods and results for predicting 
source of infection (CA, HCA, HA BSI)  
Predicted the likely source of 
infection using the three Approaches 
(A,B & C) 
Chapter 4 
Chapter 5 
Chapter 6 
Discussion and conclusions Chapter 7 
Predict? 
 
 
 
 
 
Linked study population  
Identify indicators of child 
susceptibility, in-hospital exposure 
(including invasive procedures) and 
timing of infection that could predict 
CA, HCA and HA BSI 
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6.2 Comparing the estimated proportion of CA, HCA and HA BSI 
according to each method (A, B and C) 
6.2.1 Methods 
Graphical plots were used to compare the predicted proportion of CA, HCA and HA BSI by age-
group (using the nine HA BSI thresholds). The predicted proportions from the two sensitivity 
analyses (described in Chapter 5: 1. including hospital as a random effect; 2. removal of 
children with a priori CA BSI) were also depicted graphically. For comparability, the proportions 
of CA, HCA and HA BSI for approach C were plotted on the same graph axes as approaches A 
and B, but the predicted proportions remained the same across all the HA-thresholds as the 
thresholds were not incorporated into the models. The estimated proportions were compared 
with the commonly used CA/HA BSI (48-hour/2day) threshold to determine what proportion of 
BSI would be re-categorised as HCA using the results from this thesis.  
6.2.2 Results 
The predicted proportions of CA and HCA BSI were very different between approach A 
compared to approaches B or C, whereas the predicted proportions of HA BSI were similar for 
all three approaches (Figure 6.3). There was little change in the predicted proportions of CA, 
HCA and HA BSI by day of HA-threshold from the HA2-day threshold to the HA9-day threshold, 
with the exception of the predicted proportions on the HA1-day threshold in all models. As the 
results were predominantly consistent for eight of the nine HA-thresholds, the results using 
the HA2-day threshold (for approaches A and B) will be reported for the remainder of the 
results section for consistency. 
The predicted proportion of HA BSI was the most consistently predicted category between all 
approaches A, B and C in children aged 1 month < 1 year (HA2: 18-26%) and in children aged 1-
5 years (HA2: 11-14%; Table 6.1 and Table 6.2). The proportional difference between predicted 
CA and HCA BSI in approaches A, B and C spanned a range of 48%. Approach A predicted the 
highest proportion of HCA BSI in both age-groups (1 month < 1 year: 60%; 1-5 years: 59%) and 
approach B predicted the lowest (1 month < 1 year: 13%; 1-5 years: 12%). Inversely, approach 
A predicted the lowest proportion of CA BSI (1 month < 1 year: 21%; 1-5 years: 30%) and the 
highest proportion in approach B (1 month < 1 year: 69%; 1-5 years: 77%). 
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Figure 6.3. Proportion of BSI categorised as CA, HCA or HA for approaches A, B and C (including 
sensitivity analyses) by age-group and HA threshold 
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The predicted proportions of CA and HCA BSI for approach C fell between the estimates of 
approaches A and B, whereas the predicted proportion of HA BSI was 7% higher in children 
aged 1 month < 1 year and 2% higher in children aged 1-5 years. 
Table 6.1. Final distribution of CA, HCA and HA BSI by approach A, B and C for children aged 1 month < 
1 year using the 2-day defined HA threshold 
 
Total CA BSI % HCA BSI % HA BSI % 
approach A 4,415 941 21% 2,635 60% 839 19% 
approach B 4,415 3,055 69% 557 13% 803 18% 
approach C 4,415 2,636 60% 649 15% 1,130 26% 
Table 6.2. Final distribution of CA, HCA and HA BSI by approach A, B and C for children aged 1-5 years 
using the 2-day defined HA threshold 
 
Total CA BSI % HCA BSI % HA BSI % 
approach A 6,172 1,839 30% 3,621 59% 712 12% 
approach B 6,172 4,773 77% 711 12% 688 11% 
approach C 6,172 4,205 68% 1,102 18% 865 14% 
 
6.2.2.1 Results of the sensitivity analyses 
Hospital as a random effect 
There was very little change in the predicted proportions of CA, HCA or HA BSI when hospital 
was included as a random effect, with the exception of approach A in children aged 1-5 years 
where the gap between the proportion of CA and HCA BSI was narrowed by 8%, although HCA 
BSI still accounted for the majority of BSI (Figure 6.3b). The proportion of BSI classified as CA 
increased from 30% to 34% and the proportion of BSI classified as HCA decreased from 59% to 
55%. Overall, I concluded that clustering by hospital did not appreciably affect the predicted 
distribution of CA, HCA or HA BSI 
Removal of CA BSI occurring two or more days after hospital admission  
Children with a priori CA BSIs were removed (n=129/2,559; 5%) from the dataset where their 
BSI occurred two or more days after hospital admission (n=46 children aged 1 month < 1 year; 
n=83 children aged 1-5 years). Of the 129/10,587 excluded children, approach C classified 77 
as CA, 22 as HCA and 30 as HA. The only change in the ranking of the CA, HCA and HA 
categories was observed in approach C in children aged 1 month < 1 year (Figure 6.3) where 
proportionally more Group 2 BSI (most resembling HCA; 20%) than Group 3 (most resembling 
HA BSI; 18%) were predicted. 
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6.2.3 Comparing the estimated proportions of CA, HCA and HA BSI with the 
commonly used CA/HA BSI threshold 
The literature review in Chapter 1 demonstrated that the 2-day (proxy for 48 hours) threshold 
was commonly employed to distinguish CA from HA BSI, but that timing of BSI alone has 
become insufficient to distinguish between them. Figure 6.4 illustrates the proportion of 
children that would have been classified as having CA (81% in children aged 1 month < 1 year; 
88% in children aged 1-5 years) or HA BSI (19% in children aged 1 month < 1 year; 12% in 
children aged 1-5 years) using the 2-day threshold only. Of these CA and HA BSI categories, the 
breakdown of the proportion of BSI predicted to be CA, HCA or HA using approaches A, B and C 
are subsequently shown.  
In Figure 6.4i, 81% of BSI in children aged 1 month < 1 year using the 2-day threshold only 
would be classified as CA, but when compared with the different approaches, predicted HCA 
BSI in approach A accounted for a significant proportion (74%). Although a smaller proportion, 
both approaches B and C predicted that 16% and 14% respectively were HCA. Of the 19% 
children classified as having HA BSI using the 2-day threshold only, the majority were also 
predicted to have HA BSI in all three approaches. 
Similarly in Figure 6.4ii, 88% of BSI in children aged 1 month < 1 year using the 2-day threshold 
only would be classified as CA, but when compared with the different approaches, predicted 
HCA BSI in approach A accounted for a significant proportion (67%). As with the younger age-
group, although a smaller proportion, both Approaches B and C predicted that 13% and 17% 
respectively of the 2-day threshold CA BSI were HCA BSI. Of the 12% children classified as 
having HA BSI using the 2-day threshold only, the majority were also predicted to have HA BSI 
in all three approaches. 
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Figure 6.4. Comparing model classification of children with CA, HCA or HA BSI (using day 2 of hospital 
admission as the threshold for defined HA BSI) subdivided according to specimens taken before 2 days 
after admission and 2 or more days after admission for children aged (i) 1 month < 1 year, (ii) 1-5 
years 
6.2.4 Section summary  
 The proportional estimates of HA BSI were low and consistent in all three approaches, 
with an estimated quarter of all BSI in children aged 1 month < 1 year and a sixth of all 
BSI in children aged 1-5 years. 
 Although a low and a high estimate of CA and HCA BSI was expected, the predicted 
range of proportions was very wide (range of 48%), demonstrating that the clinical and 
demographic indicators do no differentiate sufficiently between CA and HA BSI. 
CA 33% 87% 75%
HCA 67% 13% 17%
HA 0% 0% 8%
Approach
A        B C
2-day threshold
Proportional 
distribution of BSI in 
children aged 
1 – 5 years
HA (≥2 days)
12%
n = 771
CA (<2 days)
88%
n = 5,401
A        B C
n=1,756      n=4,690         n=4,039
n=3,621       n=711             n=943
n=24               n=0               n=419
CA 11% 11% 22%
HCA 0% 0% 21%
HA 89% 89% 58%
n=83              n=83             n=166
n=0                 n=0              n=159
n=688            n=688           n=446
CA 25% 84% 71%
HCA 74% 16% 14%
HA 1% 0% 16%
Approach
A        B C
2-day threshold
Proportional 
distribution of BSI in 
children aged 
1 month < 1 year
HA (≥2 days)
19%
n = 849
CA (<2 days)
81%
n = 3,566
A        B C
n=895 n=3,009        n=2,522
n=2,635         n=557            n=489
n=36               n=0              n=555
CA 5% 5% 13%
HCA 0% 0% 19%
HA 95% 95% 68%
n=46              n=46             n=111
n=0                 n=0              n=161
n=803            n=803           n=577
(i) 
(ii) 
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Further investigation is required into the types of children allocated to each group and 
the pathogens responsible.  
 Due to the high numbers of blood samples taken on admission and day 1 after 
admission in comparison to day 2-9 after admission, there is insufficient evidence to 
determine whether the 2-day threshold remains the best indicator to identify HA BSI. 
However, due to the stability of the predicted proportions between the 2-day and 9-
day threshold, I decided to report the results of the 2-day HA-threshold for the 
remainder of the chapter. 
 The comparison of the CA/HA threshold only with the predicted CA, HCA and HA BSI 
illustrates the importance of HCA BSI, distinguishing from CA BSI, which is not currently 
distinguished by the 2-day (48-hour) threshold. There is evidence to show that HCA BSI 
are becoming an important source of BSI and should be recognised formally in the 
considerations of the British empiric therapy guidance. 
6.3 Distribution of risk factors by CA, HCA and HA BSI category 
This section will present the distribution of risk factors according to the predicted CA, HCA or 
HA BSI categories (Figure 6.5). 
 
 
 
 
Figure 6.5. Clinical/demographic characteristics and time used to predict the source of infection 
6.3.1 Methods 
The distributions of demographic and clinical characteristics of children by predicted CA, HCA 
or HA BSI category were cross-tabulated and compared for approaches A, B and C using the 2-
day HA threshold. 
Clinical/
demographic 
characteristics 
and time
Source of 
infection
Causative 
pathogen
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6.3.2 Results 
6.3.2.1 Children aged 1 month < 1 year 
In all three approaches (Table 6.3), children with HA BSI had the highest prevalence of more 
than two chronic conditions (39-43%), compared to children with HCA BSI (6-28%), or CA BSI 
(1-4%). There was little proportional variation separating the three categories for children with 
only one chronic condition. 
Children with HA BSI had the highest prevalence of: congenital conditions (60-64%) compared 
to HCA BSI (14-61%) or CA BSI (5-8%); invasive procedures in the past 1-30 days (19-31%) 
compared to HCA BSI (3-24%) or CA BSI (1-7%); previous discharge in the past 1-30 days (23-
35%) compared to HCA BSI (7-37%) or CA BSI (7-11%); and indwelling devices in the past year 
(43-45%) where the proportion increased with time proximity to the BSI sample date. 
Seven (58%) of the 12 children with an a priori CA BSI and an indwelling device had their device 
inserted the day preceding the positive blood sample, suggesting that the indwelling device 
was unlikely to be the source of the BSI due to the short time frame. There was little difference 
between the proportion of CA, HCA or HA BSI for sex or ethnicity. 
  
1
8
4
 
Table 6.3. Distribution of demographic and clinical characteristics by approach A, B and C for children aged 1 month < 1 year (HA2 threshold) 
 
 
 
 
 
 
 
 
 
 
 
 
 
CA % HCA % HA2 % CA %
HCA/
HA
% HA %
Group 1 
(most like 
CA)
%
Group 2 
(most like 
HCA)
%
Group 3 
(most like 
HA)
%
boy 537 57% 1,605 61% 473 56% 1,805 59% 359 64% 451 56% 1,577 60% 359 55% 679 60% 2,615
girl 404 43% 1,030 39% 366 44% 1,250 41% 198 36% 352 44% 1,059 40% 290 45% 451 40% 1,800
White 746 79% 1,776 67% 475 57% 2,161 71% 384 69% 452 56% 1,891 72% 390 60% 716 63% 2,997
Mixed 26 3% 89 3% 26 3% 103 3% 12 2% 26 3% 91 3% 18 3% 32 3% 141
Indian subcontinent 53 6% 259 10% 96 11% 261 9% 55 10% 92 11% 239 9% 47 7% 122 11% 408
Any other Asian 7 1% 85 3% 34 4% 78 3% 17 3% 31 4% 66 3% 19 3% 41 4% 126
Black 23 2% 169 6% 54 6% 163 5% 30 5% 53 7% 144 5% 35 5% 67 6% 246
other ethnic group 23 2% 87 3% 51 6% 90 3% 21 4% 50 6% 70 3% 51 8% 40 4% 161
NK 63 7% 170 6% 103 12% 199 7% 38 7% 99 12% 135 5% 89 14% 112 10% 336
normal 815 87% 2,176 83% 549 65% 2,638 86% 379 68% 523 65% 2,360 90% 620 96% 560 50% 3,540
premature/low birthweight 126 13% 459 17% 290 35% 417 14% 178 32% 280 35% 276 10% 29 4% 570 50% 875
no chronic condition 437 46% 1,747 66% 124 15% 2,056 67% 128 23% 124 15% 1,819 69% 348 54% 141 12% 2,308
1chronic 369 39% 584 22% 166 20% 812 27% 147 26% 160 20% 691 26% 158 24% 270 24% 1,119
2chronics 95 10% 155 6% 187 22% 134 4% 126 23% 177 22% 93 4% 65 10% 279 25% 437
>2chronic 40 4% 149 6% 362 43% 53 2% 156 28% 342 43% 33 1% 78 12% 440 39% 551
no congenital condition 865 92% 2,257 86% 325 39% 2,910 95% 219 39% 318 40% 2,491 94% 554 85% 402 36% 3,447
congenital condition 76 8% 378 14% 514 61% 145 5% 338 61% 485 60% 145 6% 95 15% 728 64% 968
no invasive procedure 772 82% 2,006 76% 180 21% 2,634 86% 146 26% 178 22% 2,307 88% 518 80% 133 12% 2,958
91days<1yr 63 7% 188 7% 45 5% 196 6% 56 10% 44 5% 140 5% 3 0% 153 14% 296
31-90days 30 3% 235 9% 126 15% 133 4% 137 25% 121 15% 77 3% 8 1% 306 27% 391
7-30days 12 1% 127 5% 262 31% 19 1% 132 24% 250 31% 28 1% 52 8% 321 28% 401
1-6days 64 7% 79 3% 226 27% 73 2% 86 15% 210 26% 84 3% 68 10% 217 19% 369
no previous discharge 115 12% 300 11% 154 18% 373 12% 45 8% 151 19% 0 0% 536 83% 33 3% 569
91days<1yr 510 54% 779 30% 92 11% 1,273 42% 16 3% 92 11% 1,257 48% 34 5% 90 8% 1,381
31-90days 171 18% 922 35% 128 15% 939 31% 157 28% 125 16% 988 37% 10 2% 223 20% 1,221
7-30days 63 7% 437 17% 192 23% 303 10% 208 37% 181 23% 279 11% 25 4% 388 34% 692
1-6days 82 9% 197 7% 273 33% 167 5% 131 24% 254 32% 112 4% 44 7% 396 35% 552
no indwelling device 904 96% 2,459 93% 477 57% 2,999 98% 382 69% 459 57% 2,626 100% 593 91% 621 55% 3,840
91days<1yr last insertion 18 2% 75 3% 57 7% 39 1% 57 10% 54 7% 4 0% 2 0% 144 13% 150
31-90days last insertion 4 0% 80 3% 108 13% 4 0% 87 16% 101 13% 2 0% 3 0% 187 17% 192
7-30days last insertion 1 0% 21 1% 138 16% 1 0% 27 5% 132 16% 0 0% 34 5% 126 11% 160
1-6days last insertion 14 1% 0 0% 59 7% 12 0% 4 1% 57 7% 4 0% 17 3% 52 5% 73
Total 941 2,635 839 3,055 557 803 2,636 649 1,130 4,415
Approach A Approach B Approach C
Total
Clinical and demographic 
characteristics
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6.3.2.2 Children aged 1-5 years 
In all three approaches, children with CA BSI (Table 6.4) had the lowest proportion of 
prematurity at birth or low birth-weight, chronic conditions, congenital conditions, previous 
procedure, previous discharge or previous invasive device compared to children with HCA or 
HA BSI. This was most pronounced for patients with indwelling devices, where ≤1% of patients 
had any mention of an indwelling device in the past 1-90 days. 
The HA BSI category contained the largest proportion of children with more than two chronic 
conditions for approaches A, B and C (50%, 49% and 43% respectively), with the lowest 
proportion found in children with CA BSI (7%, 6% and 2% respectively). 
The HCA BSI category in approaches B and C contained a larger proportion of children with 
congenital conditions (B = 42%, C = 39%) than the HA BSI category (B = 30%, C = 19%), and the 
largest proportion of children with a previous discharge in the past year (particularly in the 
past 1-30 days) compared to the CA or HA BSI categories. The HCA category in approach A 
contained a smaller proportion of children with congenital or previous discharge compared to 
the HA BSI category. 
In all three approaches, children with HA BSI had the highest proportion of indwelling devices 
or invasive procedures inserted in the past 1-6 days (8-13% and 31-49% respectively) 
compared to children with HCA BSI (1-7% and 1-21% respectively) and CA BSI (0% and 1-3% 
respectively). Little difference was observed by sex or ethnicity between the CA, HCA or HA BSI 
categories. 
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Table 6.4. Distribution of demographic and clinical characteristics by approach A, B and C for children aged 1 - 5 years (HA2 threshold) 
 
 
 
 
 
 
 
 
 
 
 
 
CA % HCA % HA2 % CA %
HCA/
HA
% HA %
Group 1 
(most like 
CA)
%
Group 2 
(most like 
HCA)
%
Group 3 
(most like 
HA)
%
boy 1,054 57% 2,022 56% 407 57% 2,699 57% 391 55% 393 57% 2,331 55% 679 62% 473 53% 3,483
girl 785 43% 1,599 44% 305 43% 2,074 43% 320 45% 295 43% 1,874 45% 422 38% 393 44% 2,689
White 1,268 69% 2,449 68% 446 63% 3,251 68% 481 68% 431 63% 2,844 68% 717 65% 602 68% 4,163
Mixed 72 4% 112 3% 14 2% 170 4% 14 2% 14 2% 136 3% 40 4% 22 2% 198
Indian subcontinent 133 7% 343 9% 76 11% 412 9% 69 10% 71 10% 360 9% 140 13% 52 6% 552
Any other Asian 33 2% 119 3% 22 3% 115 2% 38 5% 21 3% 113 3% 39 4% 22 2% 174
Black 98 5% 258 7% 41 6% 324 7% 32 5% 41 6% 277 7% 86 8% 34 4% 397
other ethnic group 44 2% 124 3% 34 5% 143 3% 26 4% 33 5% 132 3% 24 2% 46 5% 202
NK 191 10% 216 6% 79 11% 358 8% 51 7% 77 11% 343 8% 55 5% 88 10% 486
normal 1,702 93% 3,306 91% 610 86% 4,429 93% 596 84% 593 86% 3,955 94% 875 79% 788 89% 5,618
premature/low birthweight 137 7% 315 9% 102 14% 344 7% 115 16% 95 14% 250 6% 226 21% 78 9% 554
no chronic condition 881 48% 1,833 51% 65 9% 2,676 56% 38 5% 65 9% 2,626 62% 115 10% 38 4% 2,779
1chronic 660 36% 880 24% 158 22% 1,394 29% 149 21% 155 23% 1,259 30% 236 21% 203 23% 1,698
2chronics 177 10% 466 13% 133 19% 435 9% 210 30% 131 19% 250 6% 284 26% 242 27% 776
>2chronic 121 7% 442 12% 356 50% 268 6% 314 44% 337 49% 70 2% 466 42% 383 43% 919
no congenital condition 1,764 96% 3,241 90% 494 69% 4,609 97% 409 58% 481 70% 4,131 98% 674 61% 694 78% 5,499
congenital condition 75 4% 380 10% 218 31% 164 3% 302 42% 207 30% 74 2% 427 39% 172 19% 673
no invasive procedure 1,630 89% 2,589 71% 146 21% 4,122 86% 97 14% 146 21% 4,118 98% 215 20% 32 4% 4,365
91days<1yr 80 4% 284 8% 39 5% 257 5% 107 15% 39 6% 0 0% 402 37% 1 0% 403
31-90days 40 2% 252 7% 72 10% 146 3% 146 21% 72 10% 9 0% 306 28% 49 6% 364
7-30days 31 2% 281 8% 229 32% 111 2% 210 30% 220 32% 26 1% 166 15% 349 39% 541
1-6days 58 3% 215 6% 226 32% 137 3% 151 21% 211 31% 52 1% 12 1% 435 49% 499
no previous discharge 1,405 76% 1,892 52% 235 33% 3,289 69% 13 2% 230 33% 3,360 80% 33 3% 139 16% 3,532
91days<1yr 182 10% 476 13% 75 11% 625 13% 34 5% 74 11% 387 9% 314 29% 32 4% 733
31-90days 84 5% 309 9% 67 9% 292 6% 104 15% 64 9% 128 3% 300 27% 32 4% 460
7-30days 64 3% 432 12% 119 17% 258 5% 242 34% 115 17% 129 3% 361 33% 125 14% 615
1-6days 104 6% 512 14% 216 30% 309 6% 318 45% 205 30% 201 5% 93 8% 538 61% 832
no indwelling device 1,783 97% 3,079 85% 345 48% 4,681 98% 190 27% 336 49% 4,203 100% 724 66% 280 32% 5,207
91days<1yr last insertion 30 2% 235 6% 80 11% 66 1% 201 28% 78 11% 2 0% 270 25% 73 8% 345
31-90days last insertion 11 1% 158 4% 93 13% 11 0% 162 23% 89 13% 0 0% 100 9% 162 18% 262
7-30days last insertion 6 0% 104 3% 136 19% 6 0% 110 15% 130 19% 0 0% 6 1% 240 27% 246
1-6days last insertion 9 0% 45 1% 58 8% 9 0% 48 7% 55 8% 0 0% 1 0% 111 13% 112
Total 1,839 3,621 712 4,773 711 688 4,205 1,101 886 6,172
Approach A Approach B Approach C
Total
Clinical and demographic 
characteristics
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6.3.3 Section summary 
 As expected, children with CA BSI had the smallest proportion of risk factors indicating 
child susceptibility or direct exposure to infection compared to the HCA or HA BSI 
categories. This is because healthy children are much less likely to develop a BSI from 
opportunistic pathogens that rely on immune-suppression to multiply, as found in 
children with HCA or HA BSI, and therefore the CA BSI group should contain the 
highest number of previously healthy children prior to a BSI, even though some 
children with CA BSI will also have underlying medical conditions. 
 The younger children (aged 1 month < 1 year) categorised as having HA BSI had more 
clinical characteristics than children with HCA BSI, whereas with an increase in age, 
children aged 1-5 years with HCA BSI had proportionally the same or more clinical 
characteristics than children with HA BSI. 
 Not all the clinical characteristics were clear predictors of CA, HCA or HA BSI.  
 A few risk factors had a low prevalence but a high predictive value to distinguish 
between CA and HCA BSI in all approaches and age-groups: more than two chronic and 
congenital conditions, indwelling devices in the past 1-30 days, and invasive 
procedures in the past 1-30 days. 
6.4 Distribution of bacterial species by time and BSI category 
This section presents the distribution of pathogens isolated from blood specimens in relation 
to the timing of hospital admission and investigates how well the predicted CA, HCA and HA 
BSI groups in approaches A, B and C can predict the causative pathogen to inform treatment 
strategies (Figure 6.6). 
 
 
 
 
 
Figure 6.6. The predicted source of infection used to predict the causative pathogen 
Clinical/
demographic 
characteristics 
and time
Source of 
infection
Causative 
pathogen
 188 
6.4.1 Methods 
The distribution and frequency of pathogen species in relation to hospital admission were 
tabulated and shown graphically by age-group for the 16 most frequently isolated pathogens 
from children with a BSI: CoNS, S. aureus (including the breakdown into MRSA and MSSA), 
GAS, GBS, S. pneumoniae, non-pyogenic streptococcus, Enterococcus spp., Micrococcus spp., E. 
coli, Klebsiella spp., Enterobacter spp., P. aeruginosa, Acinetobacter spp., Salmonella spp., N. 
meningitidis and H. influenzae. The remaining less frequently reported pathogens were 
grouped into two “other” categories for the remaining Gram-positive or Gram-negative 
pathogen species.  
6.4.2 Results 
A total of 4,650 pathogens from 52 genera were isolated from the 4,415 children with BSI aged 
1 month < 1 year, of whom 5% (n = 219 children) had polymicrobial BSI. In children aged 1-5 
years, 6,629 pathogens from 63 genera were isolated from blood, of which 7% (n = 409 
children) had polymicrobial BSI. The proportions of BSIs by pathogen and specimen date in 
relation to hospital admission for all children are summarised in Table 6.5 and Table 6.6. The 
frequency and distribution of positive blood samples by day in relation to before and the first 
30 days of hospital admission are illustrated in Figure 6.7 (children aged 1 month < 1 year) and 
Figure 6.8 (children aged 1-5 years). 
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Table 6.5. Proportional distribution of BSI by pathogen and timing of the positive specimen in relation 
to hospital admission for children aged 1 month < 1 year 
 
  
Total 
Days either side of admission to hospital (day=0) 
Pathogen 
-5d to 
+1d 
(95% CI) 
+2d 
to 
+9d 
(95% 
CI) 
+10d 
to 
+30d 
(95% 
CI) 
>30
d 
(95% 
CI) 
Gram-positive 
         
 
CoNS 1,231 76% (74-79) 9% (8-11) 8% (6-9) 7% (6-8) 
 
S. aureus 392 68% (64-73) 12% (9-15) 10% (8-13) 10% (7-13) 
 
        MSSA 337 69% (64-73) 12% (9-16) 10% (7-13) 9% (7-13) 
 
        MRSA 25 60% (41-76) 8% (2-25) 20% (9-39) 12% (4-30) 
 
Non-pyogenic 
streptococcus 
435 89% (85-91) 8% (6-11) 2% (1-4) 2% (1-3) 
 
Enterococcus spp. 193 38% (31-45) 18% (13-24) 17% (12-23) 27% (21-34) 
 
Micrococcus spp. 102 93% (86-97) 5% (2-11) 0% (0-4) 2% (1-7) 
 
Group B 
streptococcus 
213 93% (89-96) 3% (1-6) 2% (1-5) 1% (0-4) 
 
S. pneumoniae 340 94% (91-96) 6% (4-8) 1% (0-2) 0% (0-1) 
 
Group A 
streptococcus 
117 98% (93-99) 2% (1-7) 0% (0-3) 0% (0-3) 
 
Other 143 90% (83-93) 4% (2-9) 3% (1-7) 3% (2-8) 
 
          
Gram-negative 
         
 
E. coli 582 91% (88-93) 4% (3-6) 2% (1-4) 3% (2-5) 
 
Klebsiella spp. 121 52% (43-61) 12% (8-19) 12% (8-19) 23% (17-31) 
 
Enterobacter spp. 62 21% (13-33) 18% (10-29) 19% (11-31) 42% (30-54) 
 
P. aeruginosa 48 52% (38-65) 10% (5-22) 19% (10-32) 19% (10-32) 
 
Acinetobacter 
spp. 
54 85% (74-92) 7% (3-17) 2% (0-10) 5% (2-15) 
 
Salmonella spp. 25 84% (65-93) 16% (6-35) 0% (0-13) 0% (0-13) 
 
N. meningitidis 367 95% (92-97) 5% (3-8) 0% (0-1) 0% (0-1) 
 
H. influenzae 52 88% (77-94) 6% (2-16) 4% (1-13) 2% (0-10) 
  Other 173 68% (61-75) 7% (4-12) 12% (8-18) 12% (8-18) 
Total 4,650 80% (79-81) 8% (7-9) 6% (5-6) 6% (6-7) 
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Table 6.6. Proportional distribution of BSI by pathogen and timing of the positive specimen in relation 
to hospital admission for children aged 1-5 years 
 
  
Total 
Days either side of admission to hospital (day=0) 
Pathogen 
-5d to 
+1d 
(95% CI) 
+2d 
to 
+9d 
(95% 
CI) 
+10d 
to 
+30d 
(95% 
CI) 
>30
d 
(95% 
CI) 
Gram-positive 
         
 
CoNS 1,692 87% (85-88) 7% (5-8) 4% (3-5) 3% (2-4) 
 
S. aureus 571 84% (81-87) 8% (6-10) 6% (4-8) 3% (2-4) 
 
        MSSA 477 86% (82-89) 7% (5-10) 5% (3-7) 2% (1-4) 
 
        MRSA 18 56% (34-75) 17% (6-39) 17% (6-39) 11% (3-33) 
 
Non-pyogenic 
streptococcus 
871 91% (89-93) 5% (3-6) 3% (2-4) 2% (1-3) 
 
Enterococcus spp. 176 56% (49-63) 13% (9-19) 18% (13-25) 13% (8-18) 
 
Micrococcus spp. 216 93% (89-96) 5% (3-8) 1% (0-3) 1% (0-4) 
 
Group B 
streptococcus 
10 80% (52-94) 10% (2-38) 0% (0-26) 10% (2-38) 
 
S. pneumoniae 707 96% (94-97) 3% (2-5) <1% (0-1) 0% (0-1) 
 
Group A 
streptococcus 
394 96% (93-97) 4% (3-6) <1% (0-1) 0% (0-1) 
 
Other 305 89% (84-92) 7% (4-10) 3% (2-6) 2% (1-4) 
  
         
Gram-negative          
 
E. coli 170 66% (59-73) 12% (11-12) 16% (11-22) 6% (4-11) 
 
Klebsiella spp. 96 61% (51-71) 13% (8-22) 14% (8-22) 13% (7-21) 
 
Enterobacter spp. 102 65% (55-73) 12% (9-23) 15% (0-23) 9% (5-16) 
 
P. aeruginosa 86 61% (50-70) 16% (10-25) 16% (10-25) 7% (3-14) 
 
Acinetobacter 
spp. 
123 90% (84-94) 7% (1-7) 2% (1-7) 1% (0-4) 
 
Salmonella spp. 103 90% (83-95) 10% (0-4) 0% (0-4) 0% (0-4) 
 
N. meningitidis 508 94% (92-96) 6% (0-1) 0% (0-1) 0% (0-1) 
 
H. influenzae 90 88% (80-93) 6% (2-12) 6% (2-12) 1% (0-6) 
  Other 409 86% (82-89) 8% (2-6) 4% (2-6) 2% (1-4) 
Total 6,629 87% (86-88) 7% (6-7) 4% (3-4) 2% (2-3) 
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The 16 most frequently isolated pathogens accounted for 93% of BSI in children aged 1 month 
< 1 year and 89% of BSI in children aged 1-5 years. Children aged 1 month < 1 year had double 
the proportion of BSI occuring more than 10 days after hospital admission (12%) compared to 
the children aged 1-5 years (6%), but had similar proportions between day +2 to +9 (1 month < 
1 year: 8%; 1-5 years: 7%). 
6.4.2.1 Children aged 1 month < 1 year 
A total of 46/52 (88%) genera were isolated between day -5 and +1 of admission, accounting 
for the majority of all pathogens (80%; 95% CI: 79-81%). Enterococcus spp. (62%, n=120/193) 
and Enterobacter spp. (79%, n=49/62) were the only pathogens more frequently isolated in 
hospital (two or more days after hospital admission) compared to on or before admission (day 
one or less after hospital admission), and the proportion of Klebsiella spp. and P. aeruginosa 
was split evenly before and after the HA2 threshold. Only N. meningitidis, S. pneumoniae, GAS, 
Salmonella spp. were not isolated beyond 11 days into hospital admission. GBS was isolated 
over a longer period of time during IP hospital stay, most likely due to late-onset infection. 
Figure 6.7 demonstrates that all pathogens were isolated on or before admission to hospital. 
With the exception of the a priori pathogens, all other frequently reported pathogens were 
isolated consistently throughout hospital admission.  
6.4.2.2 Children aged 1-5 years 
A total of 56/63 (89%) genera were isolated between day -5 and +1 of admission, accounting 
for 87% (95% CI: 86-88%) of pathogens. All the pathogen species were more frequently 
isolated on day 1 or before of hospital admission; Enterococcus spp. was the only pathogen 
species that was most evenly distributed before and after the HA2 threshold (day 1 or less of 
hospital admission: 56%, n=99/176; 2 days or more: 44%, n=77/176). The range of isolation of 
the a priori CA pathogens after hospital admission was variable (N. meningitidis: 0-8 days; 
Salmonella spp.: 0-9 days; GAS: 0-11 days; S. pneumoniae: 0-17 days). With the exception of 1 
isolate, GBS was not isolated any later than day 7 after hospital admission in the older age-
group. 
Figure 6.8 demonstrates that, with the exception of the a priori pathogens (S. pneumoniae, 
Group A streptococcus, Salmonella spp. and N. meningitidis) and GBS, all other frequently 
reported pathogens were isolated consistently throughout hospital admission.  
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Figure 6.7. Distribution of BSI by pathogen and timing of the positive specimen in relation to hospital admission for children aged 1 month < 1 year; triangles and circles 
distinguish adjacent pathogens from each other; the dashed line indicates the HA2 threshold 
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Figure 6.8. Distribution of BSI by pathogen and timing of the positive specimen in relation to hospital admission for children aged 1 – 5 years; triangles and circles 
distinguish adjacent pathogens from each other; the dashed line indicates the HA2 threshold  
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6.4.3 Section summary 
 These results demonstrate the mixture of pathogens causing BSI in children on 
admission to hospital, where the timing of pathogens historically associated with 
hospital infection (e.g. Enterococcus spp., Klebsiella spp.) are also being isolated earlier 
before and within the first two days in hospital. 
 A copy of the peer-reviewed manuscript on the timing of bacterial BSI in children in 
relation to hospital admission for one year of linked data (April 2009 - March 2010), 
published in the Epidemiology and Infection journal, can be found in Appendix 6.(187) 
6.5 Pathogen distribution by predicted CA, HCA and HA BSI category 
So far, I have looked at the clinical and demographic characteristic distribution by approach A, 
B and C for children with CA, HCA and HA BSI to gain an understanding of how the children are 
distributed between the three groups and whether the classifications are feasible given their 
characteristics. The purpose of this section is to reveal the distribution of pathogens according 
to each predicted category (CA, HCA or HA) and determine whether there is a clear divide (or 
not) of the causative organism by predicted category.  
6.5.1 Methods 
The distribution of pathogen species according to the predicted source of infection (CA, HCA or 
HA) were cross-tabulated and compared. As a sensitivity analysis for assessing the impact of 
bacteria commonly associated with contaminating blood cultures, although they do also cause 
real invasive infection, all monomicrobial BSIs that were caused by either CoNS, Micrococcus 
spp. or diphtheroids were removed.(188-190)  
6.5.2 Results  
Table 6.7 and Table 6.9 show the distribution of pathogens between CA, HCA and HA BSI for 
approaches A, B and C; the results for approaches A and B use the HA2 threshold. 
6.5.2.1 Children aged 1 month < 1 year 
The results in Table 6.7 and Table 6.8 depict the same numbers of pathogens, but the 
percentages are calculated differently. Table 6.7 displays the percentages of the predicted 
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proportion (calculated horizontally) that each pathogen is distributed to between CA, HCA and 
HA BSI for approach A, B and C. Table 6.8 displays the percentages of the proportional 
frequency of the pathogen species found within each CA, HCA and HA group (calculated 
vertically), which is more informative for clinical decision making. 
CoNS were the most frequently reported pathogens (25-33%) in the CA, HCA and HA BSI 
categories irrespective of model approach, with the exception of N. meningitidis (38%) for CA 
BSI in approach A (Table 6.7). The majority (68-77%) of children with BSI caused by S. 
pneumoniae, GAS, N. meningitidis or Salmonella spp. in approach C were classified into group 
1 (most resembling CA BSI) and a small proportion (6-12%) were classified into group 3 (most 
resembling HA BSI). GBS was spread between the CA, HCA and HA BSI categories. 
Of the pathogens commonly associated with causing HA BSI (in the literature), approach A 
classified a very low proportion as being CA BSI: Enterococcus spp. (CA = 1%), Klebsiella spp. 
(CA = 2%), Enterobacter spp. (CA = 0%), Acinetobacter spp. (CA = 4%) and P. aeruginosa (CA = 
4%). However, approaches B and C categorised a higher proportion of these pathogens as CA 
BSI: Enterococcus spp. (CA = 21-23%), Klebsiella spp. (CA = 23-25%), Enterobacter spp. (CA = 
10-11%), Acinetobacter spp. (CA = 63-69%) and P. aeruginosa (CA = 21-27%). These pathogens, 
for which the majority are Gram-negative, are harder to treat because of innate or acquired 
antibiotic resistance within the hospital environment, particularly when the choice of BNF-C 
first-line antibiotics for CA BSI alone are directed more towards treating Gram-positive than 
Gram-negative infections.(56;191) This said, more than 50% of these pathogens were 
categorised as causing HA BSI for all three approaches. 
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Table 6.7. BSI causing pathogen breakdown by approach A, B and C for children aged 1 month < 1 year (percentage calculated by pathogen between CA, HCA and HA 
groups) 
 
 
 
 
 
 
 
 
 
 
 
 
 
CA % HCA % HA % CA % HCA/HA % HA %
Group 1 
(most like 
CA)
%
Group 2 
(most like 
HCA)
%
Group 3 
(most like 
HA)
%
Gram-positive
CoNS 42 3% 888 72% 301 24% 787 64% 154 13% 290 24% 687 56% 208 17% 336 27% 1,231
Non-pyogenic streptococcus 27 6% 355 82% 53 12% 335 77% 51 12% 49 11% 299 69% 59 14% 77 18% 435
S. aureus 15 4% 248 63% 129 33% 184 47% 84 21% 124 32% 174 44% 65 17% 153 39% 392
MSSA 13 4% 215 64% 109 32% 159 47% 73 22% 105 31% 148 44% 58 17% 131 39% 337
MRSA 2 8% 13 52% 10 40% 11 44% 4 16% 10 40% 10 40% 6 24% 9 36% 25
S. pneumoniae* 340 100% 0 0% 0 0% 340 100% 0 0% 0 0% 250 74% 50 15% 40 12% 340
Group B streptococcus 2 1% 197 92% 14 7% 146 69% 53 25% 14 7% 131 62% 16 8% 66 31% 213
Enterococcus spp. 1 1% 70 36% 122 63% 45 23% 28 15% 120 62% 40 21% 34 18% 119 62% 193
Group A streptococcus* 117 100% 0 0% 0 0% 117 100% 0 0% 0 0% 87 74% 21 18% 9 8% 117
Micrococcus  spp. 2 2% 92 90% 8 8% 86 84% 9 9% 7 7% 70 69% 16 16% 16 16% 102
Other Gram-positive 2 2% 74 73% 26 25% 63 62% 16 16% 23 23% 52 51% 23 23% 27 26% 102
Gram-negative
E. coli 9 2% 517 89% 56 10% 441 76% 87 15% 54 9% 410 70% 57 10% 115 20% 582
N. meningitidis* 367 100% 0 0% 0 0% 367 100% 0 0% 0 0% 282 77% 64 17% 21 6% 367
Klebsiella spp. 2 2% 55 45% 64 53% 23 19% 40 33% 58 48% 25 21% 17 14% 79 65% 121
Enterobacter  spp. 0% 11 18% 51 82% 6 10% 7 11% 49 79% 7 11% 10 16% 45 73% 62
Acinetobacter  spp. 2 4% 42 78% 10 19% 37 69% 9 17% 8 15% 34 63% 5 9% 15 28% 54
H. influenzae 9 17% 36 69% 7 13% 39 75% 7 13% 6 12% 38 73% 6 12% 8 15% 52
P. aeruginosa 2 4% 23 48% 23 48% 10 21% 15 31% 23 48% 13 27% 6 13% 29 60% 48
Salmonella  spp.* 25 100% 0 0% 0 0% 25 100% 0 0% 0 0% 17 68% 6 24% 2 8% 25
Other Gram-negative 16 7% 150 70% 48 22% 133 62% 34 16% 47 22% 131 61% 28 13% 55 26% 214
Total 980 21% 2,758 59% 912 20% 3,184 68% 594 13% 872 19% 2,747 59% 691 15% 1,212 26% 4,650
* a priori  CA for Approaches A and B
Pathogen Total
Approach CApproach A Approach B
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Table 6.8 BSI causing pathogen breakdown by approach A, B and C for children aged 1 month < 1 year (percentage calculated for all pathogens  within each individual CA, 
HCA and HA group) 
  
CA % HCA % HA % CA % HCA/HA % HA %
Group 1 
(most like 
CA)
%
Group 2 
(most like 
HCA)
%
Group 3 
(most like 
HA)
%
Gram-positive 548 56% 1,924 70% 653 72% 2,103 66% 395 66% 627 72% 1,790 65% 492 71% 843 70% 3,125
CoNS 42 4% 888 32% 301 33% 787 25% 154 26% 290 33% 687 25% 208 30% 336 28% 1,231
Non-pyogenic streptococcus 27 3% 355 13% 53 6% 335 11% 51 9% 49 6% 299 11% 59 9% 77 6% 435
S. aureus 15 2% 248 9% 129 14% 184 6% 84 14% 124 14% 174 6% 65 9% 153 13% 392
MSSA 13 1% 215 8% 109 12% 159 5% 73 12% 105 12% 148 5% 58 8% 131 11% 337
MRSA 2 0% 13 0% 10 1% 11 0% 4 1% 10 1% 10 0% 6 1% 9 1% 25
S. pneumoniae* 340 35% 0 0% 0 0% 340 11% 0 0% 0 0% 250 9% 50 7% 40 3% 340
Group B streptococcus 2 0% 197 7% 14 2% 146 5% 53 9% 14 2% 131 5% 16 2% 66 5% 213
Enterococcus spp. 1 0% 70 3% 122 13% 45 1% 28 5% 120 14% 40 1% 34 5% 119 10% 193
Group A streptococcus* 117 12% 0 0% 0 0% 117 4% 0 0% 0 0% 87 3% 21 3% 9 1% 117
Micrococcus  spp. 2 0% 92 3% 8 1% 86 3% 9 2% 7 1% 70 3% 16 2% 16 1% 102
Other Gram-positive 2 0% 74 3% 26 3% 63 2% 16 3% 23 3% 52 2% 23 3% 27 2% 102
Gram-negative 432 44% 834 30% 259 28% 1,081 34% 199 34% 245 28% 957 35% 199 29% 369 30% 1,525
E. coli 9 1% 517 19% 56 6% 441 14% 87 15% 54 6% 410 15% 57 8% 115 9% 582
N. meningitidis* 367 37% 0 0% 0 0% 367 12% 0 0% 0 0% 282 10% 64 9% 21 2% 367
Klebsiella spp. 2 0% 55 2% 64 7% 23 1% 40 7% 58 7% 25 1% 17 2% 79 7% 121
Enterobacter  spp. 0% 11 0% 51 6% 6 0% 7 1% 49 6% 7 0% 10 1% 45 4% 62
Acinetobacter  spp. 2 0% 42 2% 10 1% 37 1% 9 2% 8 1% 34 1% 5 1% 15 1% 54
H. influenzae 9 1% 36 1% 7 1% 39 1% 7 1% 6 1% 38 1% 6 1% 8 1% 52
P. aeruginosa 2 0% 23 1% 23 3% 10 0% 15 3% 23 3% 13 0% 6 1% 29 2% 48
Salmonella  spp.* 25 3% 0 0% 0 0% 25 1% 0 0% 0 0% 17 1% 6 1% 2 0% 25
Other Gram-negative 16 2% 150 5% 48 5% 133 4% 34 6% 47 5% 131 5% 28 4% 55 5% 214
Total 980 100% 2,758 100% 912 100% 3,184 100% 594 100% 872 100% 2,747 100% 691 100% 1,212 100% 4,650
Pathogen Total
Approach CApproach A Approach B
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No pathogen was categorised as 100% CA or HCA by any of the three approaches. 
Enterobacter spp. was the only pathogen that was classified as causing more HCA than CA BSI 
by all three approaches, and the four a priori pathogens were the only pathogens classified as 
causing more CA than HCA BSI. 
6.5.2.2 Children aged 1-5 years 
The results in Table 6.9 and Table 6.10 depict the same numbers of pathogens, but the 
percentages are calculated differently. Table 6.9 displays the percentages of the predicted 
proportion (calculated horizontally) that each pathogen is distributed to between CA, HCA and 
HA BSI for approach A, B and C. Table 6.10 displays the percentages of the proportional 
frequency of the pathogen species found within each CA, HCA and HA group (calculated 
vertically), which is more informative for clinical decision making. 
CoNS were the most frequent pathogen (25-35%) in each CA, HCA and HA category 
irrespective of approach for children aged 1-5 years, with the exception of CA BSI in approach 
A, where S. pneumoniae (38%) was the most frequently reported pathogen (Table 6.9). 
A high proportion (81-93%) of the pathogens commonly associated with CA BSI (S. 
pneumoniae, GAS, N. meningitidis and Salmonella spp.) in approach C were clustered in the 
group considered to most resemble CA (group 1), where only 2-5% were clustered in the HA 
BSI group and 5-15% in the HCA group (Table 6.10). 
Of the pathogens commonly associated with HA BSI, approach A classified a very low 
proportion as being CA BSI: Enterococcus spp. (CA = 1%), Klebsiella spp. (CA = 0%), 
Enterobacter spp. (CA = 1%), Acinetobacter spp. (CA = 4%) and P. aeruginosa (CA = 0%). As with 
the younger age-group, approach B categorised a higher proportion of these pathogens as 
being CA than what was expected: Enterococcus spp. (CA = 35%), Klebsiella spp. (CA = 18%), 
Enterobacter spp. (CA = 27%), P. aeruginosa (CA = 26%). 
As with the younger age-group, no pathogen was categorised as uniquely CA or HCA. 
Compared to the younger age-group, P. aeruginosa and Klebsiella spp., in addition to 
Enterobacter spp., were predicted to cause more HCA than CA BSI (>50%). The four a priori 
pathogens were predicted to predominantly cause more CA BSI than HCA BSI in all three 
approaches. 
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Table 6.9. BSI causing pathogen breakdown by approach A, B and C for children aged 1-5years (percentage calculated by pathogen between CA, HCA and HA groups) 
 
 
 
 
 
 
 
 
 
 
 
 
 
CA % HCA % HA % CA % HCA/HA % HA %
Group 1 
(most 
like CA)
%
Group 2 
(most 
like HCA)
%
Group 3 
(most 
like HA)
%
Gram-positive
CoNS 76 4% 1,388 82% 228 13% 1,263 75% 208 12% 221 13% 1,110 66% 313 18% 269 16% 1,692
Non-pyogenic streptococcus 39 4% 749 86% 83 10% 700 80% 91 10% 80 9% 654 75% 131 15% 86 10% 871
S. pneumoniae* 707 100% 0 0% 0 0% 707 100% 0 0% 0 0% 578 82% 104 15% 25 4% 707
S. aureus 25 4% 452 79% 94 16% 374 65% 105 18% 92 16% 338 59% 118 21% 115 20% 571
MSSA 19 4% 392 81% 71 15% 325 67% 88 18% 69 14% 292 61% 101 21% 89 18% 482
MRSA 0 0% 11 55% 9 45% 8 40% 3 15% 9 45% 8 40% 6 30% 6 30% 20
Group A streptococcus* 394 100% 0 0% 0 0% 394 100% 0 0% 0 0% 341 87% 35 9% 18 5% 394
Micrococcus  spp. 7 3% 193 89% 16 7% 176 81% 25 12% 15 7% 167 77% 33 15% 16 7% 216
Enterococcus  spp. 1 1% 98 56% 77 44% 64 36% 35 20% 77 44% 46 26% 51 29% 79 45% 176
Group B streptococcus 1 10% 7 70% 2 20% 8 80% 0 0% 2 20% 8 80% 0% 2 20% 10
Other Gram-positive 6 3% 179 83% 31 14% 138 64% 48 22% 30 14% 119 55% 45 21% 52 24% 216
Gram-negative
N. meningitidis* 508 100% 0 0% 0 0% 508 100% 0 0% 0 0% 473 93% 22 4% 13 3% 508
E. coli 2 1% 107 63% 61 36% 66 39% 47 28% 57 34% 59 35% 57 34% 54 32% 170
Acinetobacter spp. 7 6% 103 84% 13 11% 100 81% 11 9% 12 10% 86 70% 25 20% 12 10% 123
Salmonella spp.* 103 100% 0 0% 0 0% 103 100% 0 0% 0 0% 87 84% 15 15% 1 1% 103
Enterobacter spp. 2 2% 63 62% 37 36% 29 28% 37 36% 36 35% 17 17% 40 39% 45 44% 102
Klebsiella  spp. 0 0% 58 60% 38 40% 17 18% 42 44% 37 39% 8 8% 44 46% 44 46% 96
H. influenzae 6 7% 73 81% 11 12% 70 78% 9 10% 11 12% 61 68% 19 21% 10 11% 90
P. aeruginosa 0 0% 50 58% 36 42% 22 26% 31 36% 33 38% 13 15% 29 34% 44 51% 86
Other Gram-negative 17 3% 415 83% 66 13% 335 67% 99 20% 64 13% 299 60% 121 24% 81 16% 498
Total 1,901 29% 3,935 59% 793 12% 5,074 77% 788 12% 767 12% 4,464 67% 1,202 18% 966 15% 6,629
* a priori  CA for Approaches A and B
Pathogen Total
Approach CApproach A Approach B
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Table 6.10 BSI causing pathogen breakdown by approach A, B and C for children aged 1-5 years (percentage calculated for all pathogens within each individual CA, HCA and 
HA group) 
 
 CA % HCA % HA % CA % HCA/HA % HA %
Group 1 
(most 
like CA)
%
Group 2 
(most 
like HCA)
%
Group 3 
(most 
like HA)
%
Gram-positive 1,256 66% 3,066 78% 531 67% 3,824 75% 512 65% 517 67% 3,361 75% 830 69% 662 69% 4,853
CoNS 76 4% 1,388 35% 228 29% 1,263 25% 208 26% 221 29% 1,110 25% 313 26% 269 28% 1,692
Non-pyogenic streptococcus 39 2% 749 19% 83 10% 700 14% 91 12% 80 10% 654 15% 131 11% 86 9% 871
S. pneumoniae* 707 37% 0 0% 0 0% 707 14% 0 0% 0 0% 578 13% 104 9% 25 3% 707
S. aureus 25 1% 452 11% 94 12% 374 7% 105 13% 92 12% 338 8% 118 10% 115 12% 571
MSSA 19 1% 392 10% 71 9% 325 6% 88 11% 69 9% 292 7% 101 8% 89 9% 482
MRSA 0 0% 11 0% 9 1% 8 0% 3 0% 9 1% 8 0% 6 0% 6 1% 20
Group A streptococcus* 394 21% 0 0% 0 0% 394 8% 0 0% 0 0% 341 8% 35 3% 18 2% 394
Micrococcus  spp. 7 0% 193 5% 16 2% 176 3% 25 3% 15 2% 167 4% 33 3% 16 2% 216
Enterococcus  spp. 1 0% 98 2% 77 10% 64 1% 35 4% 77 10% 46 1% 51 4% 79 8% 176
Group B streptococcus 1 0% 7 0% 2 0% 8 0% 0 0% 2 0% 8 0% 0% 2 0% 10
Other Gram-positive 6 0% 179 5% 31 4% 138 3% 48 6% 30 4% 119 3% 45 4% 52 5% 216
Gram-negative 645 34% 869 22% 262 33% 1,250 25% 276 35% 250 33% 1,103 25% 372 31% 304 31% 1,776
N. meningitidis* 508 27% 0 0% 0 0% 508 10% 0 0% 0 0% 473 11% 22 2% 13 1% 508
E. coli 2 0% 107 3% 61 8% 66 1% 47 6% 57 7% 59 1% 57 5% 54 6% 170
Acinetobacter spp. 7 0% 103 3% 13 2% 100 2% 11 1% 12 2% 86 2% 25 2% 12 1% 123
Salmonella spp.* 103 5% 0 0% 0 0% 103 2% 0 0% 0 0% 87 2% 15 1% 1 0% 103
Enterobacter spp. 2 0% 63 2% 37 5% 29 1% 37 5% 36 5% 17 0% 40 3% 45 5% 102
Klebsiella  spp. 0 0% 58 1% 38 5% 17 0% 42 5% 37 5% 8 0% 44 4% 44 5% 96
H. influenzae 6 0% 73 2% 11 1% 70 1% 9 1% 11 1% 61 1% 19 2% 10 1% 90
P. aeruginosa 0 0% 50 1% 36 5% 22 0% 31 4% 33 4% 13 0% 29 2% 44 5% 86
Other Gram-negative 17 1% 415 11% 66 8% 335 7% 99 13% 64 8% 299 7% 121 10% 81 8% 498
Total 1,901 100% 3,935 100% 793 100% 5,074 100% 788 100% 767 100% 4,464 100% 1,202 100% 966 100% 6,629
Pathogen Total
Approach CApproach A Approach B
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Although there is increasing recognition of the evolving epidemiology of bacteria causing BSIs 
and some pathogens, previously thought of as causing HA BSI, may be isolated on admission to 
hospital from children with genuine CA BSI, it is difficult to accept such high proportions of CA 
BSI that approaches B and C report. These results have been challenged and discussed with 
microbiology and clinical colleagues around the idea that the true proportions lie somewhere 
between the results of approach A and approach B/C. More information about other forms of 
healthcare contact for these young patients, in addition to the IP data presented in this thesis, 
may help to further differentiate between children with different pathogens causing BSI. 
6.5.2.3 Sensitivity analysis: removal of CoNS, Micrococcus spp. and diphtheroids 
The total proportion of mono-microbial BSI removed from the dataset was 21% (1,294/6,172) 
in children aged 1 month < 1 year (CoNS=1,126; Micrococcus spp.=99; diphtheroids=69) and 
42% (1,839/4,422) in children aged 1-5 years (CoNS=1,515; Micrococcus spp.=201; 
diphtheroids=123).  
The results of the proportion of BSI categorised as CA, HCA or HA BSI after removing the 
mono-microbial BSIs from the models are shown in Table 6.11 and Table 6.12. There was very 
little change in the proportional ranking of CA, HCA and HA BSI in the younger age-group; 
however, the gap between the lower and upper threshold of CA (range: 40%) and HCA BSI 
(range: 38%) was narrower compared to the 48% range for both in the original approaches. 
The most change was seen in approach A, where the proportion of CA BSI increased from 21% 
to 34% (and there was an increase in the numbers of children with CA BSI from 941 to 1,066), 
and there was a 12% reduction in the proportion of HCA BSI; the proportion of HA BSI varied 
by 1%. 
In the older age-group, the removal of the pathogens had the largest effect in approach A for 
children aged 1-5 years. The proportion of CA BSI increased from 30% to 56% of all BSI in that 
age-group, with more children being categorised into this group compared to the other two 
categories, where the proportion of HCA BSI decreased and the proportion of HA BSI stayed 
the same. In this age-group, all three approaches showed the majority of BSIs were attributed 
to the CA BSI group. 
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Table 6.11 Results of proportion of CA, HCA and HA BSI using the day 2 defined HA threshold when 
CoNS, Micrococcus spp. and diphtheroids were removed for children aged 1 month < 1 year 
  Total CA BSI % HCA BSI % HA BSI % 
approach A 3,121 1,066 34% 1,508 48% 547 18% 
approach B 3,121 2,300 74% 297 10% 524 17% 
approach C 3,121 1,965 63% 628 20% 528 17% 
 
Table 6.12 Results of proportion of CA, HCA and HA BSI using the day 2 defined HA threshold when 
CoNS, Micrococcus spp. and diphtheroids were removed for children aged 1-5 years 
  Total CA BSI % HCA BSI % HA BSI % 
approach A 4,333 2,412 56% 1,453 34% 468 11% 
approach B 4,333 3,499 81% 381 9% 453 10% 
approach C 4,333 2,965 68% 771 18% 597 14% 
6.5.3 Section summary 
 The distribution of pathogen species for CA BSI approach A contained very few 
infections caused by the Gram-negative pathogens and Enterococcus spp. traditionally 
associated with HA BSI, which was the opposite in approaches B and C 
 There was little clarity about pathogens causing CA or HCA BSI for the majority of the 
most frequently isolated pathogens in both age-groups, except for N. meningitidis, S. 
pneumoniae, GAS and Salmonella spp. which were considered to predominantly cause 
CA BSI 
 Enterobacter spp. (in both age-groups), Klebsiella spp. and P. aeruginosa (in children 
aged 1-5 years) were the only pathogens to be classified as causing predominantly HCA 
BSI amongst the subgroup who were not classified as HA. 
 The removal of CoNS, Micrococcus spp., and diphtheroids, which are often considered 
as contaminants of blood cultures, did not appreciably alter the predicted proportion 
of BSI in children. 
6.6 Discussion 
This chapter reports the first national estimates of the proportion of CA, HCA and HA BSI in 
children in England. There is a consistent predicted proportion of HA BSI in both children aged 
1 month < 1 year (≤25%) and children aged 1-5 years (≤13%). However, there was a large 
overlap in the predicted proportion of CA and HCA BSI, illustrating that the clinical risk factors 
in this analysis alone are not sufficient to fully predict the proportion of CA and HCA BSI. There 
was some evidence that a few clinical predictors were useful in distinguishing between CA and 
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HCA BSI (e.g. indwelling devices in the last 1-30 day, more than two chronic conditions, and 
invasive procedures in the last 1-30 days before the BSI), but their observed prevalence is low. 
This is also the first time that the national distribution of pathogens in relation to hospital 
admission has been investigated. The most striking observation is that there was a complete 
mix of pathogens isolated from children before or on admission to hospital, and particularly a 
proportion of HCA BSI that might be wrongly categorised as CA if using the historic 48-hour 
distinction between pathogens causing CA BSI or HA BSI observed in the past. The distribution 
of pathogens between the CA, HCA and HA BSI categories for the three approaches also show 
that the models are not accurate enough to differentiate fully between pathogens causing CA 
as opposed to HCA BSI. From a clinical decision making point of view, the distribution of 
pathogens within each CA, HCA and HA group highlights the proportion of different species 
causing BSI, where proportionally more Gram-negative pathogens causing BSIs in children with 
HCA or HA BSI than for CA BSI across all the approaches. 
The results presented here emphasise the movement of bacterial species commonly 
associated with the hospital environment into the community. The modelling of a child’s 
movement between hospitals and the community will become an increasingly important part 
of monitoring and modelling the evolving epidemiology of BSI, particularly in terms of not just 
the pathogen species but also the antimicrobial susceptibility and administered antibiotics. 
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Chapter 7. Discussion 
7.1 Aim of the thesis 
The aim of this thesis was to use demographic and clinical characteristics from national, 
administrative data to predict the relative proportion of CA, HCA and HA BSI in children in 
order to inform population based BSI prevention strategies. 
7.1.1 Objectives 
The three objectives of this thesis were: 
1. To link microbiology surveillance and clinical data and evaluate the effect of match-
weight choice on the final linked dataset 
2. To develop statistical models to identify patient and clinical characteristics associated 
with CA, HCA and HA BSI in children 
3. To predict the proportion of CA, HCA and HA BSI occurring in children in England and 
the distribution of causative pathogens in each group 
The six previous chapters included in-depth discussions of the three objectives. This chapter 
aims to discuss the strengths and limitations of the study as a whole, and its clinical, public 
health and research implications. Conference presentations arising from the work in this thesis 
are described in Appendix 7. 
7.2 Key findings 
The key findings of this thesis were: 
1. Using probabilistic linkage, I successfully linked 80% of all positive blood specimen 
records from children in England between 1st April 2007 and 31st March 2011 to clinical 
HES IP data. Of the unlinked specimen records, 49% were not eligible for inclusion 
based on country (e.g. Wales) or age (older children and adults potentially included 
due to lack of date of birth data). Of the other 51% unlinked specimen records, 43% 
had no NHS number, which is the strongest and most reliable patient identifier when 
linking. Alternative strategies for calculating match-weights did not appreciably 
improve the linkage rate. 
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2. Three statistical models were developed using the clinical and demographic 
characteristics identified in the linked dataset. However, few characteristics (more 
than two chronic conditions, indwelling devices, and hospital discharge in the month 
prior to the BSI) had high positive predictive value for pathogens causing HCA-BSI 
compared to CA-BSI. Moreover, there were few children with these characteristics. 
3. Using three different statistical models, the prevalence of CA BSI ranged from 21-77% 
and the HCA BSI ranged from 12-60%. These large ranges likely reflect the relatively 
small number of children with predictive characteristics that differentiate CA from HCA 
BSI. The three models consistently attributed a low proportion of BSI to HA BSI, which 
accounted for a quarter or less of all children aged 1 month < 1 year, and a sixth or less 
of all children aged 1-5 years.  
4. A total of 80% (Table 6.5) and 87% (Table 6.6) of all isolated pathogen species causing 
BSI in children aged 1 month < 1 year and 1-5 years respectively (including the 16 most 
frequently isolated bacterial species) were isolated prior to, or on day 0 or 1 of hospital 
admission, (i.e. before the 2-day threshold for distinguishing between CA and HA BSI). 
Bacterial species historically associated with causing HA BSI were more frequently 
isolated on or before hospital admission than during hospital admission in this study 
(except for Enterococcus spp. and Enterobacter spp. in children aged 1 month < 1 
year). This suggests an important role of HCA BSI, or that HA type pathogens are 
circulating in the community, reflecting the shortening of average length of hospital 
stay and increasing healthcare contact.(192;193)  
7.3 Strengths and limitations 
7.3.1 Objective 1: Link microbiology surveillance and clinical data and 
evaluate the effect of match-weight choice on the final linked dataset 
I created a linked dataset that is nationally representative of children with microbiologically 
confirmed BSI who were admitted to hospital in England. It is representative because clinicians 
who suspect a BSI would take a blood sample to determine the invasive organism and its 
antibiotic susceptibility to treat accordingly, and the child would be admitted to hospital due 
to the severity of the infection. I have also estimated the rate per 100,000 population by age-
group to inform the overall impact that BSIs have on the paediatric population in England, 
demonstrating the higher burden of BSI in the younger age-group (1 month < 1 year) 
compared to the older children (1-5 years) in terms of the general child population. One 
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limitation that couldn’t be measured was the proportion of children with a clinical diagnosis of 
BSI but a negative blood culture, potentially resulting from the administration of antibiotics 
before the blood sample was taken. 
Between April 2007 and March 2011, the proportion of linked records increased by 8% (from 
76.7% to 84.4%) as the patient identifier completion improved over time. Despite only 51-70% 
completion of the strongest identifier, NHS number, in LabBase2 compared to the 91-97% 
completion in HES (between 2007 and 2011), the probabilistic linkage method linked 25% 
more records (MW-Child total linked: 81%, n=17,141/21,074 OPIEs) than linkage using NHS 
number alone (total linked: 58%, n=12,212/21,074 OPIEs; NHS number deterministic linkage). 
A limitation of the linkage was the variable detail about the unlinked child records, where 92% 
of these were either reported from a UK laboratory external to England, or had no identifiable 
age, or had incomplete NHS number record. Where data was reported, there were no 
statistically significant differences by age or sex between the linked and unlinked LabBase2 
records. 
After the final dataset was chosen following the probabilistic linkage, I was able to determine 
linkage error within HES when comparing the results to the linked OPIEs (Figure 3.17). I 
identified a small proportion of multiple HESids that were linked to the same OPIE (i.e. 
indicating multiple children linking to one infection episode), but on closer inspection the 
multiple HESids corresponded to the same child. This has been found in a similar study looking 
at anonymised HES data.(194) However, I did not investigate internal linkage error within the 
HES data when the same HESid was assigned; I assumed that records with the same HESid 
were for the same child.  
The calculation of match-weights and the linkage was possible because of my privileged access 
to both LabBase2 and HES data within the HPA (now PHE). The linkage methods discussed here 
are now being used for other applications within PHE, alongside other departments who are 
investigating the use of probabilistic linkage for other datasets.(195) Although the resulting 
differences in match-weights were minimal, they could be very different in other scenarios and 
therefore highlight the important consideration of how match-weights are calculated when 
linking new datasets.  
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7.3.2 Objective 2: Develop statistical methods to identify patient and clinical 
characteristics associated with CA, HCA and HA BSI in children 
Three statistical approaches were used to estimate the proportion of BSI attributable to CA, 
HCA and HA based on clinical characteristics, as there was no established gold standard 
method. This is the first time that the contribution of CA, HCA and HA BSI in children in 
England has been examined at a national scale. The HES data allows for an accurate, 
retrospective search of previous IP contact, providing a rich profile of IP hospital records. I 
divided children into two age-groups because of the large variation in the number of BSIs in 
children aged 1 month < 1 year and 1-5 years and the varying clinical lookback period prior to 
each child’s index case of BSI, due to practical age restrictions. 
The linked dataset enabled the timing of the BSI detection in relation to day of hospital 
admission to be incorporated into the models, in addition to the added value of clinical 
characteristics to a microbiology dataset that is entirely lacking the clinical context. Clinical 
indicators, such as invasive surgical procedures and presence of chronic conditions, where 
reported in HES, were strongly associated with the risk of HA BSI. Additional information on 
indwelling devices inserted at the bedside and previous antibiotic treatment, which were not 
available in the dataset, may have strengthened the models.  
In the models used in this thesis, the HA definition was adjusted along a time-threshold to 
overlap the commonly used 2-day (after hospital admission) threshold. A limitation in 
interpreting whether the 2-day threshold was still an appropriate time-measurement was 
biased due to blood sampling practice, where the majority of samples were taken on day 0 and 
day 1 of hospital admission. In considering the relationship of the timing of specimen date in 
relation to hospital admission, a recent Danish study in adults found no precise time threshold 
between CA, HCA and HA BSI.(21) The identification of BSIs later during a hospital admission 
(after day 1) may go undetected due to lower levels of sampling, or where sampling is 
performed after a course of antibiotics has begun that reduces the likelihood of a positive 
culture. Therefore, later detection of BSI in a hospital admission may be due to either the start 
of a true infection, or the re-emergence of an ongoing infection following unsuccessful 
antibiotic treatment.  
A limitation for two of the statistical approaches (A and B) was assuming that four pathogens 
could only cause a priori CA BSI rather than HCA or HA BSI. Although based on evidence in the 
literature, in practice the time it would take for the bacteria to multiply between the onset of 
infection to being detectable in the blood, would vary depending on the bacteria and the child. 
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There was also no method to determine if all these BSI were truly CA BSI, which is why 
approach C was applied to test any other associations. A small number of children with a priori 
CA BSI had a catheter inserted shortly before their positive sample was taken, which according 
to European Centre for Disease Prevention and Control guidance may suggest that they had a 
HCA BSI, however, these four pathogens are not commonly associated with causing infection 
via indwelling devices and therefore the insertion was considered to be 
unrelated.(8;72;75;78;165) The timing in hours of hospital admission and when the blood 
specimen was taken was lacking from both data sources, which may have provided greater 
precision in the models in indicating, within a 24-hour period, how closely these two variables 
occurred in relation to one another. I have previously discussed the strengths and limitations 
of the probability thresholds and best subset framework selection in Chapter 5. 
7.3.3 Objective 3: Predict the proportion of CA, HCA and HA BSI occurring in 
children and the distribution of causative pathogens in each group 
My results show that at most, a quarter of all microbiology confirmed BSIs were estimated to 
be HA, although the timing is partly collinear with blood sampling predominantly occurring at 
the time of hospital admission and length of hospital stay. The remaining proportion of BSI 
ranged from 21-77% for CA and 60-12% for HCA BSI. Although the estimates were not 
consistent, the results showed that HCA BSI was estimated to be an important component in 
the epidemiology of BSI in children, as reflected in the limited published literature.(8;72)  
The daily recording of pathogens causing BSI by day of admission shows unequivocally that i) 
95% of pathogens classified as causing a priori CA BSI (S. pneumoniae, GAS, N. meningitidis and 
Salmonella spp.) were isolated close to the day of hospital admission, and ii) pathogens 
commonly associated with HA-BSI were also frequently isolated early on in children’s hospital 
admissions. Overall, 80% (children aged 1 month < 1 year) and 87% (children aged 1-5 years) of 
pathogen species were isolated less than 2 days after hospital admission. This reflects the 
dilemma over the large range of pathogens in the first two days of hospital admission when 
considering empiric antibiotic therapy.  
The putative source of where a BSI is acquired is important to target preventative strategies in 
order to reduce infection and to indicate antibiotic treatment to which the pathogens are likely 
to be sensitive. There were two potential reasons why the models failed to consistently 
discriminate between sources of infection:  
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i. Information on clinical risk factors was not sufficiently detailed to capture likely source 
of exposure, particularly with respect to the severity of underlying medical conditions 
or invasive procedures, and therefore insufficient in their ability to fully differentiate 
between CA, HCA and HA BSI. This may introduce unmeasured confounding and 
therefore more accurate recording of these risk factors is needed. Data on prior 
antibiotic treatment was also unavailable, which would be useful in indicating 
treatment for a bacterial infection prior to the BSI and additional information of 
previous healthcare contact.(9;23)   
ii. Historically, pathogens that were circulating in separate environments (e.g. 
community, hospital) have now disseminated into the different populations, seen with 
the emergence of HCA BSI, where healthcare is expanding into the community and is 
becoming an extension of the hospital environment, leading to less separation 
between the different environments. Therefore the assumption that the type of 
patient environment (e.g. hospital, community) reflects the type of pathogen and 
hence the type of antibiotic susceptibility, no longer applies. 
This thesis included children with BSI, denoted by a positive blood culture. Children with 
clinical diagnosis of a BSI and a negative culture result who would also have been treated 
empirically with antibiotics were not included, and were unquantifiable, because LabBase2 did 
not collect negative culture data, and so no information on the invasive pathogen would have 
been available. 
I did not examine patterns of antibiotic resistance in recorded BSIs in the cohort because the 
antibiotic susceptibility was not consistently tested and/or reported by the laboratories. 
Therefore, I did not investigate antibiotic susceptibility within the cohort by CA, HCA and HA 
BSI category. I was also not able to accurately determine rates of BSI in the population, as 
there was no clear denominator population of children at risk within the hospital setting 
versus the community setting who did not acquire a BSI. In addition, the effects of different 
health interventions, such as the introduction of care bundles and antibiotic policies, were not 
adjusted for when analysing the data, however, this was not what this thesis was concerned 
with investigating and therefore was outside the remit of the work. 
My study is based on the assumption that clinical characteristics and the timing of the BSI can 
help predict the source of the invasive pathogen, and therefore its antibiotic susceptibility. 
Although estimated predictions in my study are not precise or sufficiently detailed, they do 
suggest that the growing mix of children acquiring CA and HCA BSI from the community setting 
(as well as HA BSI in hospital), supported by the findings in the literature review.(8;61;62;65-
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68;71) This is likely to increase as the mix of children becomes more heterogeneous in the 
future as healthcare provision outside of the hospital continues to diversify. 
7.4 What this thesis adds 
7.4.1 Implications for clinical practice 
The results of this thesis demonstrate that the majority of BSIs in children in England are CA or 
HCA and are caused by a wide range of pathogens, including those usually associated with 
causing HA BSI. The treatment for the wide distribution of pathogens isolated before or on 
admission to hospital is not reflected in the current BNF-C guidance for pathogens, which 
currently considers only one group: CA BSI.(56) An implication of this work would be to utilise 
the results found in this thesis, enhanced with future work to incorporate antibiotic 
susceptibility data, to determine the distribution of pathogens and their antimicrobial 
susceptibility patterns in relation to timing of hospital admission. For clinicians, this would give 
a probability of confirmed BSI to inform future empiric antibiotic therapy guidelines and 
contribute towards work that has been taking place at the European level to investigate the 
appropriateness of empiric antibiotic regimens using pooled antimicrobial resistance 
laboratory data from select European hospitals.(196)  
The implication that the poor performance of the clinical and time predictors used in the 
models to determine CA, HCA and HA BSI at a national level has highlighted the level of 
uncertainty in knowing what antibiotic treatment is most likely to be effective. Bedside tests 
would offer a more rapid method to identify the antimicrobial susceptibility of the pathogen, 
overcoming the 48-hour wait for a blood culture result, providing a quick decision regarding 
first line antibiotic treatment.(197) 
7.4.2 Implications for Public Health 
This thesis shows that children are presenting to hospital with BSIs caused by a wide range of 
pathogens. I have shown how to perform the data linkage and the results from my work can be 
used, going forward, to monitor the patterns of pathogens causing BSI to inform preventive BSI 
strategies. The limited clinical details in HES and lack of information on antibiotic treatment in 
HES could be potentially addressed through primary care data linkage, which captures a more 
comprehensive, although not perfect, longitudinal picture of patient care over time as the 
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majority of medical contact takes place in primary care, including antibiotic 
prescriptions.(198;199)  
Due to a recent change in data collection and replacement of the LabBase2 system with an 
upgraded version (Second Generation Surveillance System; SGSS), pathogen and antimicrobial 
sensitivity for all positive tests performed in participating laboratories can now be reported 
and monitored centrally. In future work, consistently tested and reported antibiotic 
susceptibility results would provide nationally representative scientific evidence to further 
inform empiric therapy of children with BSI. The SGSS database also intends to collect negative 
blood culture information in the future, which will increase our understanding of children with 
clinical sepsis (identified in HES) but with a negative blood culture. To put the size of this into 
context, a regional, south-west London study investigating invasive paediatric bacterial 
infections found that only 2.6% (n=482/18,366) of all blood cultures taken during a 3-year 
study period (2009-2011) were positive and determined to be clinically significant.(163) 
Although not possible at a national level yet, additional linkage to hospital prescribing data 
would also affirm whether an antibiotic was prescribed during the hospital spell.  
The results from this thesis and the linkage methodology, as well as the future work to 
incorporate antibiotic susceptibility data, is part of the work that contributes towards the UK 
Government’s five-year (2013-2018) antimicrobial resistance strategy.(10) This work is also 
timely because the National Institute for Health and Care Excellence are currently developing 
new sepsis guidelines on behalf of NHS England, who have made sepsis a clinical priority to 
improve the outcome of patients in 2015 and 2016.(200) Most recently in May 2016, David 
Cameron announced an aim of halving the number of HCA BSI by 2020, with a focus on Gram-
negative species.(201) This public health call highlights the balance between setting a simple, 
understandable ambition and the complexity of the attribution of BSI highlighted by this 
thesis.  
7.4.3 Implications for Research 
This thesis has demonstrated the value of enhancing individual datasets by linking them 
together to produce information that would otherwise be unobtainable, both at an event 
specific time-point (the BSI) and from a longitudinal perspective (of medical records for each 
child prior to the BSI). One next step would be to focus on condition-specific, prospective 
cohorts, such as children with cancer or children with indwelling catheters, to determine the 
 212 
risks of BSI and antibiotic resistance. This approach could provide more specific indicators for 
prevention strategies in these high risk groups.  
Another step would be to link the new SGSS antimicrobial resistance data to the clinical HES 
data. This would enhance the understanding of the bacterial species distribution in relation to 
timing of hospital admission by adding information on resistance patterns of the bacteria 
isolated from children already in hospital compared to bacteria isolated from children 
presenting to hospital from the community. 
Thirdly, the extension of linkage to other datasets, such as GP, A&E, OP and/or prescribing 
data would contribute towards further evaluation of the data quality, and would help to better 
understand previous healthcare contact and prior administration of antibiotics, indicating 
previous infection. 
The results from this thesis inform the epidemiology of BSI in children but do not directly 
impact on antibiotic treatment choices. Given the limitations of the data’s capabilities in 
distinguishing between CA, HCA and HA BSI and therefore guiding empiric therapy, more direct 
and practical solutions are needed to inform the antibiotic treatment, such as point-of-care 
(bedside) tests. Bedside tests for BSI detection are currently being developed and would 
provide an efficient testing method to tailor antibiotic treatment to each patient, avoiding 
time wastage, improving patient outcome and reducing the exposure to unnecessary 
antibiotics.(197) Results of such bedside tests could eventually be monitored nationally.  
This PhD demonstrates the proof of principal for the internal linkage of HES and LabBase2. This 
work highlights the value and importance of combining these datasets. The steps that were 
taken to access the data took over a year and highlights the need for streamlining the data 
linkage processes without compromising data security and information governance; this will 
enhance research capabilities in academia and public health. This thesis has already been used 
as the foundation for developments of further work in the field of healthcare-associated 
infection epidemiology. The linkage methods used have contributed towards the literature 
that has previously been described as lacking guidance on methods of data linkage.(202) This 
thesis was also one of the key drivers in gaining access to identifiable HES data for the HCAI & 
AMR department for a selection of departmental public health and surveillance projects. 
Subsequently, there has been a central effort from multiple PHE departments to develop the 
permissions and deliver a PHE-wide agreement with the HSCIC for access to HES data for a 
much wider range of infectious disease surveillance strategies. This has already made a 
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considerable contribution to outbreak responses, case finding and long-term public health 
epidemiology projects.  
7.5 Closing remarks 
This thesis demonstrates the value and power of using established administrative datasets to 
enhance the epidemiology of BSI in children. I described and summarised the complex and 
dynamic process of categorising and interpreting infection with the aim of reducing and 
appropriately treating BSI. Although this thesis highlights the limitations of the clinical 
characteristics captured in HES to differentiate between CA or HCA BSI in the models, the 
strength is that there is now national evidence to show that the majority of BSIs occur in 
children presenting to hospital from the community caused by a wide range of pathogens, of 
which HCA BSI plays an important role. The focus of further surveillance should be on better 
understanding exposure to infection in the community setting and investigating the 
antimicrobial susceptibility of these pathogens.  
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Appendix Chapter 1b: PubMed search strategy 
  Last extraction: March 6th 2012   
  Limits used: Humans   
      
 Search CA No. of papers 
#1 community-acquired Infections 13,121 
      
  HA (including HCA)   
#2 hospital-associated infections 262 
#3 healthcare-related infections 85 
#4 cross infection 60,476 
#5 catheter-related infections 3,843 
#6 nosocomial infections 64,091 
#7 hospital infections 178,362 
#8 hospital infection 174,468 
#9 hospital acquired 40,473 
#10 hospital-acquired 3,852 
#11 hospital-acquired infections 3,420 
#12 #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10  263,184 
      
  BSI   
#13 bloodstream infections  9,108 
#14 bloodstream infection 8,078 
#15 bacteremia 23,339 
#16 bacteraemia 23,339 
#17 septicemia  95,414 
#18 septicaemia 95,414 
#19 sepsis 90,537 
#20 septic shock 16,510 
#21 #12 OR #13 OR #14 OR #15 OR #17 OR #19 107,634 
      
  Paediatric cases   
#22 child 1,463,568 
      
  Systematic review search for adults and children   
#23 systematic[sb] AND (#1 AND #12 AND #21) 28 
      
  Literature search for adults and children, and children only   
#24 #1 AND #12 AND #21 1,424 
#25 #1 AND #12 AND #21 AND #22 303 
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Appendix Chapter 4a: ICD-10 codes identifying chronic conditions in 
children 
Chronic condition ICD-10 Codes 
Mental 
health/behavioural  
E24.4, F00-F01, F02.8, F03-F48, F50, F53, F54, F55, F59, F60-79, 
F80.0-F80.2, F80.8, F80.9, F81-F84, F88, F89, F90-F99, G24.0, 
G31.2, G40.5, G62.1, G72.0, G72.1, I42.6, K29.2, K70, K85.2, K85.3, 
K86.0, O35.4, R78.1-R78.5, X60-X84, Y10-Y34, Y47, Y49, , Y87.0, 
Y87.2, Z09.3, Z50.2, Z50.3, Z50.4, Z71.4, Z71.5, Z72.2, Z86.4, Z86.5, 
Z91.4, Z91.5  
Cancer/blood 
disorders  
C00-C97, D00-D02, D05-D09, D12, D13, D14.1-D14.4, D15, D20, 
D32-D35, D37-D48, D50, D56.0-D56.2, D56.4, D56.8, D56.9, D57.0-
D57.2, D57.8, D58, D61.0, D61.9, D63.0, D64, D66, D67, D68.0-
D68.2, D68.4-D68.9, D69, D70-D76, D80-D84, E34.0, E88.3, G13.0, 
G13.1, G53.2, G53.3, G55.0, G63.1, G73.1, G73.2, G94.1, M36.0, 
M36.2-M36.4, M36.1, M49.5, M82.0, M90.4, M90.6, M90.7, 
N08.1, N08.2, N16.1, Y43.1-Y43.3, Y84.2, Z08, Z51.0-Z51.2, Z54.1, 
Z54.2, Z85, Z86.0, Z86.2, Z92.3  
Chronic infections  A15-A19, A50, A81, B18, B20-B24, B37.1, B37.5, B37.6, B37.7, 
B38.1, B39.1, B40.1, B44.0, B44.7, B45, B46, B48.7, B50.0, B50.8*, 
B51.0, B51.8*, B52.8*, B52.0, B55, B57.2-B57.5, B58.0, B59, B67, 
B69, B73, B74, B78.7, B90-B94, E35.0, F02.1, F02.4, K23.0, K23.1, 
K67.3, K93.0, K93.1, M00, M01.1, M49.0, N33.0, P35.0-P35.2, 
P35.8, P35.9, P37.0, P37.1, R75, Z21  
 Respiratory   E84, G47.3, J41-J47, J60-J70, J80-J86, J96.1, J98, P27, P75, S17, 
S27, S28, T27, T91.4, Y55.6, Z43.0, Z93.0, Z94.2 
Metabolic/endocrine/ 
digestive/ 
renal/genitourinary  
D55, D63.8, E00, E03.0, E03.1, E07.1, E10-E14, E22.0, E23.0, E25, 
E26.8, E29.1, E31, E34.1, E34.2, E34.5, E34.8, E66, E70-E72, E74-
E78, E79.1-E79.9,E80.0-E80.3, E80.5, E80.7, E83, E85, E88.0, E88.1, 
E88.2, E88.8, E88.9, G13.2, G59.0, G63.2, G63.8, G63.3, G73.5, 
G73.6, G99.0, G99.8, I68.8, I79.2, K20, K21.0, K22, K23.8, K25-K28, 
K29.0, K29.1, K29.3-K29.9, K31, K50-K52, K55, K57, K59.2, K63.0-
K63.3, K66, K72-K76, K80-K83, K85.0, K85.1, K85.8, K85.9, K86.1-
K86.9, K87.0, K90, L99.0, M07.4, M07.5, M09.1, M09.2, M14.2-
M14.5, M90.8, N00-N05, N07, N08.3, N08.4, N11-N15, N16.0, 
N16.2, N16.3, N16.4, N16.5, N16.8, N18, N19, N20-N23, N25, N26, 
N28, N29, N31, N32, N33.8, N35, N36, N39.1, N39.3, N39.4, N40-
N42, N70-N74, N80-N82, N85, N86, N87,N88, N92, O24, S36, S37, 
S38, S39.6, S39.7, T06.5, T28, P96.0, T82.4, T83.1, T83.2, T83.4-
T83.9, T85.5, T86.1, T86.4, Y42.1, T91.5, Y42.3, Y60.2, Y61.2, Y62.2, 
Y84.1, Z43.2-Z43.4, Z46.5, Z49, Z86.3, Z90.3, Z90.4, Z93.2-Z93.5, 
Z93.6, Z93.8, Z94.0, Z99.2 
Musculoskeletal/skin  G55.1-G55.3, G63.5, G63.6, G73.7, J99.0, J99.1, L10, L11.0, L11.8, 
L11.9, L12-L14, L28, L40-L45, L57, L58.1, L59,L62.0, L87, L88, L90, 
L92, L95, L93, L98.5, M05, M06, M07.0-M07.3, M07.6, M08, 
M09.0, M09.8, M10-M13, M14.0, M14.6, M14.8, M30-M35, M40-
M43, M45- M48,M50-M54, M60-M62, M63.8, M80.1-M80.9, 
M81.1-M81.9, M82.1, M82.8, M84.0-M84.2, M84.8, M84.9, M85, 
M86.3-M86.6, M89, M90.0, M91-M94, N08.5, S13, S22.0-S22.2, 
S22.5, S23, S32, S33, S68.3, S68.4, S68.8, S77, S78, S87, S88, S97, 
S98.0, S98.2-S98.4, T02, T04, T05, T20.3, T20.7, T21.3, T21.7, 
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Chronic condition ICD-10 Codes 
T22.3, T22.7, T23.2, T23.3, T23.6, T23.7, T24.3, T24.7, T25.2, T25.3, 
T25.6, T25.7, T29.3, T29.7, T30.3, T30.7, T31.2-T31.9, T32.2-T32.9, 
T87.3-T87.6, T91.2 T91.8, T92.6, T93.1, T93.4, T93.6, T94.0, T94.1, 
T95.0, T95.1, T95.4, T95.8, T95.9, Y45.4, Y83.5, Z89.1, Z89.2, Z89.5-
Z89.8, Z97.1 
Neurological  F80.3, G40.0-G40.4, G40.6-G40.9, G41, G80-G83, H05.1-H05.9, 
H13.3, H17, H18, H19.3, H19.8, H21, H26, H27, H28.0-H28.2, H31, 
H32.8, H33, H34, H35, H40, H42.0, H43, H44, H47, H54.0- H54.2, 
H54.4, H60.2, H65.2-H65.4, H66.1-H66.3, H69.0, H70.1, H73.1, 
H74.0-H74.3, H75.0, H80, H81.0, H81.4, H83.0, H83.2, H90.0, 
H90.3, H90.5, H90.6, H91, I00-I28, I31-I39, I41, I42.0-I42.5, I42.7-
I42.9, I43.0, I43.1, I43.2-I43.8, I44.1-I44.7, I45.1-I45.9, I46-I51, 
I52.8, I70-I71, I72.1-I72.4, I72.8, I72.9, I73-I77, I79.0, I79.1, I79.8, 
I81-I82, I98-I99, M03.6, N08.8, P10, P21.0, P52, P57, P90, P91.1, 
P91.2, P91.6, R56.8, S05-S08, S12, S14, S24, S26, S34, S44, S54, 
S64, S74, S84, S94, T06.0-T06.2, T26, T82.0-T82.3, T82.5-T82.9, 
T85.2, T85.3, T86.2, T90.4, T90.5, T91.1, T91.3, T92.4, Y46.0-Y46.6, 
Y60.5, Y61.5, Y62.5, Y84.0, Z44.2, Z45.0, Z45.3, Z50.0, Z94.1, Z95  
Codes indicating non-
specific chronic 
condition 
R62, R63.3, Z43.1, Z51.5, Z75.5, Z93.1, Z99.3  
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Appendix Chapter 4b: OPCS codes identifying indwelling devices 
OPCS Code Description 
A123 – A129 Insertion of stent or creation of connection from ventricle of brain 
A131 – A145 Procedure associated with cerebroventricular shunt 
G341 – G349 
Procedure associated with artificial opening into stomach (e.g. 
gastrostomy) 
G445 Fibre-optic endoscopic percutaneous insertion of gastrostomy (PEG) 
J661 
Percutaneous drainage of lesion of pancreas and insertion of 
cystogastrostomy tube NEC 
K634 – K635 Coronary arteriography using one or two catheters 
K651 – K659 Catheterisation of heart 
L704 Open cannulation of artery 
L911 – L919 
Vein related operations associated with insertion or removal of central 
venous catheter 
L921 – L929 Unblocking on access catheter 
L934 Open cannulation of vein 
L942 – L949 
Percutaneous transluminal cannulation of vein, insertion/replacement 
of subcutaneous port or stent, venoplasty or angioplasty 
L997 
Percutaneous transluminal insertion of peripherally inserted central 
catheter 
X411 – Z412 Insertion/removal of ambulatory peritoneal dialysis catheter 
X421 Insertion of temporary peritoneal dialysis catheter 
Y512 Approach to organ through gastrostomy 
 
OPCS codes: identifying non-invasive/low risk for adverse event procedures 
Code Description 
E852 
R36-R43 
Non-invasive ventilation 
Obstetric scans 
U01-U21 Diagnostic imaging 
U22-U40 Diagnostic tests 
U50-U54 Rehabilitation 
X44 Administration of vaccine 
X48-X49 Plaster case/support of limb 
X52 Oxygen therapy 
X60 Rehabilitation assessment 
X61 Complimentary therapy 
X62 Assessments 
X63-X64 Retired codes 
X65 Radiotherapy 
X66 Cognitive behavioural therapy 
X67-X68 Preparation for radio/brachytherapy 
X70-X97 Specified drug therapy 
Y95-Y96 Non-operations relating to fetus and embryo 
Y90 Non-operations 
Y99 Donor status 
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Appendix Chapter 5: Summary figures depicting all the AIC and BIC values from the approach A and approach B model 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 5Ai. Approach A: best fitting AIC or BIC model (in red) in comparison to all other models (total 1,023 models) to predict HA BSI in children aged 1 month < 1 year 
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Appendix 5Aii. Approach A: best fitting AIC or BIC model (in red) in comparison to all other models (total 1,023 models) to predict CA BSI in children aged 1 month < 1 year  
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Appendix 5Aiii. Approach A: best fitting AIC or BIC model (in red) in comparison to all other models (total 551models) to predict HA BSI in children aged 1-5 years  
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Appendix 5A iv. Approach A: best fitting AIC or BIC model (in red) in comparison to all other models (total 551 models) to predict CA BSI in children aged 1-5 years  
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Appendix 5Bi. Approach A: Adjusted OR results for explanatory variables in the final models (HA1-HA9) with HA BSI as the outcome in children aged 1 month < 1 year  
Approach A
1m<1y HA outcome AOR P-value AOR P-value AOR P-value AOR P-value AOR P-value AOR P-value AOR P-value AOR P-value AOR P-value
Age in days (FP=1; linear) (FP=1) (FP=1) (FP=1) (FP=1) (FP=1) (FP=1) (FP=1) (FP=1)
0.99 <0.001 0.99 0.99 1.00 <0.001 0.99 0.99 1.00 <0.001 0.99 0.99 1.00 <0.001 0.99 0.99 1.00 <0.001 0.99 0.99 1.00 <0.001 0.99 0.99 1.00 <0.001 0.99 0.99 1.00 <0.001 0.99 0.99 1.00 <0.001 0.99 0.99
Postnatal stay (FP = 0) (FP = -2, -0.5) (FP = -2,0) (FP = -0.5,-0.5) (FP = -1,0) (FP = -2,0) (FP = -2,0) (FP = -2,0) (FP = -2,0)
0.88 0.001 0.82 0.95 0.99 <0.001 0.99 0.99 0.99 <0.001 0.99 0.99 2.58 <0.001 1.84 3.62 0.99 <0.001 0.99 0.99 0.99 <0.001 0.99 0.99 0.99 <0.001 0.99 0.99 0.99 <0.001 0.99 0.99 0.99 <0.001 0.99 0.99
1.19 <0.001 1.12 1.28 0.71 <0.001 0.63 0.80 1.17 <0.001 1.10 1.24 0.65 <0.001 0.55 0.76 0.69 <0.001 0.61 0.78 0.68 <0.001 0.60 0.78 0.66 <0.001 0.58 0.75 0.68 <0.001 0.60 0.78
Ethnicity
White 1.00 1.00 1.00 1.00 1.00 1.00 1.00
Mixed 1.21 0.386 0.79 1.85 1.32 0.357 0.73 2.37 1.05 0.890 0.54 2.03 0.85 0.650 0.41 1.73 0.87 0.713 0.41 1.83 0.83 0.631 0.38 1.79 0.95 0.889 0.43 2.06
Indian subcontinent 1.45 0.004 1.13 1.87 1.68 0.003 1.19 2.37 1.48 0.043 1.01 2.16 1.29 0.211 0.87 1.93 1.38 0.121 0.92 2.08 1.33 0.179 0.88 2.01 1.30 0.227 0.85 1.99
Any other Asian 1.30 0.236 0.84 2.02 1.50 0.159 0.85 2.64 1.38 0.297 0.75 2.52 1.44 0.247 0.78 2.68 1.26 0.488 0.66 2.39 1.25 0.495 0.66 2.39 1.08 0.816 0.55 2.11
Black 1.15 0.417 0.82 1.61 1.30 0.261 0.82 2.07 1.18 0.529 0.71 1.96 1.26 0.382 0.75 2.13 1.28 0.373 0.75 2.19 1.35 0.279 0.78 2.32 1.09 0.762 0.62 1.93
other ethnic group 1.03 0.872 0.69 1.56 1.79 0.023 1.09 2.96 1.69 0.056 0.99 2.89 1.43 0.209 0.82 2.50 1.50 0.161 0.85 2.65 1.54 0.138 0.87 2.72 1.44 0.222 0.80 2.57
NK 1.30 0.069 0.98 1.72 1.89 <0.001 1.32 2.70 1.88 0.001 1.28 2.76 2.02 <0.001 1.36 2.99 2.17 <0.001 1.45 3.23 2.21 <0.001 1.48 3.29 2.16 <0.001 1.44 3.24
boy 1.00 1.00 1.00 1.00 1.00 1.00
girl 1.14 0.089 0.98 1.33 1.26 0.035 1.02 1.55 1.24 0.066 0.99 1.56 1.27 0.053 1.00 1.61 1.20 0.144 0.94 1.54 1.31 0.035 1.02 1.69
normal birth 1.00 1.00 1.00 1.00 1.00 1.00
Premature/low birthweight 1.34 0.013 1.07 1.69 1.83 <0.001 1.38 2.44 1.97 <0.001 1.45 2.68 2.00 <0.001 1.45 2.74 2.17 <0.001 1.57 2.99 2.16 <0.001 1.56 2.99 2.14 <0.001 1.55 2.95 2.10 <0.001 1.51 2.92 1.92 <0.001 1.38 2.67
Chronic conditions
no chronic 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
1 chronic 0.82 0.046 0.67 1.00 1.59 0.002 1.19 2.12 1.79 0.001 1.28 2.50 2.01 <0.001 1.40 2.87 2.12 <0.001 1.44 3.11 2.11 <0.001 1.43 3.14 2.06 <0.001 1.38 3.07 2.04 0.001 1.34 3.10 2.18 <0.001 1.42 3.37
2 chronic 1.34 0.029 1.03 1.75 3.43 <0.001 2.46 4.77 4.28 <0.001 2.97 6.16 4.51 <0.001 3.06 6.64 4.89 <0.001 3.25 7.35 4.47 <0.001 2.94 6.80 4.77 <0.001 3.13 7.27 4.70 <0.001 3.03 7.30 5.12 <0.001 3.27 8.03
>2 chronic 2.55 <0.001 1.93 3.37 5.87 <0.001 4.19 8.22 7.30 <0.001 5.05 10.54 8.40 <0.001 5.70 12.39 9.43 <0.001 6.29 14.16 8.79 <0.001 5.81 13.30 9.54 <0.001 6.29 14.45 9.60 <0.001 6.23 14.80 9.84 <0.001 6.32 15.31
not recorded 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
Congenital condition(s) 2.57 <0.001 2.09 3.16 4.46 <0.001 3.48 5.72 4.98 <0.001 3.82 6.48 4.99 <0.001 3.79 6.56 4.68 <0.001 3.54 6.19 4.81 <0.001 3.62 6.40 4.50 <0.001 3.39 5.97 4.49 <0.001 3.35 6.02 4.11 <0.001 3.07 5.52
No. of days since last indwelling device insertion
no device 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
91 days<1 yr 1.15 0.491 0.77 1.73 1.08 0.749 0.69 1.69 1.45 0.118 0.91 2.31 1.30 0.279 0.81 2.11 1.20 0.455 0.74 1.96 1.22 0.428 0.74 2.00 1.27 0.343 0.78 2.07 1.45 0.146 0.88 2.40 1.39 0.203 0.84 2.29
31-90 days 1.48 0.037 1.02 2.15 1.75 0.005 1.18 2.61 1.72 0.009 1.14 2.58 1.96 0.001 1.30 2.95 1.96 0.001 1.30 2.96 1.90 0.002 1.26 2.88 2.01 0.001 1.33 3.04 2.23 <0.001 1.47 3.38 2.18 <0.001 1.44 3.29
7-30 days 3.68 <0.001 2.20 6.18 4.87 <0.001 2.94 8.06 5.79 <0.001 3.48 9.63 6.83 <0.001 4.07 11.46 6.78 <0.001 4.05 11.34 6.56 <0.001 3.95 10.88 6.62 <0.001 4.02 10.92 7.17 <0.001 4.33 11.88 8.15 <0.001 4.94 13.44
1-6 days 1.90 0.056 0.98 3.67 4.36 <0.001 2.27 8.38 4.91 <0.001 2.59 9.29 6.07 <0.001 3.20 11.54 5.58 <0.001 2.98 10.44 6.68 <0.001 3.58 12.47 4.94 <0.001 2.70 9.02 5.93 <0.001 3.21 10.96 4.74 <0.001 2.58 8.70
No. of days since last invasive procedure
no procedure 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
91 days<1 yr 1.37 0.058 0.99 1.89 1.44 0.110 0.92 2.26 1.49 0.124 0.90 2.47 1.58 0.099 0.92 2.71 1.72 0.058 0.98 3.02 1.98 0.019 1.12 3.50 2.02 0.015 1.15 3.57 2.01 0.021 1.11 3.63 2.52 0.003 1.38 4.59
31-90 days 1.50 0.006 1.12 2.00 2.24 <0.001 1.55 3.25 2.63 <0.001 1.77 3.92 2.90 <0.001 1.92 4.40 3.31 <0.001 2.15 5.09 3.62 <0.001 2.33 5.62 3.66 <0.001 2.36 5.68 3.75 <0.001 2.38 5.89 4.36 <0.001 2.77 6.88
7-30 days 3.25 <0.001 2.39 4.41 5.17 <0.001 3.61 7.42 6.43 <0.001 4.39 9.43 7.56 <0.001 5.08 11.25 9.23 <0.001 6.12 13.94 9.68 <0.001 6.38 14.71 9.46 <0.001 6.24 14.36 9.58 <0.001 6.25 14.71 9.40 <0.001 6.09 14.51
1-6 days 8.44 <0.001 6.27 11.37 7.57 <0.001 5.42 10.58 7.39 <0.001 5.13 10.65 6.50 <0.001 4.42 9.56 6.47 <0.001 4.32 9.68 4.82 <0.001 3.17 7.33 3.88 <0.001 2.54 5.92 3.11 <0.001 1.99 4.85 3.17 <0.001 2.02 4.97
No. of days between last discharge and current admission
no previous discharge 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
91 days<1 yr 0.63 0.001 0.48 0.83 0.20 <0.001 0.11 0.35 0.13 <0.001 0.07 0.24 0.10 <0.001 0.05 0.19 0.10 <0.001 0.05 0.20 0.09 <0.001 0.05 0.18 0.07 <0.001 0.03 0.14 0.07 <0.001 0.04 0.15 0.05 <0.001 0.03 0.11
31-90 days 0.61 <0.001 0.46 0.81 0.16 <0.001 0.09 0.27 0.10 <0.001 0.05 0.17 0.08 <0.001 0.05 0.15 0.09 <0.001 0.05 0.16 0.07 <0.001 0.04 0.13 0.06 <0.001 0.03 0.11 0.06 <0.001 0.03 0.11 0.05 <0.001 0.03 0.10
7-30 days 0.59 0.001 0.43 0.80 0.18 <0.001 0.11 0.30 0.12 <0.001 0.07 0.22 0.10 <0.001 0.05 0.17 0.10 <0.001 0.05 0.17 0.09 <0.001 0.05 0.17 0.07 <0.001 0.04 0.14 0.08 <0.001 0.04 0.14 0.07 <0.001 0.04 0.13
1-6 days 0.77 0.124 0.56 1.07 0.28 <0.001 0.16 0.47 0.18 <0.001 0.10 0.32 0.15 <0.001 0.09 0.27 0.16 <0.001 0.09 0.28 0.16 <0.001 0.09 0.29 0.14 <0.001 0.07 0.25 0.15 <0.001 0.08 0.27 0.15 <0.001 0.08 0.27
95% CI 95% CI 95% CI 95% CI95% CI 95% CI 95% CI 95% CI 95% CI
HA9HA4 HA5 HA6 HA7 HA8
Fractional polynomial (FP) 2
Fractional polynomial (FP) 1
HA1 HA2 HA3
Fractional polynomial (FP) 1
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Appendix 5Bii. Approach A: Adjusted OR results for explanatory variables in the final models (HA1-HA9) with CA BSI as the outcome in children aged 1 month < 1 year  
No. of obs      =      3090 No. of obs      =      3576 No. of obs      =      3661 No. of obs      =      3704  No. of obs      =      3736 No. of obs      =      3759 No. of obs      =      3781 No. of obs      =      3808 No. of obs      =      3827
Approach A
1m<1y CA outcome AOR P-value AOR P-value AOR P-value AOR P-value AOR P-value AOR P-value AOR P-value AOR P-value AOR P-value
Age in days (FP = 0.5,2) (FP = 0.5,2) (FP = 0.5,2) (FP = 0.5,2) (FP = 0.5,2) (FP = 1,2) (FP = 1,2) (FP = 1,2) (FP = 0.5,2)
23.93 <0.001 12.55 45.60 22.31 <0.001 11.93 41.75 22.83 <0.001 12.22 42.67 22.57 <0.001 12.10 42.12 22.53 <0.001 12.08 42.03 5.74 <0.001 3.66 9.02 5.69 <0.001 3.63 8.92 5.60 <0.001 3.58 8.78 21.82 <0.001 11.72 40.62
0.83 <0.001 0.78 0.88 0.84 <0.001 0.79 0.89 0.83 <0.001 0.78 0.88 0.83 <0.001 0.78 0.88 0.83 <0.001 0.78 0.88 0.72 <0.001 0.64 0.80 0.72 <0.001 0.64 0.80 0.72 <0.001 0.65 0.80 0.83 <0.001 0.79 0.89
Postnatal stay (FP = -2,0) (FP = -2,0) (FP = -0.5,-0.5) (FP = -0.5,-0.5) (FP = -0.5,-0.5) (FP = -2,0) (FP = -2,0) (FP = -2,0) (FP = -2,0)
1.00 <0.001 1.00 1.00 1.00 <0.001 1.00 1.00 2.02 <0.001 1.50 2.73 2.01 <0.001 1.49 2.70 1.98 <0.001 1.47 2.67 1.00 0.001 1.00 1.00 1.00 0.001 1.00 1.00 1.00 0.001 1.00 1.00 1.00 <0.001 1.00 1.00
0.73 <0.001 0.63 0.85 0.72 <0.001 0.63 0.83 1.12 <0.001 1.07 1.17 1.12 <0.001 1.07 1.17 1.11 <0.001 1.06 1.17 0.74 <0.001 0.64 0.85 0.73 <0.001 0.63 0.85 0.73 <0.001 0.63 0.85 0.74 <0.001 0.64 0.85
Ethnicity
White 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
Mixed 0.60 0.048 0.36 1.00 0.64 0.072 0.39 1.04 0.60 0.042 0.37 0.98 0.59 0.033 0.36 0.96 0.59 0.035 0.36 0.96 0.59 0.037 0.36 0.97 0.60 0.042 0.37 0.98 0.61 0.046 0.37 0.99 0.60 0.041 0.37 0.98
Indian subcontinent 0.61 0.004 0.43 0.85 0.60 0.002 0.44 0.84 0.59 0.001 0.42 0.81 0.58 0.001 0.42 0.80 0.58 0.001 0.42 0.80 0.58 0.001 0.42 0.80 0.58 0.001 0.42 0.80 0.58 0.001 0.42 0.80 0.58 0.001 0.42 0.79
Any other Asian 0.23 <0.001 0.10 0.51 0.23 <0.001 0.10 0.52 0.23 <0.001 0.10 0.51 0.23 <0.001 0.10 0.51 0.22 <0.001 0.10 0.49 0.22 <0.001 0.10 0.50 0.21 <0.001 0.10 0.48 0.21 <0.001 0.10 0.47 0.22 <0.001 0.10 0.48
Black 0.36 <0.001 0.22 0.57 0.36 <0.001 0.23 0.58 0.36 <0.001 0.23 0.57 0.36 <0.001 0.23 0.58 0.36 <0.001 0.23 0.57 0.36 <0.001 0.23 0.57 0.36 <0.001 0.23 0.57 0.34 <0.001 0.22 0.55 0.34 <0.001 0.21 0.53
other ethnic group 0.60 0.046 0.36 0.99 0.68 0.135 0.41 1.13 0.67 0.116 0.41 1.10 0.67 0.115 0.41 1.10 0.68 0.126 0.41 1.11 0.68 0.134 0.42 1.12 0.67 0.113 0.41 1.10 0.68 0.121 0.41 1.11 0.66 0.097 0.40 1.08
NK 0.80 0.204 0.57 1.13 0.86 0.367 0.61 1.20 0.84 0.307 0.60 1.17 0.85 0.330 0.61 1.18 0.85 0.345 0.61 1.19 0.83 0.268 0.60 1.15 0.82 0.232 0.59 1.14 0.83 0.253 0.59 1.15 0.82 0.228 0.59 1.13
normal birth 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
Premature/low birthweight 1.56 0.009 1.12 2.18 1.62 0.004 1.17 2.23 1.64 0.003 1.19 2.28 1.63 0.003 1.18 2.25 1.62 0.003 1.17 2.24 1.64 0.003 1.19 2.26 1.63 0.003 1.18 2.25 1.63 0.003 1.18 2.24 1.57 0.006 1.14 2.15
Chronic conditions
no chronic 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
1 chronic 1.96 <0.001 1.62 2.38 2.05 <0.001 1.70 2.47 2.02 <0.001 1.68 2.43 2.03 <0.001 1.69 2.44 2.02 <0.001 1.68 2.42 2.05 <0.001 1.71 2.47 2.05 <0.001 1.70 2.46 2.05 <0.001 1.70 2.47 2.01 <0.001 1.68 2.42
2 chronic 2.37 <0.001 1.67 3.36 2.57 <0.001 1.84 3.61 2.61 <0.001 1.87 3.65 2.54 <0.001 1.82 3.55 2.51 <0.001 1.80 3.49 2.49 <0.001 1.79 3.46 2.45 <0.001 1.76 3.40 2.42 <0.001 1.74 3.36 2.34 <0.001 1.69 3.25
>2 chronic 1.62 0.043 1.02 2.57 1.74 0.014 1.12 2.72 1.69 0.018 1.10 2.62 1.68 0.019 1.09 2.60 1.70 0.017 1.10 2.62 1.69 0.017 1.10 2.61 1.64 0.026 1.06 2.52 1.62 0.028 1.05 2.49 1.48 0.073 0.96 2.26
not recorded 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
Congenital condition(s) 0.62 0.006 0.45 0.87 0.66 0.013 0.48 0.92 0.65 0.008 0.47 0.89 0.63 0.004 0.46 0.86 0.59 0.001 0.43 0.81 0.61 0.002 0.44 0.84 0.58 0.001 0.42 0.80 0.56 <0.001 0.41 0.77 0.53 <0.001 0.39 0.72
No. of days since last indwelling device insertion
no device 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
91 days<1 yr 0.64 0.180 0.34 1.23 0.75 0.370 0.41 1.40 0.79 0.453 0.43 1.46 0.75 0.362 0.41 1.38 0.74 0.331 0.40 1.36 0.76 0.382 0.42 1.40 0.79 0.432 0.43 1.44 0.81 0.502 0.44 1.49 0.78 0.416 0.43 1.42
31-90 days 0.17 0.002 0.06 0.53 0.24 0.009 0.08 0.70 0.22 0.005 0.08 0.64 0.23 0.007 0.08 0.67 0.23 0.007 0.08 0.67 0.26 0.013 0.09 0.75 0.27 0.015 0.09 0.77 0.28 0.017 0.10 0.79 0.25 0.011 0.09 0.73
7-30 days 0.11 0.042 0.01 0.92 0.19 0.121 0.02 1.55 0.21 0.146 0.03 1.71 0.23 0.163 0.03 1.82 0.23 0.160 0.03 1.80 0.27 0.210 0.03 2.11 0.26 0.203 0.03 2.06 0.27 0.209 0.03 2.10 0.26 0.199 0.03 2.03
1-6 days 3.70 0.121 0.71 19.33 8.16 0.009 1.70 39.21 6.17 0.008 1.62 23.52 6.92 0.004 1.83 26.23 6.31 0.003 1.84 21.59 7.15 0.002 2.08 24.61 4.09 0.006 1.51 11.09 3.24 0.012 1.29 8.13 2.49 0.040 1.04 5.94
No. of days since last invasive procedure
no procedure 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
91 days<1 yr 0.83 0.337 0.58 1.21 0.73 0.087 0.52 1.05 0.71 0.059 0.50 1.01 0.71 0.057 0.50 1.01 0.72 0.064 0.51 1.02 0.74 0.095 0.52 1.05 0.75 0.112 0.53 1.07 0.76 0.126 0.54 1.08 0.76 0.123 0.54 1.08
31-90 days 0.65 0.057 0.41 1.01 0.58 0.017 0.37 0.91 0.57 0.014 0.37 0.89 0.57 0.012 0.36 0.88 0.57 0.012 0.37 0.88 0.65 0.060 0.41 1.02 0.66 0.074 0.42 1.04 0.67 0.081 0.43 1.05 0.60 0.023 0.39 0.93
7-30 days 0.35 0.002 0.18 0.69 0.34 0.001 0.18 0.66 0.33 0.001 0.17 0.65 0.34 0.001 0.18 0.66 0.35 0.002 0.18 0.68 0.44 0.021 0.22 0.88 0.47 0.030 0.23 0.93 0.45 0.022 0.23 0.89 0.35 0.001 0.18 0.67
1-6 days 3.41 <0.001 2.01 5.81 1.44 0.088 0.95 2.20 1.20 0.379 0.80 1.81 1.06 0.775 0.71 1.59 1.01 0.950 0.68 1.51 0.94 0.749 0.63 1.40 0.84 0.405 0.57 1.26 0.81 0.305 0.55 1.21 0.76 0.173 0.52 1.13
No. of days between last discharge and current admission
no previous discharge 1.00 1.00 1.00
91 days<1 yr 0.83 0.442 0.52 1.33 0.81 0.370 0.51 1.29 0.81 0.384 0.51 1.30
31-90 days 0.69 0.136 0.43 1.12 0.67 0.100 0.41 1.08 0.66 0.092 0.41 1.07
7-30 days 0.55 0.024 0.32 0.93 0.53 0.018 0.32 0.90 0.53 0.018 0.32 0.90
1-6 days 0.71 0.195 0.43 1.19 0.70 0.165 0.42 1.16 0.71 0.187 0.43 1.18
Fractional polynomial (FP) 1
Fractional polynomial (FP) 2
HA9
95% CI95% CI 95% CI 95% CI 95% CI 95% CI 95% CI 95% CI 95% CI
HA3 HA4 HA5 HA6 HA7
Fractional polynomial (FP) 2
Fractional polynomial (FP) 1
HA1 HA2 HA8
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Appendix 5Biii. Approach A: Adjusted OR results for explanatory variables in the final models (HA1-HA9) with HA BSI as the outcome in children aged 1-5 years  
Approach A
1-5yrs HA outcome AOR P-value AOR P-value AOR P-value AOR P-value AOR P-value AOR P-value AOR P-value AOR P-value AOR P-value
Age in days (FP = 1) (FP = 1) (FP = 1) (FP = 1) (FP = 1) (FP = 1) (FP = 1) (FP = 1) (FP = 1)
0.99 0.002 0.99 0.99 0.99 0.007 0.99 0.99 0.99 0.010 0.99 0.99 0.99 0.003 0.99 0.99 0.99 <0.001 0.99 0.99 0.99 <0.001 0.99 0.99 0.99 <0.001 0.99 0.99 0.99 <0.001 0.99 0.99 0.99 <0.001 0.99 0.99
Ethnicity
White 1.00 1.00 1.00 1.00
Mixed 0.65 0.046 0.42 0.99 0.65 0.194 0.34 1.24 0.67 0.270 0.33 1.36 0.68 0.350 0.30 1.53
Indian subcontinent 1.25 0.056 0.99 1.56 1.53 0.012 1.10 2.13 1.46 0.052 1.00 2.13 1.49 0.066 0.97 2.29
Any other Asian 1.22 0.310 0.83 1.80 1.20 0.525 0.68 2.13 0.85 0.634 0.43 1.67 0.72 0.410 0.33 1.57
Black 1.00 0.975 0.75 1.32 1.36 0.142 0.90 2.05 1.21 0.435 0.75 1.95 1.58 0.081 0.95 2.64
other ethnic group 0.93 0.693 0.64 1.35 1.51 0.094 0.93 2.45 1.50 0.144 0.87 2.57 1.75 0.066 0.96 3.16
NK 1.25 0.064 0.99 1.59 1.60 0.005 1.15 2.22 1.79 0.001 1.25 2.57 1.51 0.049 1.00 2.27
normal birth 1.00
Premature/low birthweight 1.28 0.134 0.93 1.78
Chronic conditions
no chronic 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
1 chronic 1.17 0.079 0.98 1.39 2.76 <0.001 2.00 3.82 4.29 <0.001 2.77 6.64 4.32 <0.001 2.69 6.95 5.88 <0.001 3.34 10.37 5.32 <0.001 2.89 9.80 5.89 <0.001 3.00 11.58 6.98 <0.001 3.35 14.55 7.94 <0.001 3.50 18.02
2 chronic 1.20 0.138 0.94 1.51 3.74 <0.001 2.58 5.43 6.63 <0.001 4.11 10.68 7.55 <0.001 4.53 12.58 11.29 <0.001 6.21 20.51 11.84 <0.001 6.28 22.33 15.24 <0.001 7.62 30.49 16.28 <0.001 7.65 34.65 19.55 <0.001 8.48 45.06
>2 chronic 1.99 <0.001 1.57 2.53 8.98 <0.001 6.25 12.89 16.89 <0.001 10.60 26.91 19.71 <0.001 11.98 32.42 31.56 <0.001 17.58 56.65 32.05 <0.001 17.19 59.75 41.34 <0.001 20.88 81.84 50.16 <0.001 23.89 105.32 60.07 <0.001 26.40 136.67
not recorded 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
Congenital condition(s) 1.80 <0.001 1.47 2.20 2.24 <0.001 1.76 2.86 2.35 <0.001 1.80 3.06 2.48 <0.001 1.90 3.24 2.29 <0.001 1.73 3.03 2.19 <0.001 1.64 2.93 2.20 <0.001 1.64 2.95 2.36 <0.001 1.74 3.19 2.36 <0.001 1.74 3.20
No. of days since last indwelling device insertion
no device 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
91 days<1 yr 0.86 0.301 0.64 1.15 0.96 0.838 0.68 1.37 0.98 0.930 0.67 1.44 0.95 0.810 0.64 1.41 0.93 0.728 0.62 1.40 0.88 0.564 0.58 1.35 0.92 0.715 0.59 1.43 1.03 0.908 0.66 1.61 1.13 0.608 0.71 1.78
31-90 days 1.08 0.641 0.78 1.49 1.46 0.040 1.02 2.10 1.68 0.008 1.14 2.47 1.77 0.005 1.19 2.62 1.67 0.015 1.11 2.52 1.77 0.008 1.16 2.70 1.91 0.003 1.24 2.93 2.09 0.001 1.34 3.27 2.38 <0.001 1.51 3.73
7-30 days 2.15 <0.001 1.55 2.99 2.55 <0.001 1.79 3.64 3.03 <0.001 2.08 4.42 3.15 <0.001 2.15 4.62 3.59 <0.001 2.42 5.33 3.89 <0.001 2.59 5.83 4.31 <0.001 2.85 6.52 4.96 <0.001 3.24 7.60 5.37 <0.001 3.49 8.28
1-6 days 1.57 0.048 1.00 2.45 2.06 0.003 1.28 3.32 1.97 0.009 1.19 3.27 2.12 0.004 1.27 3.54 2.22 0.003 1.30 3.76 2.13 0.007 1.23 3.67 2.03 0.014 1.15 3.59 2.04 0.019 1.13 3.70 2.00 0.026 1.09 3.69
No. of days since last invasive procedure
no procedure 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
91 days<1 yr 1.11 0.512 0.82 1.51 1.89 0.008 1.18 3.02 2.54 0.001 1.48 4.36 2.87 <0.001 1.64 5.02 2.78 0.001 1.53 5.04 3.29 <0.001 1.78 6.08 3.19 <0.001 1.69 6.03 3.24 <0.001 1.69 6.22 2.94 0.001 1.52 5.71
31-90 days 1.96 <0.001 1.42 2.71 5.57 <0.001 3.60 8.62 8.06 <0.001 4.91 13.24 8.28 <0.001 4.94 13.90 9.46 <0.001 5.49 16.31 11.83 <0.001 6.73 20.80 10.97 <0.001 6.12 19.66 10.75 <0.001 5.91 19.58 9.66 <0.001 5.26 17.74
7-30 days 4.54 <0.001 3.43 6.00 15.57 <0.001 10.77 22.51 26.68 <0.001 17.55 40.54 30.75 <0.001 19.89 47.55 34.24 <0.001 21.62 54.21 40.01 <0.001 24.72 64.77 40.15 <0.001 24.42 66.02 37.95 <0.001 22.77 63.23 30.87 <0.001 18.39 51.84
1-6 days 7.30 <0.001 5.61 9.51 15.63 <0.001 11.15 21.90 21.21 <0.001 14.45 31.14 20.47 <0.001 13.74 30.51 19.72 <0.001 12.93 30.10 20.05 <0.001 12.82 31.35 16.60 <0.001 10.44 26.40 13.61 <0.001 8.43 21.98 11.21 <0.001 6.84 18.36
No. of days between last discharge and current admission
no previous discharge 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
91 days<1 yr 1.13 0.311 0.89 1.42 0.56 0.004 0.38 0.83 0.45 0.001 0.28 0.71 0.43 <0.001 0.26 0.69 0.44 0.001 0.26 0.72 0.45 0.003 0.27 0.76 0.42 0.002 0.25 0.72 0.36 <0.001 0.21 0.63 0.39 0.001 0.22 0.68
31-90 days 0.84 0.230 0.63 1.12 0.30 <0.001 0.20 0.47 0.22 <0.001 0.13 0.35 0.21 <0.001 0.13 0.34 0.18 <0.001 0.10 0.30 0.17 <0.001 0.10 0.29 0.16 <0.001 0.09 0.27 0.14 <0.001 0.08 0.24 0.13 <0.001 0.07 0.24
7-30 days 0.69 0.006 0.53 0.90 0.19 <0.001 0.13 0.28 0.10 <0.001 0.07 0.16 0.09 <0.001 0.05 0.13 0.07 <0.001 0.04 0.11 0.06 <0.001 0.04 0.11 0.06 <0.001 0.03 0.09 0.05 <0.001 0.03 0.08 0.06 <0.001 0.03 0.10
1-6 days 0.63 <0.001 0.49 0.80 0.23 <0.001 0.16 0.32 0.14 <0.001 0.10 0.21 0.12 <0.001 0.08 0.18 0.10 <0.001 0.07 0.16 0.10 <0.001 0.07 0.16 0.09 <0.001 0.06 0.14 0.08 <0.001 0.05 0.12 0.08 <0.001 0.05 0.13
Fractional polynomial (FP) 1
HA1 HA2 HA3 HA4 HA5 HA7
95% CI
HA8 HA9HA6
95% CI 95% CI 95% CI95% CI 95% CI 95% CI 95% CI 95% CI
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Appendix 5Biv. Approach A: Adjusted OR results for explanatory variables in the final models (HA1-HA9) with CA BSI as the outcome in children aged 1-5 years  
No. of obs      =      4793  No. of obs      =      5460  No. of obs      =      5576 No. of obs      =      5619  No. of obs      =      5666 No. of obs      =      5694 No. of obs      =      5731 No. of obs      =      5756 No. of obs      =      5776
Approach A
1-5y CA outcome AOR P-value AOR P-value AOR P-value AOR P-value AOR P-value AOR P-value AOR P-value AOR P-value AOR P-value
Age in days (FP = 1) (FP = -2,-1) (FP = -2,-1) (FP = -2,-1) (FP = -2,-1) (FP = -2,-1) (FP = -2,-1) (FP = -2,-1) (FP = -2,-1)
1.00 <0.001 1.00 1.00 1.36 <0.001 1.16 1.60 1.38 <0.001 1.17 1.62 1.37 <0.001 1.16 1.60 1.36 <0.001 1.16 1.60 1.36 <0.001 1.16 1.60 1.36 <0.001 1.16 1.60 1.37 <0.001 1.16 1.60 1.37 <0.001 1.16 1.60
0.36 <0.001 0.22 0.58 0.35 <0.001 0.21 0.56 0.36 <0.001 0.22 0.58 0.36 <0.001 0.22 0.58 0.36 <0.001 0.22 0.58 0.36 <0.001 0.22 0.58 0.35 <0.001 0.22 0.57 0.35 <0.001 0.22 0.57
Ethnicity
White 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
Mixed 1.03 0.875 0.74 1.43 1.08 0.639 0.78 1.50 1.08 0.628 0.78 1.50 1.10 0.547 0.80 1.53 1.11 0.524 0.80 1.54 1.10 0.559 0.80 1.52 1.11 0.541 0.80 1.53 1.11 0.528 0.80 1.54 1.11 0.541 0.80 1.53
Indian subcontinent 0.80 0.050 0.64 1.00 0.79 0.035 0.64 0.98 0.78 0.028 0.63 0.97 0.78 0.023 0.63 0.97 0.77 0.021 0.62 0.96 0.78 0.022 0.63 0.96 0.77 0.020 0.62 0.96 0.77 0.020 0.62 0.96 0.78 0.021 0.62 0.96
Any other Asian 0.59 0.013 0.39 0.89 0.58 0.008 0.39 0.87 0.57 0.006 0.38 0.86 0.58 0.007 0.39 0.86 0.58 0.008 0.39 0.87 0.58 0.008 0.39 0.87 0.58 0.008 0.39 0.87 0.58 0.008 0.39 0.87 0.58 0.008 0.39 0.87
Black 0.71 0.008 0.55 0.91 0.74 0.020 0.58 0.95 0.74 0.016 0.57 0.94 0.74 0.018 0.58 0.95 0.74 0.017 0.58 0.95 0.75 0.020 0.58 0.96 0.73 0.014 0.57 0.94 0.73 0.013 0.57 0.94 0.73 0.011 0.57 0.93
other ethnic group 0.69 0.048 0.48 1.00 0.76 0.144 0.53 1.10 0.76 0.136 0.53 1.09 0.77 0.146 0.53 1.10 0.77 0.158 0.54 1.11 0.76 0.144 0.53 1.10 0.76 0.136 0.53 1.09 0.76 0.143 0.53 1.10 0.77 0.146 0.53 1.10
NK 1.25 0.060 0.99 1.57 1.23 0.070 0.98 1.53 1.23 0.060 0.99 1.54 1.21 0.091 0.97 1.50 1.20 0.102 0.96 1.49 1.19 0.118 0.96 1.48 1.18 0.129 0.95 1.47 1.18 0.131 0.95 1.47 1.17 0.162 0.94 1.45
Chronic conditions
no chronic 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
1 chronic 1.54 <0.001 1.33 1.78 1.53 <0.001 1.33 1.75 1.51 <0.001 1.32 1.74 1.50 <0.001 1.30 1.72 1.50 <0.001 1.30 1.72 1.48 <0.001 1.29 1.70 1.47 <0.001 1.28 1.69 1.48 <0.001 1.29 1.69 1.47 <0.001 1.28 1.69
2 chronic 1.45 0.002 1.15 1.84 1.50 <0.001 1.19 1.88 1.51 <0.001 1.20 1.89 1.51 <0.001 1.20 1.89 1.50 <0.001 1.20 1.88 1.49 <0.001 1.19 1.87 1.49 0.001 1.19 1.87 1.47 0.001 1.18 1.85 1.47 0.001 1.17 1.84
>2 chronic 1.70 <0.001 1.27 2.28 1.88 <0.001 1.42 2.50 1.84 <0.001 1.39 2.44 1.79 <0.001 1.35 2.36 1.78 <0.001 1.35 2.36 1.75 <0.001 1.33 2.32 1.75 <0.001 1.33 2.31 1.73 <0.001 1.31 2.28 1.68 <0.001 1.28 2.22
not recorded 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
Congenital condition(s) 0.63 0.002 0.47 0.84 0.60 <0.001 0.46 0.80 0.60 <0.001 0.45 0.79 0.60 <0.001 0.45 0.79 0.57 <0.001 0.43 0.76 0.57 <0.001 0.43 0.75 0.56 <0.001 0.42 0.73 0.56 <0.001 0.42 0.73 0.55 <0.001 0.42 0.73
No. of days since last indwelling device insertion
no device 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
91 days<1 yr 0.43 <0.001 0.28 0.67 0.46 <0.001 0.29 0.71 0.46 0.001 0.30 0.71 0.46 0.001 0.30 0.72 0.47 0.001 0.30 0.72 0.47 0.001 0.30 0.72 0.47 0.001 0.30 0.73 0.48 0.001 0.31 0.74 0.49 0.001 0.32 0.76
31-90 days 0.20 <0.001 0.10 0.40 0.24 <0.001 0.12 0.47 0.24 <0.001 0.13 0.47 0.25 <0.001 0.13 0.48 0.25 <0.001 0.13 0.48 0.25 <0.001 0.13 0.49 0.26 <0.001 0.13 0.49 0.26 <0.001 0.13 0.50 0.27 <0.001 0.14 0.52
7-30 days 0.17 <0.001 0.07 0.42 0.20 <0.001 0.08 0.48 0.20 <0.001 0.09 0.48 0.21 <0.001 0.09 0.49 0.21 <0.001 0.09 0.51 0.21 <0.001 0.09 0.51 0.22 0.001 0.09 0.52 0.22 0.001 0.09 0.53 0.23 0.001 0.10 0.56
1-6 days 0.38 0.022 0.17 0.87 0.52 0.096 0.24 1.13 0.49 0.067 0.22 1.05 0.49 0.071 0.23 1.06 0.48 0.063 0.23 1.04 0.49 0.066 0.23 1.05 0.46 0.047 0.22 0.99 0.47 0.051 0.22 1.00 0.47 0.046 0.22 0.99
No. of days since last invasive procedure
no procedure 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
91 days<1 yr 0.85 0.315 0.61 1.17 0.85 0.305 0.62 1.16 0.85 0.304 0.62 1.16 0.86 0.335 0.63 1.17 0.86 0.339 0.63 1.17 0.86 0.353 0.63 1.18 0.86 0.324 0.63 1.17 0.86 0.331 0.63 1.17 0.85 0.316 0.63 1.16
31-90 days 0.64 0.037 0.41 0.97 0.67 0.055 0.44 1.01 0.66 0.047 0.43 0.99 0.65 0.043 0.43 0.99 0.65 0.044 0.43 0.99 0.65 0.043 0.43 0.99 0.64 0.036 0.43 0.97 0.64 0.031 0.42 0.96 0.63 0.026 0.42 0.95
7-30 days 0.61 0.038 0.38 0.97 0.59 0.026 0.37 0.94 0.58 0.020 0.36 0.92 0.58 0.019 0.36 0.91 0.56 0.013 0.35 0.88 0.55 0.010 0.35 0.87 0.53 0.007 0.34 0.84 0.52 0.005 0.33 0.82 0.49 0.002 0.31 0.77
1-6 days 1.69 0.017 1.10 2.60 1.01 0.954 0.69 1.47 0.95 0.775 0.66 1.37 0.87 0.445 0.60 1.25 0.80 0.229 0.56 1.15 0.75 0.118 0.53 1.07 0.68 0.031 0.48 0.97 0.64 0.010 0.45 0.90 0.60 0.003 0.42 0.84
No. of days between last discharge and current admission
no previous discharge 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
91 days<1 yr 0.64 <0.001 0.51 0.80 0.61 <0.001 0.49 0.76 0.62 <0.001 0.50 0.76 0.62 <0.001 0.50 0.76 0.62 <0.001 0.50 0.76 0.62 <0.001 0.50 0.77 0.63 <0.001 0.51 0.77 0.63 <0.001 0.51 0.77 0.63 <0.001 0.51 0.78
31-90 days 0.56 <0.001 0.41 0.76 0.53 <0.001 0.39 0.70 0.53 <0.001 0.40 0.71 0.53 <0.001 0.40 0.72 0.53 <0.001 0.40 0.71 0.53 <0.001 0.40 0.71 0.54 <0.001 0.40 0.72 0.54 <0.001 0.40 0.72 0.54 <0.001 0.41 0.72
7-30 days 0.38 <0.001 0.27 0.54 0.34 <0.001 0.25 0.48 0.34 <0.001 0.25 0.48 0.34 <0.001 0.24 0.47 0.34 <0.001 0.24 0.47 0.34 <0.001 0.25 0.48 0.35 <0.001 0.25 0.48 0.35 <0.001 0.25 0.49 0.36 <0.001 0.26 0.50
1-6 days 0.41 <0.001 0.31 0.55 0.44 <0.001 0.33 0.58 0.44 <0.001 0.33 0.57 0.44 <0.001 0.34 0.58 0.45 <0.001 0.34 0.59 0.46 <0.001 0.35 0.60 0.47 <0.001 0.36 0.61 0.47 <0.001 0.36 0.61 0.48 <0.001 0.37 0.62
Fractional polynomial (FP) 1
Fractional polynomial (FP) 2
95% CI95% CI
CA1 CA2
95% CI 95% CI
CA3 CA4 CA8 CA9
95% CI 95% CI 95% CI 95% CI 95% CI
CA5 CA6 CA7
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Appendix 5Ci. Approach B: best fitting AIC or BIC model (in red) in comparison to all other models (total 1,023 models) to predict HA BSI in children aged 1 month < 1 year  
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Appendix 5Cii. Approach B: best fitting AIC or BIC model (in red) in comparison to all other models (total 551 models) to predict HA BSI in children aged 1-5 years  
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Appendix 5Di. Approach B: Adjusted OR results for explanatory variables in the final models (HA1-HA9) with HA BSI as the outcome in children aged 1 month < 1 year; the 
denominator contains either a priori CA or defined HA BSI cases  
No. of obs      =      2173 No. of obs      =      1651 No. of obs      =      1556 No. of obs      =      1509  No. of obs      =      1473     No. of obs      =      1446   No. of obs      =      1426 No. of obs      =      1400 No. of obs      =      1378
Approach B
1m<1y HA outcome AOR P>z AOR P>z AOR P>z AOR P>z AOR P>z AOR P>z AOR P>z AOR P>z AOR P>z
Age in days (FP = -0.5) (FP = -0.5) (FP = -0.5) (FP = 1) (FP = 1) (FP = 1) (FP = 1) (FP = 1) (FP = 1)
6.19 <0.001 4.39 8.72 6.29 <0.001 3.94 10.04 9.36 <0.001 5.45 16.06 0.99 <0.001 0.99 0.99 0.99 <0.001 0.99 0.99 0.99 <0.001 0.99 0.99 0.99 <0.001 0.99 0.99 0.99 <0.001 0.99 0.99 0.99 <0.001 0.99 0.99
Postnatal stay (FP = -2) (FP = -2) (FP = -2) (FP = 2,2) (FP = 1) (FP = 1) (FP = 1) (FP = 0) (FP = 0)
1.00 <0.001 1.00 1.00 1.00 <0.001 1.00 1.00 1.00 <0.001 1.00 1.00 0.22 0.007 0.07 0.66 0.99 0.090 0.98 1.00 0.99 0.083 0.98 1.00 0.99 0.095 0.98 1.00 0.77 0.014 0.63 0.95 0.76 0.011 0.62 0.94
119.46 0.011 2.99 4775.93
Ethnicity
White 1.00 1.00 1.00 1.00 1.00 1.00 1.00
Mixed 1.26 0.457 0.68 2.35 0.35 0.100 0.10 1.22 0.29 0.047 0.08 0.99 0.25 0.033 0.07 0.89 0.25 0.037 0.07 0.92 0.24 0.033 0.06 0.89 0.23 0.034 0.06 0.90
Indian subcontinent 2.09 <0.001 1.42 3.08 2.23 0.026 1.10 4.53 2.67 0.008 1.29 5.51 2.55 0.014 1.20 5.39 2.30 0.032 1.07 4.91 2.70 0.013 1.24 5.88 2.65 0.023 1.14 6.15
Any other Asian 4.34 0.001 1.76 10.67 7.89 0.005 1.84 33.83 8.34 0.007 1.78 38.95 8.32 0.007 1.77 39.07 8.18 0.009 1.69 39.50 9.16 0.008 1.76 47.59 10.24 0.008 1.83 57.27
Black 2.62 0.001 1.50 4.57 3.90 0.005 1.50 10.12 2.85 0.049 1.00 8.08 2.98 0.041 1.04 8.49 2.82 0.060 0.96 8.31 1.46 0.543 0.43 4.90 1.10 0.887 0.31 3.84
other ethnic group 1.23 0.525 0.65 2.32 2.07 0.206 0.67 6.42 2.65 0.098 0.83 8.43 2.78 0.086 0.86 8.97 2.93 0.072 0.91 9.45 2.98 0.084 0.87 10.26 2.57 0.181 0.64 10.24
NK 1.21 0.360 0.80 1.82 2.01 0.039 1.04 3.88 2.10 0.035 1.05 4.19 2.03 0.050 1.00 4.10 1.95 0.071 0.94 4.04 2.19 0.043 1.02 4.66 2.34 0.034 1.07 5.15
normal birth 1.00 1.00 1.00 1.00 1.00 1.00
Premature/low birthweight 2.20 0.004 1.28 3.79 2.09 0.006 1.23 3.54 2.16 0.005 1.26 3.71 2.23 0.004 1.29 3.85 2.83 0.001 1.50 5.33 3.11 0.001 1.59 6.11
Chronic conditions
no chronic 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
1 chronic 0.55 <0.001 0.43 0.71 1.08 0.667 0.75 1.56 1.27 0.279 0.82 1.97 1.28 0.334 0.78 2.11 1.35 0.274 0.79 2.33 1.33 0.311 0.76 2.33 1.33 0.319 0.76 2.35 1.33 0.355 0.73 2.45 1.44 0.275 0.75 2.75
2 chronic 0.73 0.094 0.50 1.06 2.31 <0.001 1.47 3.60 3.46 <0.001 2.09 5.72 3.39 <0.001 1.92 5.99 4.09 <0.001 2.24 7.48 3.80 <0.001 2.04 7.06 3.57 <0.001 1.90 6.72 4.16 <0.001 2.13 8.10 4.65 <0.001 2.30 9.38
>2 chronic 2.05 0.002 1.30 3.21 6.74 <0.001 4.01 11.30 10.52 <0.001 5.94 18.64 11.08 <0.001 5.81 21.13 13.91 <0.001 7.09 27.29 13.53 <0.001 6.79 26.94 13.49 <0.001 6.73 27.01 15.92 <0.001 7.64 33.15 18.11 <0.001 8.38 39.14
not recorded 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
Congenital condition(s) 3.70 <0.001 2.68 5.11 6.97 <0.001 4.86 10.01 9.59 <0.001 6.43 14.30 11.03 <0.001 6.91 17.60 10.04 <0.001 6.18 16.30 9.91 <0.001 6.05 16.25 9.52 <0.001 5.79 15.66 10.23 <0.001 6.07 17.23 10.55 <0.001 6.12 18.19
No. of days since last indwelling device insertion
no device 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
91 days<1 yr 1.34 0.376 0.70 2.58 1.45 0.330 0.68 3.09 1.66 0.214 0.75 3.68 1.22 0.677 0.48 3.13 1.31 0.580 0.51 3.38 1.28 0.610 0.49 3.35 1.30 0.595 0.50 3.36 1.41 0.476 0.55 3.66 1.31 0.592 0.49 3.48
31-90 days 6.67 <0.001 2.29 19.39 8.68 <0.001 2.86 26.31 9.58 <0.001 3.01 30.47 11.27 <0.001 3.27 38.87 11.10 <0.001 3.21 38.33 10.75 <0.001 3.09 37.46 10.77 <0.001 3.10 37.36 13.96 <0.001 3.93 49.53 15.23 <0.001 4.18 55.40
7-30 days 15.57 0.008 2.08 116.74 24.27 0.002 3.22 182.96 29.71 0.001 3.91 225.96 30.42 0.001 3.83 241.42 31.91 0.001 3.98 255.98 37.80 0.001 4.60 310.40 41.13 0.001 4.93 343.28 47.24 <0.001 5.55 402.32 56.48 <0.001 6.47 492.95
1-6 days 0.97 0.936 0.46 2.03 1.63 0.235 0.73 3.64 1.92 0.136 0.81 4.55 2.19 0.096 0.87 5.50 2.15 0.119 0.82 5.63 2.69 0.051 1.00 7.27 2.63 0.063 0.95 7.31 2.81 0.056 0.97 8.09 2.26 0.137 0.77 6.63
No. of days since last invasive procedure
no procedure 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
91 days<1 yr 1.64 0.021 1.08 2.50 1.46 0.213 0.81 2.63 1.32 0.427 0.67 2.61 1.02 0.960 0.45 2.29 0.91 0.835 0.40 2.11 1.02 0.969 0.44 2.36 1.06 0.886 0.46 2.48 1.17 0.728 0.47 2.91 1.54 0.366 0.60 3.91
31-90 days 2.20 0.002 1.33 3.64 2.39 0.004 1.33 4.30 2.65 0.003 1.39 5.04 1.96 0.061 0.97 3.98 1.83 0.107 0.88 3.81 1.98 0.072 0.94 4.16 2.04 0.059 0.97 4.28 2.37 0.028 1.10 5.12 2.84 0.010 1.29 6.26
7-30 days 7.17 <0.001 3.74 13.76 11.45 <0.001 5.77 22.73 14.70 <0.001 7.16 30.21 15.56 <0.001 7.09 34.18 15.67 <0.001 7.09 34.65 16.92 <0.001 7.59 37.75 17.47 <0.001 7.83 38.94 19.45 <0.001 8.51 44.47 24.97 <0.001 10.54 59.12
1-6 days 4.37 <0.001 2.96 6.44 5.53 <0.001 3.52 8.71 5.82 <0.001 3.52 9.64 6.26 <0.001 3.54 11.09 6.44 <0.001 3.49 11.86 5.13 <0.001 2.70 9.77 4.58 <0.001 2.36 8.90 4.50 <0.001 2.23 9.10 5.49 <0.001 2.65 11.37
No. of days between last discharge and current admission
no previous discharge 1.00 1.00 1.00 1.00 1.00 1.00
91 days<1 yr 0.14 <0.001 0.08 0.27 0.12 <0.001 0.06 0.23 0.10 <0.001 0.05 0.21 0.10 <0.001 0.05 0.21 0.11 <0.001 0.05 0.25 0.07 <0.001 0.03 0.18
31-90 days 0.24 <0.001 0.13 0.45 0.21 <0.001 0.11 0.40 0.17 <0.001 0.09 0.34 0.18 <0.001 0.09 0.35 0.19 <0.001 0.09 0.39 0.16 <0.001 0.07 0.35
7-30 days 0.37 0.004 0.19 0.73 0.36 0.004 0.18 0.73 0.35 0.004 0.17 0.71 0.36 0.005 0.18 0.74 0.38 0.013 0.17 0.81 0.28 0.002 0.13 0.63
1-6 days 0.61 0.166 0.31 1.23 0.65 0.237 0.32 1.33 0.63 0.216 0.31 1.30 0.68 0.291 0.33 1.39 0.81 0.608 0.37 1.78 0.74 0.471 0.33 1.67
Fractional polynomial (FP) 1
Fractional polynomial (FP) 2
95% CI 95% CI 95% CI95% CI 95% CI 95% CI
Fractional polynomial (FP) 1
95% CI
HA7 HA8 HA9
95% CI 95% CI
HA6HA1 HA2 HA3 HA4 HA5
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Appendix 5Dii. Approach B: Adjusted OR results for explanatory variables in the final models (HA1-HA9) with HA BSI as the outcome in children aged 1-5 years; the 
denominator contains either a priori CA or defined HA BSI cases 
No. of obs      =      3,090 No. of obs      =      2,399 No. of obs      =      2,280 No. of obs      =      2,234  No. of obs      =      2,189 No. of obs      =      2,160 No. of obs      =      2,130 No. of obs      =      2,105  No. of obs      =      2,084
Approach B
1-5yrs HA outcome AOR P-value AOR P>z AOR P>z AOR P>z AOR P>z AOR P>z AOR P>z AOR P>z AOR P>z
Age in days (FP = -2,-1) (FP = 1) (FP = 1) (FP = 1) (FP = 1) (FP = 1) (FP = 1)
0.64 <0.001 0.51 0.82 0.99 0.078 0.99 1.00 0.99 0.042 0.99 0.99 0.99 0.033 0.99 0.99 0.99 0.032 0.99 0.99 0.99 0.059 0.99 1.00 0.99 0.056 0.99 1.00
4.14 <0.001 2.07 8.27
boy 1.00 1.00
girl 1.14 0.134 0.96 1.35 1.02 0.860 0.80 1.30
Ethnicity
White 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
Mixed 0.55 0.029 0.32 0.94 0.46 0.053 0.21 1.01 0.33 0.038 0.11 0.94 0.35 0.054 0.12 1.02 0.41 0.118 0.13 1.26 0.29 0.041 0.09 0.95 0.33 0.068 0.10 1.09 0.38 0.117 0.12 1.27 0.35 0.102 0.10 1.23
Indian subcontinent 1.39 0.028 1.04 1.87 1.52 0.044 1.01 2.27 1.89 0.023 1.09 3.28 1.83 0.045 1.01 3.31 1.95 0.042 1.02 3.71 1.96 0.049 1.00 3.82 1.97 0.057 0.98 3.96 2.17 0.032 1.07 4.41 2.08 0.047 1.01 4.30
Any other Asian 2.01 0.008 1.20 3.37 2.62 0.005 1.34 5.14 2.44 0.111 0.81 7.30 2.63 0.108 0.81 8.55 3.24 0.060 0.95 11.08 3.70 0.044 1.03 13.28 4.14 0.034 1.12 15.38 4.50 0.026 1.20 16.86 4.94 0.018 1.31 18.55
Black 1.12 0.521 0.79 1.61 1.32 0.253 0.82 2.13 1.21 0.563 0.63 2.33 1.37 0.359 0.70 2.69 1.57 0.215 0.77 3.21 1.62 0.205 0.77 3.42 1.39 0.422 0.62 3.09 1.25 0.604 0.54 2.91 1.06 0.900 0.43 2.59
other ethnic group 1.05 0.857 0.63 1.76 1.96 0.033 1.06 3.64 1.87 0.118 0.85 4.12 2.19 0.061 0.97 4.97 2.37 0.047 1.01 5.53 2.23 0.075 0.92 5.40 2.35 0.068 0.94 5.87 2.59 0.043 1.03 6.49 2.67 0.039 1.05 6.77
NK 1.10 0.541 0.82 1.48 1.60 0.017 1.09 2.35 2.10 0.005 1.25 3.52 1.84 0.033 1.05 3.24 1.94 0.031 1.06 3.53 1.80 0.074 0.94 3.41 2.03 0.033 1.06 3.89 1.99 0.046 1.01 3.90 1.80 0.100 0.89 3.64
normal birth 1.00 1.00 1.00
Premature/low birthweight 1.40 0.089 0.95 2.07 1.63 0.048 1.01 2.66 1.53 0.104 0.92 2.56
Chronic conditions
no chronic 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
1 chronic 0.91 0.332 0.74 1.11 3.05 <0.001 1.87 4.98 2.98 <0.001 1.75 5.10 4.29 <0.001 2.26 8.17 3.97 <0.001 1.97 7.98 4.51 <0.001 2.05 9.90 5.80 <0.001 2.44 13.79 6.93 <0.001 2.63 18.24
2 chronic 0.92 0.595 0.68 1.25 4.48 <0.001 2.58 7.79 4.92 <0.001 2.72 8.90 7.95 <0.001 3.95 16.00 9.18 <0.001 4.37 19.28 12.05 <0.001 5.32 27.30 13.95 <0.001 5.67 34.32 18.50 <0.001 6.87 49.86
>2 chronic 1.47 0.018 1.07 2.03 12.12 <0.001 7.14 20.57 13.27 <0.001 7.54 23.35 24.65 <0.001 12.61 48.20 28.25 <0.001 13.82 57.77 39.16 <0.001 17.71 86.59 49.55 <0.001 20.69 118.64 64.68 <0.001 24.64 169.77
not recorded 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
Congenital condition(s) 2.44 <0.001 1.77 3.36 6.87 <0.001 4.83 9.77 3.11 <0.001 2.04 4.74 3.32 <0.001 2.15 5.12 3.68 <0.001 2.28 5.93 3.54 <0.001 2.16 5.80 3.59 <0.001 2.16 5.95 3.76 <0.001 2.24 6.30 3.79 <0.001 2.24 6.41
No. of days since last indwelling device insertion
no device 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
91 days<1 yr 1.51 0.102 0.92 2.49 4.80 <0.001 2.90 7.95 1.66 0.094 0.92 3.01 1.54 0.169 0.83 2.83 1.65 0.136 0.85 3.19 1.66 0.142 0.84 3.24 1.70 0.130 0.86 3.38 1.97 0.057 0.98 3.97 2.15 0.034 1.06 4.36
31-90 days 3.48 0.001 1.71 7.07 18.72 <0.001 9.50 36.87 4.72 <0.001 2.16 10.31 5.07 <0.001 2.29 11.23 6.01 <0.001 2.62 13.77 6.20 <0.001 2.68 14.32 6.61 <0.001 2.79 15.66 7.90 <0.001 3.27 19.11 8.58 <0.001 3.54 20.79
7-30 days 7.82 <0.001 3.28 18.66 75.06 <0.001 32.24 174.74 9.67 <0.001 3.91 23.89 10.03 <0.001 4.05 24.83 11.67 <0.001 4.68 29.10 12.28 <0.001 4.89 30.84 13.61 <0.001 5.38 34.40 15.49 <0.001 6.08 39.43 18.57 <0.001 7.21 47.81
1-6 days 2.82 0.008 1.31 6.09 28.40 <0.001 13.50 59.76 3.06 0.011 1.29 7.27 3.31 0.008 1.37 7.97 3.82 0.004 1.52 9.60 3.97 0.005 1.52 10.32 3.98 0.006 1.49 10.62 4.03 0.007 1.46 11.10 3.56 0.017 1.26 10.10
No. of days since last invasive procedure
no procedure 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
91 days<1 yr 1.22 0.335 0.82 1.81 1.65 0.100 0.91 2.98 1.86 0.048 1.00 3.46 2.74 0.006 1.34 5.61 3.29 0.001 1.58 6.85 3.21 0.003 1.49 6.90 3.12 0.005 1.42 6.87 3.10 0.006 1.39 6.94
31-90 days 1.87 0.012 1.15 3.04 4.28 <0.001 2.27 8.07 4.31 <0.001 2.21 8.42 5.59 <0.001 2.64 11.81 6.80 <0.001 3.15 14.66 6.72 <0.001 3.03 14.92 6.48 <0.001 2.86 14.71 6.52 <0.001 2.82 15.08
7-30 days 5.89 <0.001 3.74 9.27 22.74 <0.001 13.45 38.45 26.51 <0.001 15.44 45.51 36.24 <0.001 19.76 66.46 44.09 <0.001 23.46 82.86 49.19 <0.001 25.57 94.63 52.01 <0.001 26.68 101.39 44.37 <0.001 22.41 87.84
1-6 days 5.82 <0.001 4.12 8.23 19.41 <0.001 12.34 30.55 19.49 <0.001 12.10 31.39 20.93 <0.001 12.31 35.61 23.06 <0.001 13.16 40.43 21.65 <0.001 11.90 39.39 18.14 <0.001 9.67 34.03 16.35 <0.001 8.39 31.88
No. of days between last discharge and current admission
no previous discharge 1.00 1.00 1.00 1.00 1.00 1.00 1.00
91 days<1 yr 1.46 0.010 1.10 1.95 1.24 0.277 0.84 1.83 0.55 0.059 0.29 1.02 0.54 0.065 0.28 1.04 0.51 0.052 0.26 1.01 0.47 0.041 0.23 0.97 0.48 0.051 0.23 1.00
31-90 days 1.48 0.037 1.02 2.14 1.53 0.081 0.95 2.45 0.47 0.039 0.23 0.96 0.44 0.034 0.21 0.94 0.44 0.040 0.20 0.97 0.43 0.037 0.19 0.95 0.38 0.024 0.16 0.88
7-30 days 2.07 <0.001 1.43 3.00 2.78 <0.001 1.78 4.33 0.41 0.009 0.21 0.80 0.33 0.002 0.16 0.66 0.29 0.001 0.14 0.60 0.24 <0.001 0.11 0.51 0.23 <0.001 0.11 0.50
1-6 days 1.78 <0.001 1.30 2.43 4.19 <0.001 2.95 5.94 0.67 0.170 0.38 1.19 0.63 0.131 0.34 1.15 0.48 0.025 0.26 0.91 0.41 0.009 0.21 0.80 0.41 0.011 0.21 0.82
95% CI 95% CI 95% CI 95% CI
Fractional polynomial (FP) 1
Fractional polynomial (FP) 2
95% CI
HA6 HA7 HA8 HA9
95% CI 95% CI 95% CI 95% CI
HA1 HA2 HA3 HA4 HA5
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